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Abstract
MAGEA1 and -A2 impair the stabilization and activation of p53 in presence of a
genotoxic stress. MAGEA (Melanoma AntiGEn-A) genes are silenced in the vast
majority of healthy human adult tissues. However, a re-expression is commonly
observed in various types of cancer. Several studies demonstrated a correlation
between MAGEA expression and advanced cancer stages as well as increased
resistance to chemotherapy. However, the functions of MAGEA proteins in cancer
cells remain largely unknown. Here, we present evidence that MAGEA1 and
MAGEA2 (but not -A3, -A4, -A6 and -A12) diminish the sensitivity of breast
cancer cells to the chemotherapeutic agent doxorubicin. We link this resistance
to reduced DNA damage-induced apoptosis. Furthermore, we demonstrate that
MAGEA1 and -A2 proteins directly interact with the tumor suppressor p53 and
inhibit its stabilization and activation. We link the decreased activation and
lowered half-life of stress-induced p53 to an impaired phosphorylation of its...
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Abstract 
MAGEA1 and -A2 impair the stabilization and activation of p53 in 
presence of a genotoxic stress. 
MAGEA (Melanoma AntiGEn-A) genes are members of the cancer 
testis antigens (CTAs). They are silenced in the vast majority of 
healthy human adult tissues. However, a re-expression is commonly 
observed in various types of cancer. Several studies demonstrated a 
correlation between MAGEA expression and advanced cancer stages, 
malignant transformation as well as increased resistance to 
chemotherapy. These observations emphasize that MAGEA proteins 
could have oncogenic properties and favor cancer development. 
However, the functions of MAGEA proteins in cancer cells remain 
largely unknown. In order to study the functions of the MAGEA 
commonly expressed in cancer, we used the MCF-7 breast cancer cell 
line to derive clones stably expressing them. Here, we present 
evidence that MAGEA1 and MAGEA2 (but not -A3, -A4, -A6 and -A12) 
diminish the sensitivity of breast cancer cells to the 
chemotherapeutic agent doxorubicin. We link this resistance to 
reduced DNA damage-induced apoptosis in presence of MAGEA 
expression. Furthermore, we demonstrate that the mechanism is 
p53-dependent. MAGEA1 and -A2 proteins directly interact with the 
DNA binding domain of the tumor suppressor and inhibit the 
stabilization and activation of p53 in cells exposed to a genotoxic 
stress. We link the decreased activation and lowered half-life of 
stress-induced p53 to an impaired phosphorylation of its N-terminal 
xiii 
 
region in presence of MAGEA1 or -A2. Our data suggest that 
preventing MAGEA proteins to bind and inhibit p53 could be an 
interesting strategy to combat cancers that harbor the wt version of 
the tumor suppressor.  
Resveratrol induces DNA damage in colon cancer cells by poisoning 
topoisomerase II and activates the ATM kinase to trigger p53-
dependent apoptosis. 
Resveratrol (trans-3,4’,5-trihydroxystilbene) is a natural polyphenol 
synthesized by various plants such as grape vine.  Resveratrol (RSV) is 
a widely studied molecule, largely for its chemopreventive effect in 
different mouse cancer models. We propose a mechanism underlying 
the cytotoxic activity of RSV on colon cancer cells. Our data show that 
resveratrol induces apoptosis, as observed by the cleavage of PARP-1 
and chromatin condensation. We show that the tumor suppressor 
p53 is activated in response to RSV and participates to the apoptotic 
process.  Additionally, we show that HCT-116 p53 wt colon carcinoma 
cells are significantly more sensitive than HCT-116 p53 -/- cells to 
RSV. RSV induces DNA damage including double strand breaks, as 
evidenced by the presence of multiple γ-H2AX foci in 50% of cells 
after a 24h treatment with 25 µM RSV. The formation of DNA 
damage does not appear to rely on a pro-oxidant effect of the 
molecule, inhibition of topoisomerase I, or DNA intercalation. Rather, 
we show that DNA damage is the consequence of type II 
topoisomerase poisoning. Exposure of HCT-116 cells to RSV leads to 
activation of the Ataxia Telangiectasia Mutated (ATM) kinase, and 
ATM is required to activate p53.  
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Chapter 1: cancer 
 
World wild cancer statistics published by the International 
Agency on Cancer estimates that 32.6 million people are currently living 
with cancer. In 2012, more than 14 million new cancer cases were 
diagnosed and 8.2 million people died from it1. Among men, lung, 
prostate, colorectum, stomach and liver cancers were the most 
represented cancer types while breast, colorectum, lung, cervix and 
stomach cancers were the most prevalent among women. In developed 
countries such as USA, cancer was the second cause of death in 2012 
(22.9% of total death) behind heart diseases (23.7%) [Hoyert et al., 
2012]. Data available for Belgium are generally older. In 2009, among 
103,816 deaths, 27,973 were due to cancer. Digestive tract and 
respiratory organs tumors were the main represented types of cancer 
(50,6%) 2. According to the World Health Organization, some cancers 
may be prevented by a healthier behavior. Indeed, high body mass 
index, low fruit and vegetable intake, lack of physical activity, tobacco 
and alcohol (ab)use are presumably responsible for 30% of cancers. In 
the next two decades, previsions expect an increase of 70% in cancer 
cases reaching 22 million annual cases
3
.  
                                                 
1
 http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx 
2
 http://statbel.fgov.be/fr/binaries/FR%20-%20Tableau%201.3_T_pdf_tcm326-210617.pdf 
3
 http://www.who.int/mediacentre/factsheets/fs297/en/ 
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Cancer is a general term that includes a group of diseases in 
which abnormal cells divide without control and invade other tissues and 
organs. Cancer cells can spread to other parts of the body through the 
blood and lymph systems
4
. Cancers are classified based on their origin. 
For example a carcinoma describes a type of cancer developing form 
epithelial cells. Carcinoma may further be divided into subclasses based 
on tissue architecture and cancer cell features (adenocarcinoma, 
squamous cell carcinoma, etc…). On the other hand, sarcomas arise from 
non-hematopoetic mesenchymal cells (cartilage, fat, muscle or bones). 
Finally, hematopoetic cells give rise to leukemias or lymphomas5. 
 
 
 
 
 
 
 
 
 
                                                 
4
 National cancer institute website 
5 www.cancer.org 
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1.1. Hallmarks of cancer 
 
In their famous review article, Hanahan and Weinberg described 
ten distinctive and complementary cellular characteristics that enable 
tumor growth and metastatic dissemination [Hanahan and Weinberg, 
2011]. In this chapter, a short review of each of these will be described. 
On Figure 1, these hallmarks of cancer are enumerated and symbolized 
by an icon.  
 
Figure 1 : Hallmarks of cancer. This chart summarizes ten hallmarks observed in cancer cells. All 
hallmarks are further described below. Modified from Hanahan and Weinberg, 2011. 
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1.1.1. Resisting Cell death 
  
Programmed cell death (PCD) defines different pathways 
involved in the removal of unnecessary or damaged cells in our tissues. 
Observed in any animals yet analyzed, PCD shapes our body during 
development by sculpting (e.g. fingers), removing unwanted structures 
(e.g. tail of the frog), controlling the cell numbers and eliminating non-
functional cells [Jacobson et al., 1997]. 
 
Apoptosis, reviewed in the following chapter, plays a critical role 
in protecting our tissue from cancer development. [Kroemer et al., 1995; 
Hanahan and Weinberg, 2011]. The number of cellular conditions 
leading to apoptosis is significant and pathways variable: oncogene 
signaling, DNA damage, hypoxia and reactive oxygen species (ROS) are 
all able to trigger apoptosis [Kroemer et al., 1995]. Unfortunately, cancer 
cells often acquire resistance to apoptosis by corrupting key regulators. 
Combinations of mutations leading to impaired apoptosis are probably 
as high as the number of cancers itself but some events are defined as 
crucial. Among them, mutation of TP53 occurs in more than 50% of all 
cancers. The tumor suppressor p53 is a major regulator of apoptosis 
since it regulates, as transcription factor, the expression of many genes 
such as BAK, BAX, NOXA, PUMA, DR5, Fas… 
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Autophagy, another form of PCD, seems to play a bivalent role. It 
may either confer a protection against the transformation of a normal 
cell or be beneficial for the cancer cell submitted to stresses. Autophagy 
degrades and recycles proteins and organelles to regenerate 
nucleotides, amino acids, fatty acids, sugars as well as energy, thus 
supporting the metabolism and allowing cell survival in starvation 
situation [Rabinowitz and White, 2010]. In normal cells, autophagy 
prevents tumor initiation by suppressing inflammation [White et al., 
2010] and chronic tissue damages [Guo et al., 2013]. On the other hand, 
autophagy sustains cancer cells metabolism by recycling nutrient and 
energy in tumors ineffectively vascularized. Moreover, after 
radiotherapy or chemotherapy treatments, autophagy-mediated 
cytoprotective effects have been observed. Indeed, it has been proposed 
that severely stressed cancer cells can enter a state of reversible 
dormancy thanks to autophagy [White and Dipaola, 2009]. If the 
environment becomes favorable again, the tumor cell quits dormancy 
and may recreate tumors.  
 
1.1.2. Avoiding immune destruction 
 
 Ability to avoid immune-dependent destruction remains to be 
firmly established as one of the hallmarks of cancer but several studies 
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point out a relationship between cancer progression and a deficient 
immune system. 
In 2009, an Australian team demonstrated that 
immunocompromised persons were more prone to develop cancer 
[Vajdic and van Leeuwen, 2009]. Reports on mice deficient for various 
components of the immune system further reinforced the link between 
immune deficiency and cancer [Teng et al., 2008; Kim et al., 2007]. 
Epidemiological studies also support a role of the immune system in 
cancer prevention: patients showing tumors massively infiltrated with 
cytotoxic T lymphocytes (CTLs) and Natural Killers (NKs) have better 
prognosis than patients with tumors less infiltrated. In the same context, 
transplants from a cancer-free donor to an immunocompromised 
recipient may develop tumors [Strauss and Thomas, 2010]. Authors 
raised the possibility that the donor functional immune environment 
maintained cancer cells in dormancy. Once transplanted, the 
immunosuppressed environment of the new host allows cell division. 
Mechanistically speaking, immune evasion requires immune 
system impairment. For example, TGF-β is often produced by cancer 
cells in order to paralyze infiltrated CTLs or NKs. Also, tumor cells can 
actively recruit immunosuppressive cells such as regulatory T cells 
(Tregs) [Hanahan and Weinberg, 2011]. 
All the above elements seem to highlight immune evasion as a 
highly plausible hallmark of cancer. 
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1.1.3. Enabling replicative immortality 
 
Immortality is the quality or state of something that will never 
die. In a cellular context, replicative immortality is the ability to divide 
indefinitely. Usually, the number of cell division is limited by two 
hurdles: senescence and cell death [Hanahan and Weinberg, 2011]. 
When a cell reaches a determined amount of division, it enters in an 
irreversible state of non-proliferation called replicative senescence. 
When a cell contains mutations allowing to bypass senescence, 
additional divisions will lead to the second barrier, cell death. 
Nevertheless, sometimes cells overcome both senescence and cell 
death. This transition has been defined as cell immortalization.  
Each time a human cell replicates, each chromosomes ends, the 
telomeres, is shortened by 50-150 nucleotides [Smogorzewska et al., 
2000]. When critically short telomeres are detected, a signal driving cell 
entry into replicative senescence is triggered. This process can be seen 
as a clocking device that allows replication induction until probabilities of 
oncogene activation or deleterious mutations are too high [Shay and 
Wright, 2000; Shay and Wright, 2002]. 
As a consequence, transition to immortality is only conceivable 
with the existence of a mechanism that counteracts telomere 
shortening. In cancer, multiple evidences demonstrate that protecting 
the ends of chromosome plays a central role in unlimited proliferation 
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[Smogorzewska et al., 2000]. It seems that more than 90 percent of 
cancers reactivate or overexpress the telomerase [Shay and Wright, 
2002]. By extending telomeric DNA, the telomerase counters replication 
dependent chromosome erosion and allows resistance to senescence 
and cell death. 
Without surprise, telomerase is an important field of research in 
cancer biology. Inhibiting the telomerase would force the cancer cell to 
enter into senescence. Nevertheless, side effects on cells naturally 
expressing the telomerase, such as hematopoetic progenitors, germline 
cells, stem cells and cells with a high renewal rate may represent a clear 
drawback of telomerase based therapies. 
 
1.1.4. Inducing Angiogenesis 
 
Angiogenesis is the ability to build a capillary network.  A majority 
of tumors grow capillaries to receive oxygen and nutrients and in the 
same time get rid of carbon dioxide and metabolic wastes. Even if not 
perfect, cancer angiogenesis is based on the same inducers and 
inhibitors as embryonic angiogenesis. Among many factors that trigger 
or inhibit vessels formation, Vascular endothelial growth factor-A (VEGF-
A) and Trombospondin-1 (TSP-1) are two good examples. VEGF-A is a 
ligand that binds to VEGF receptors (VEGFR-1, -2 or -3) and triggers new 
blood vessel formation. On the other hand, TSP-1 binds transmembrane 
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receptors at the surface of endothelial cells and represses vessel 
formation. In tumors, the balance between the two factors is 
deregulated, therefore vessel formation leads to incomplete or 
abnormal networks. Amid aberrations inventoried, precocious capillary 
sprouting, excessive capillary branching, distorted and enlarged vessels, 
erratic blood flow and even micro-hemorrhages are frequently observed 
[Nagy and Dvorak, 2010; Baluk et al., 2005]. Worthy of note, in the 
majority of cancers, the size of the blood vessel network is unrelated to 
cancer aggressiveness. For example, pancreatic ductal adenocarcinomas 
are almost free from capillaries but 5-year survival rates are lower than 
15% 6 [Olive et al. 2009]. This could be surprising since blood stream is 
important for cancer cells colonization. However, the lymphatic system 
is also responsible for metastasic dissemination. Finally, it is interesting 
to note that some oncogenes, like Myc or Ras, enhance angiogenic 
factors production [Hanahan and Weinberg, 2011]. 
  
                                                 
6
 http://www.cancer.org/cancer/pancreaticcancer/detailedguide/pancreatic-cancer-survival-rates 
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1.1.5. Metastasis formation  
 
Metastasis formation is a multi-step process that involves the 
journey of a cancer cell from a primary tumor site to another 
localization. On the invasion site, cancer cells nest, grow and rebuild a 
secondary tumor, the metastasis. The metastatic process is clearly 
inefficient. It is estimated that a tumor of 1cm size, corresponding to one 
billion cells, can infiltrate the circulatory system with one million cells 
per day. The number of natural defenses and the high number of non-
compatible invasion sites limit to less than 0.1% the number of cells 
actually developing a metastasis. Unfortunately for us, it still represents 
thousands of cells and 90% of all cancer deaths are associated to the 
presence of metastasis [Van Zijl et al., 2001; Valastyan and Weinberg, 
2011]. For a carcinoma, the metastatic process is divided into 7 steps:  
 
Local invasion of the surrounding tissue. This first step is crucial 
and differs by the type of invasion induced. Cancer cells may move 
collectively, as a tissue, or by single cell progression via mesenchymal or 
amoeboid transition and invasion. During cancer progression, tumor 
cells modify their physiological and morphological characteristics to get 
around obstacles. Among those transformations, there is the epithelial 
to mesenchymal transition (EMT : “molecular and cellular program by 
which epithelial cells shed their differentiated characteristics, including 
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cell-cell adhesion, planar and apical-basal polarity, and a lack of motility, 
and acquire instead mesenchymal features, including motility, 
invasiveness and a heightened resistance to apoptosis.” [Polyak and 
Weinberg, 2009]), the collective to amoeboid transition (CAT: this 
specifies the detachment of a specific carcinoma cell from the tumor by 
the use of amoeboid migration. Cells undergoing CAT show little 
connection with the extracellular matrix (ECM) and migrate through 
“holes” in the ECM without degrading it) and the mesenchymal to 
amoeboid transition (MAT : Mesenchymal cells produce matrix 
metalloproteases (MMPs) that help them to move through the ECM. If, 
for any reason, the extracellular proteolysis is blocked, MAT transition 
allows the cancer cell to continue its progression through amoeboid 
progression) [Van Zijl et al., 2001]. 
 
Intravasation in the lumen of lymphatic or blood vessels. 
Although lymphatic dissemination is regularly observed, it seems that 
blood dissemination represents the main path of metastatic 
dissemination [Gupta and Massagué, 2006]. Blood vessels possess a 
basement membrane usually inhibiting cell movement. However, as 
mentioned earlier, cancer capillaries networks are tortuous and prone to 
leakiness. Moreover, weak interactions between endothelial cells 
facilitate the intravasation of cancer cells. Finally, intravasation of 
carcinoma cells may be assisted by cytokine such as TGF-β [Giampieri et 
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al., 2009] or by cells like tumor activated macrophages (TAMs) 
[Hernandes et al., 2009]. 
 
Survival in the circulation. In the circulation, carcinomas cells are 
renamed “circulating tumor cells” (CTCs). The circulation entails many 
stresses that cells have to deal with to survive. Firstly, lack of anchorage 
to the ECM is supposed to trigger anoikis, an apoptotic process triggered 
by the loss of anchorage to the substratum. However, since the average 
diameter of a carcinoma cell is 30µm and since average capillaries 
possess a diameter of less than 8µm, carcinoma cells are rapidly blocked 
in some capillaries, re-enter the surrounding ECM and evade anoikis 
before it even starts [Valastyan and Weinberg, 2011]. 
In the bloodstream, CTCs also suffer from predation by circulating 
immune cells and from physical stresses (pressure, movement…). A 
rather unexpected mechanism of defense consists in the expression at 
their surface of the membrane bound tissue factor (Tf) which is the 
receptor for coagulation factors VIIa and X. As consequence, CTCs shield 
themselves in platelets aggregation allowing them to escape physical 
stresses or immune destruction [Van Zijl et al., 2011; Valastyan and 
Weinberg, 2011]. 
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Arrest at a distant organ site. It is common knowledge that cells 
originating from a particular cancer do not nest and create metastasis 
anywhere in the body. Some organs seem more appropriate than others. 
Already in 1889, Stephen Paget described an organ specific pattern of 
metastasis. For example, breast carcinoma rather invades bones, lungs 
and brain while colorectal cancers show a preference for the liver. This 
last example may be explained by the liver vascularization acting as a 
trap. CTCs, coming from the guts, are outgushed in the portal vein and 
rapidly arrive in liver capillaries with a diameter smaller than their size 
[Valastyan and Weinberg, 2011]. It remains to be determined whether 
CTCs are able to actively select the best environment for them, or if 
passive trapping in the capillaries is the sole mechanism for site 
selection.  
 
Extravasation. Here, several hypothesis stand and may be 
applied in parallel by CTCs. First, Al Medhi et al. proposed a mechanism 
in which CTCs trapped in microcapillaries continue to grow and develop 
a microtumor [Al-Mehdi et al., 2000]. Tumor growth may eventually 
break endothelial tight junctions, creating a hole in the capillaries 
allowing cells to invade the stroma. This hypothesis does not take into 
account anoikis, nevertheless, it is likely that specific CTCs are able to 
downregulate anoikis due to the spectrum of mutations they contain. In 
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addition, CTCs could undergo extravasation, the transfer of the cell from 
the lumen of the capillaries to the ECM of the colonized organ. 
Mechanistically, evidences suggest differences with intravasation, even if 
TAMs also help CTCs to cross the endothelial barrier [Qian and Pollard, 
2010].  
 
Micrometastasis formation. The new environment differs from 
the initial tumor site. Characteristics of the invaded organ, such as the 
type of stromal cells, ECM constituents or growth factors available may 
not be suitable for the newly arrived carcinoma cells. Some recent 
studies raised the hypothesis that cancer cells may prepare the invasion 
site before actually leaving the primary tumor. Systemic signals may be 
released in the blood to modify the normal behavior of fibroblasts in the 
future invaded organ. For example, on the invasion site, cells expressing 
MMP9 were shown to be recruited, remodel the ECM and release 
cytokines. This hypothesis is currently questioned and under intense 
debate [Psaila and Lyden, 2009]. Another hypothesis to CTCs adaptation 
to a new environment is simply its autonomous program. Cells express 
proteins and use pathways that dodge the harmful conditions imposed 
by the foreign environment. 
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Metastatic colonization. Once survival on the new site is 
achieved, proliferation is not guaranteed. Indeed, cells may enter a 
quiescent state and fail to replicate. In breast cancer, this has been 
linked to a lack of adhesion with the surrounding ECM. Moreover, if cells 
effectively begin to divide, the apoptotic rate may be so intense that 
they will never be able to develop a metastasis. Mechanisms responsible 
for apoptosis, in this case, are poorly understood but failure to induce 
neoangiogenesis may be a key to understand the high apoptotic rate 
[Chambers et al., 2002]. 
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1.1.6. Genome instability and mutation 
 
A majority of hallmarks displayed by cancer cells are acquired 
following successive mutations. Among mutations inventoried, 
mutations in the components of the genomic maintenance machinery, in 
the surveillance system or in processes triggered in response to severe 
stresses (apoptosis, senescence…) are observed. In normal condition, 
tumor suppressors inhibit cell transformation. Unfortunately, when a 
mutation directly strikes a tumor suppressor gene impairing its function, 
these processes are altered. With a sufficient amount of mutations, 
cancer cells progress and develop metastasis. 
There is an endless combination of mutations leading to cancer 
but cancer requires mutations of genes involved in the regulation of cell 
division and in the cell control/surveillance mechanisms. Moreover, 
mutations altering genome maintenance and repair are selectively 
conserved since they increase the probability of new mutations 
[Hanahan and Weinberg, 2011]. 
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1.1.7. Tumor promoting inflammation 
 
It has been observed that every tumor is at least slowly infiltrated 
by immune cells [Dvorak, 1986]. It has first been thought that it was a 
consequence of tumor formation and therefore a normal reaction of the 
body. However, since 2000, compelling evidences demonstrate that 
inflammation may enhance progression of cancer instead of preventing 
it. More precisely, inflammation can facilitate tumor progression by 
delivering growth factors (e.g. EGF), survival factors, proangiogenic 
factors (e.g. VEGF) and ECM modifying enzymes (e.g. MMPs) [Hanahan 
and Weinberg, 2011]. 
 
1.1.8. Deregulating the energy metabolism 
 
In tumors, due to limited access to oxygen, an adjustment of the 
energy metabolism is compulsory. The tumor is a micro-environment in 
which glycolysis becomes favored. Interestingly, even in presence of a 
sufficient amount of oxygen, cancer cells rather use glycolysis.  Otto 
Warburg was the first scientist to observe this effect thereafter named 
“Warburg effect” in his honor. As consequence, GLUT1, the glucose 
transporter, is overexpressed and the oncogene RAS increases the levels 
of HIF1α and HIF2α in order to boost glycolysis. It is difficult to explain 
why cancer cells favor an energy pathway 18 fold less efficient in term of 
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ATP generated by mole of glucose engaged.  A hypothesis is that 
intermediates of glycolysis may be used in other pathways involved in 
cell division.  
Hanahan and Weinberg question this hallmark as a real one or as side 
effect carried out by protein involved in other hallmarks [Hanahan and 
Weinberg, 2011]. 
 
1.1.9. Sustaining proliferative signaling 
 
 Normal cell division of is tightly controlled by growth-promoting 
signals. One of the main characteristics of cancer cells consists in freeing 
themselves from external signals in order to sustain chronic proliferation 
[Hanahan and Weinberg, 2011]. Mechanisms responsible for the 
autonomous cell division are various. Cancer cells may produce growth 
factors, resulting in an autocrine stimulation of cell division. They may 
also activate stromal cells to receive growth factors. For example, cancer 
cells secrete CSF-1 or TGF-β1 and in return receive EGF or stromal cell 
derived factor (CXCL12) from activated TAMs or cancer-associated 
fibroblasts, respectively. Another mechanism consists in overexpressing 
membrane receptors. The cell, thus, becomes hypersensitive to growth 
stimuli. Finally, growth factor independence may proceed from 
mutations leading to the constitutive activation of actors regulating cell 
division. Concerning activating mutations, several well-known 
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mechanisms have been described. In melanoma, B-Raf mutation affects 
the protein structure and activates the MAPK pathway. Mutations may 
also occur in negative feedback loops, leading to constant proliferation. 
A good example could be inhibitory mutations affecting PTEN 
phosphatase which normally counteracts PI3-Kinase effects [Datta et al., 
1997; Cantley and Neel, 1999].  
 
1.1.10. Evading growth suppressors 
 
Cell division is tightly supervised by powerful programs analyzing 
molecular check-points and taking decision based on information 
received. Those programs depend on tumor suppressor genes such as Rb 
and p53. 
RB controls the cell cycle based on the integration of signals 
coming from the intra- and extra-cellular signaling. A cell deficient for Rb 
activity, will typically be compromised in its ability to regulate the so-
called “restriction point” of the G1 phase of the cell cycle. This condition, 
therefore favors a non-controlled proliferation. 
On the other hand, p53 nicknamed “guardian of the genome” is 
activated in response to various detrimental stimuli such as DNA damage 
or oncogene activation. In response, p53 triggers cell cycle arrest, 
senescence or even apoptosis.  
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Those two tumor suppressors, even if capital, are part of a larger 
network. Hence, mutation leading to the impairment of one tumor 
suppressor is not sufficient to generate a cancer cell. Indeed, many 
additional events are required [Hanahan and Weinberg, 2011]. 
 
1.2. Future direction 
 
As explained by Hanahan and Weinberg, hallmarks of cancer are 
useful but incomplete tools to fully describe cancer. It only represents 
current knowledge about the disease and many layers of complexity will 
surely be added in the future. Therefore, until a complete understanding 
of the molecular processes leading to cancer development and 
progression, accent must be put on prevention to reduce cancer 
prevalence and death among the population.   
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Chapter 2: Apoptosis. 
 
First observed in 1885 by Fleming, apoptosis is a programmed 
cell death (PCD) that has been defined by Kerr and his colleagues in 
1972. The apoptotic phenomenon is characterized by a nuclear and 
cytoplasmic condensation, DNA fragmentation, membrane blebbing 
and formation of apoptotic bodies. Importantly, apoptosis does not lead 
to inflammation. This last characteristic allows preservation of intact 
surrounding tissues [Kerr et al., 1972; Lawen, 2003; Fink and Cookson, 
2005; Parrish et al., 2013]. 
PCD describes types of cell death that are programmed in time 
and localization during the development of an organism. Programmed 
features of PCD lead to the hypothesis that pathways involved had to be 
genetically encoded and that cell death was part of the cell biology such 
as glycolysis or mitosis [Lockshin and Zakeri, 2001]. Concrete evidence 
came in 1966 with observations on the frog Rana temporaria. If RNA and 
protein synthesis is inhibited (by treatment with actinomycin D and 
cycloheximide), regression of the Rana temporaria tadpoles is impeded 
[Tata, 1966; lockshin, 1969]. Further evidences of genetically induced 
apoptosis came in 1977 when Sulston and Horvitz demonstrated that 
13% of somatic cells of C. elegans embryo die predictably, shortly after 
appearing [Sulston and Horvitz, 1977]. In 1982, a gene determining the 
fate of C. Elegans cells is described, ced-3. Sequencing of ced-3 gene led 
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to the identification of a mammalian isoform of ced-3, the “interleukin-
1β-converting enzyme” later renamed caspase-1 [Yuan et al., 1993; Pop 
and Salvesen, 2009]. This breakthrough led to the description of the 
mammalian caspases family, proteases currently linked to apoptosis or 
inflammation [Lawen, 2003; Creagh et al., 2003].  
 
2.1. Caspases 
 
In humans, 12 caspases are identified. They are divided into two 
groups on the basis of their function.  
The first group of caspases contains all caspases involved in 
apoptosis and is divided into two subgroups based on structure and 
timing of activation during cell death. The first subgroup is referred to as 
the initiator caspases (caspases-2, -8, -9 and -10). They possess a long 
pro-domain and are responsible for the activation of caspases belonging 
to the second subgroup.  The second subgroup contains the effector 
caspases or “downstream caspases” (caspases-3, -6 and -7). They 
contain a small pro-domain and are responsible for the cleavage of 
cellular proteins [Fink and Cookson, 2005; Pop and Salvesen, 2009; 
Parrish et al., 2013; McIlwain et al., 2013].  
The second group of caspases contains caspases related to 
caspases-1 (Caspase-1, -4, -5, -12). These caspases play a role in the 
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inflammation process. For example, caspase-1 was shown to mature pro-
IL-1β into mature IL-1β but also IL-18 and IL-33 [Chowdhury et al., 2008]. 
 Finally, caspase-14 is not classified a member of these two 
groups since it has specific functions and seems implicated in the 
differentiation process of keratinocytes [Chowdhury et al., 2008; 
McIlwain et al., 2013]. 
 
 
Figure 2 : Structures and association of human caspases. All caspases possess a similar structure 
composed of a large and a small subunit. Caspases are proteases either responsible for apoptosis 
with initiator and executioner caspases or responsible for inflammation. The caspase family 
includes 13 isoforms differing by their cellular functions. They possess or not DED or CARD 
domains depending on their cellular role.  Modified from Taylor et al., 2008. 
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Figure 3 : General mechanism of maturation of pro-caspases into active caspases. Two 
procaspases in close proximity will be cleaved on two specific cleavage site (Asp-X). This induces 
a structure rearrangement that allows the binding of their respective small units creating and 
ultimately, formation of an active heterotetramer containing two large subunits and two small 
subunits. Modified from Chowdhury et al., 2008. 
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2.1.1. Apoptotic caspases 
 
2.1.1.1. Initiator caspases 
 
Caspase-2 (Casp-2), caspase-8 (Casp-8), caspase-9 (Casp-9) and 
caspase-10 (Casp-10) are the initiator caspases.  They may further be 
divided into two groups depending on upstream signals inducing their 
activation. Casp-8 and -10 are type I initiator caspases since their 
activation is “extrinsic” while the activation of casp-9 is “intrinsic” (type II 
initiator caspase). Those modes of activation will be discussed later in 
the chapter [Pop and Salvesen, 2009; McIlwain et al., 2013].  
Structurally, type II initiator caspases contain a CARD domain 
(CAspase Recruitment Domain) while type I caspases have two DED 
domains (Death Effector Domain) (Figure 2). CARD and DED domains 
interact with other proteins to bring two monomers in close proximity. 
Moreover, they all possess a catalytic domain divided in two subunits: a 
small one (± 10kDa) and a long one (± 20kDa) (Figure 2) [McIlwain et al., 
2013; Fuentes-prior et al., 2004; Salvesen and Ashkenazi, 2011]. 
In the absence of an apoptotic stimulus, initiator caspases exist in 
an inactive form, the procaspase monomer. Initiator caspases are 
activated by dimerization of two procaspases under the model of 
“induced proximity”. This model hypothesizes that upstream signals 
triggers the dimerization of two procaspases monomers by inducing a 
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close proximity between them [Muzio et al., 1997; Boatright and 
Salvesen, 2003; Chang et al., 2003]. This proximity allows self-cleavage 
into two small subunits and two large subunits which together form a 
heterotetramer (Figure 3) [Fuentes-prior and Salvesen, 2004; Salvesen 
and Ashkenazi, 2011].  
Caspase 2 is an initiator caspase (Erreur ! Source du renvoi 
introuvable.) that deserves a specific paragraph since it does not directly 
activates effector caspases. Caspase-2 is also found as an inactive 
monomer and like other initiator caspases, is activated through close 
proximity-induced dimerization. Pro-caspase-2 activation requires 
formation of the so-called PIDDosome. The PIDDosome is a protein 
complex composed by five “p53-induced protein with a death domain” 
(PIDD), seven “RIP-associated ICH-1/CED-3 homologous protein with a 
death domain” (RAIDD) and seven caspase-2 molecules (Figure 10) 
[Parrish et al., 2013]. It has been proposed that active caspase-2 is able 
to cleave Bid into tBid thus leading to mitochondrial membrane 
permeabilization [Bouchier-Hayes et al., 2009; Olsson et al., 2009]. PIDD 
genes expression is induced following p53 activation, therefore caspase-
2 is thought to be important for p53-dependent apoptosis. Finally, 
recent studies demonstrate that caspase-2 can be activated in absence 
of PIDD suggesting that other mechanisms may exist [Manzl et al., 2009]. 
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2.1.1.2. Effector caspases 
 
Caspase-3 (Casp-3), caspase-6 (Casp-6) and caspase-7 (Casp-7), 
the effector caspases, are characterized by the lack of a DED or CARD 
domain. Only the catalytic domain remains [Fuentes-prior and Salvesen, 
2004].  
Like initiator caspases, effector caspases are inactive and exist in 
absence of stress as procaspases. Inactive effector caspases are in a 
dimeric form and require cleavage by initiator caspases to be operative. 
As shown in Figure 4, initiator caspases cleave effector procaspases on 
the L2 loop (and L2’) that holds the two subunits of each monomer. This 
cleavage allows more flexibility from the L3 and L4 loops and helps to 
change the conformation from an inactive into an active dimer [Riedl 
and Shi, 2004]. 
 Activated effector caspases are responsible for all morphological 
changes that occur during apoptosis. Casp-3 and -7 share almost the 
same substrate and inhibitor specificity. Still, they diverge by the N-
terminal part of the protein thought to be responsible for subcellular 
localization [Fuentes-prior and Salvesen, 2004]. Substrates cleaved by 
Casp-6 are different which suggests a role slightly different from the 
other effector caspases. 
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Figure 4 : Effector pro-caspase 7 activation. On the left of the panel, the active-site loops are 
presented in green before the cleavage and in blue after the proteolytic processing. Cleavages 
increase the general flexibily of the protein and allow the activation [Riedl and Shi, 2004]. 
 
Figure 5 : FAS and TNF receptor activation. Death receptors are activated by external binding of 
a specific ligand. A) Activation of Fas induces the recruitment of procaspase-8 via FADD 
molecules and leads to caspase-8 activation. B) Activation of TNF receptors lead to two different 
outcomes. Either complex I is formed and induces NF-kB activation or formation and detachment 
of complex II induces cell death by caspase-8 recruitment and activation via FADD molecules. 
From Li and Yuan, 2008.   
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2.2. Pathways of apoptosis 
 
Many stimuli induce caspases activation but three main pathways 
are defined: (1) the extrinsic pathway of apoptosis (or death receptor 
pathway), (2) the intrinsic pathway of apoptosis (or mitochondrial 
apoptosis pathway) and finally (3) the granzyme-dependent pathway.  
Those pathways differ by the adapters and initiators required but all aim 
at activating effector caspases. A recapitulative figure of the apoptotic 
pathways may be found at the end of this chapter (Figure 10).  
 
2.2.1. Extrinsic apoptosis 
 
The extrinsic apoptosis pathway or “death receptor pathway of 
apoptosis” is triggered by external signaling. At the surface of the cell 
stands a family of transmembrane death receptors. These receptors are 
members of the tumor necrosis factor (TNF) receptor superfamily of 
receptors. They contain multiple cysteine-rich repeats as well as a death 
domain (DD) and are able to transduce the external death signal to the 
inside of the cell following the binding of a specific ligand. Members of 
this family include tumor necrosis factor receptor 1 (TNFR1 aka DR1, 
CD120a, p55 and p60), Fas (aka DR2, Apo-1 an CD-95), Death receptor 3 
(DR3 aka Apo-3, LARD, TRAMP and WSL1), TNF-related apoptosis-
inducing ligand receptor 1 (TRAILR1 aka DR4 or APO-2), TNF-related 
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apoptosis-inducing ligand receptor 2 (TRAIL2 aka DR5, KILLER and 
TRICK2), Death Receptor 6 (DR6), ectodysplasin A receptor (EDAR) and 
nerve growth factor receptor (NGFR) [Li and Yuan, 2008; Andera, 2009].  
The classical model for Fas-induced cell death states that Fas 
receptors are activated by binding of the Fas ligand (FasL) mainly 
produce by activated cytotoxic T Lymphocytes (LTc) and by Natural 
killers (NK). Binding of FasL induces Fas receptor trimerization and 
triggers a conformational change in the cytosolic part of the receptor. It 
exposes the DD of Fas allowing the recruitment of FADD (FAS-Associated 
Death Domain) through DD-DD interaction (Figure 5). Indeed, FADD 
contains a DD as well as a DED similar to the DED of caspases. FADD acts 
as an intermediate between pro-caspase-8 and the Fas receptor to 
create a complex called the Death-Inducing-Signaling-Complex (DISC). 
DISC allows several pro-caspases 8 to be close enough to be activated 
[Carrington et al., 2006]. Nevertheless, this model does not fit with 
recent observations made by NMR. Recently, Wang et al. created and 
analyzed by X-ray a hybrid crystal composed of mouse Fas receptor 
(mFas) and Human FADD (hFADD). This crystal seems to reflect rather 
well the human complex since analysis in solution of this chimera trough 
electron microscopy and mass spectrometry demonstrates that the size, 
the shape and stoechiometry appears to be conserved. According to 
Wang et al., the complex is composed by five Fas receptors and five 
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FADD. This new model bears a close similarity to the PIDDosome 
responsible for the activation of caspase-2 [Wang et al., 2010].  
 
 
Figure 6: NF-kB activation by TNFR1. Triggering of TNFR induces activation of the IKK complex. 
IKK complex triggers the phosphorylation of IκB, the Nf-κB (p50 and RelA complex) inhibitor. 
Released from its inhibition, NF-kB enters the nucleus and induces genes related to inflammation 
or cell survival. Modified from Pelzer and Thome, 2011.  
 
Activation of death receptors does not necessarily cause cell 
death. For example, the binding of TNFα on TNFR1 may lead to two 
different outcomes. Shortly after binding, the activated TNFR1 
oligomerizes and forms a complex with TRADD, RIP, TRAF2 and c-IAP1 
(Figure 5 and Figure 6). This structure called “complex I” activates the Iκκ 
complex, induces phosphorylation of IκB, the NF-κB repressor. NF-κB 
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controls the expression of numerous genes including pro-inflammatory 
cytokines like IL-1α, IL-8, COX-2, CCL-3… Interestingly, NF-κB also 
promotes cell survival by expression of anti-apoptotic proteins like BCL-
2, BCL-XL, cIAP, FLIP… (Figure 6) 
7
. 
On the other hand, the DD domain of TRADD and RIP can recruit 
procaspase-8 to form “complex II”. This leads to caspases-8 activation 
according to the “induced proximity model” and ultimately to apoptosis 
[Creagh et al., 2003; Micheau and Tschopp, 2003; Li and Yuan, 2008] 
The final outcome between cell death or survival depends on the 
balance between complex I and II. For example, NF-κB is able to induce 
the expression of c-FLIP (Cellular FLICE (FADD-like IL-1β-converting 
enzyme)-inhibitory protein (aka FLAME-1, FLICE-1, CASPER, CASH, MRIT, 
CLARP and usurpin)). Three c-FLIP isoforms exist: a long, a short and a 
“Raji” one (respectively c-FLIPL, c-FLIPS and c-FLIPR). They act as 
repressors of apoptosis induced by receptors such as Fas, TNFR1… 
Briefly, all c-FLIP isoforms possess two DED domains and therefore 
compete for FADD binding. The mechanism is quiet simple, with c-FLIPS 
and c-FLIPR proximity between procaspases-8 is inadequate and 
procaspases-8 are unable to induce their auto-activation. c-FLIPL acts in a 
similar manner if at high concentration at the DISC. Nevertheless, some 
studies demonstrate that c-FLIPL may act as a pro-apoptotic molecule 
under the condition of strong receptor activation or in the presence of a 
                                                 
7
 http://www.bu.edu/nf-kb/gene-resources/target-genes/ 
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high amount of the short isoforms (c-FLIPS and c-FLIPR). If one of these 
conditions occur, c-FLIPL stimulates the activation of caspase-8 at the 
DISC. In addition to caspases-8, two other c-FLIPL targets have been listed 
to this day: p43-FLIP and p22-FLIP. Both cleaved forms are inducers of 
NF-κB activity by binding to the Iκκ complex [Lavrik and Krammer, 2012]. 
 
Figure 7: BCL-2 family members. BCL-2 proteins are composed by one to four BCL-2 homology 
(BH) domains. The number of BH domains determines the classification into subcategories: anti-
apoptotic (four different BH domains), pro-apoptotic (three BH domains) and BH3-only with only 
one BH domain. 
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2.2.2. Intrinsic pathway of apoptosis 
 
Also called “mitochondrial pathway”, this pathway of apoptosis is 
triggered by different stimuli including DNA-targeting drugs [Chipuck and 
Green, 2008; Li and Yuan, 2008]. Intrinsic apoptosis involves the 
permeabilization of the mitochondrial outer membrane (MOMP for 
Mitochondrial Outer Membrane Permeabilization) by the pro-apoptotic 
members of the B-cell CLL/Lymphoma 2 (BCL-2) family. MOMP allows 
the release, into the cytosol, of apoptotic effectors such as cytochrome C 
(cyt C), SMAC/DIABLO, Omi/htrA2, AIF and EndoG localized in the 
mitochondrial intermembrane space. These proteins are important for 
caspases activation and DNA fragmentation. The release in the cytosol of 
such effectors often seals cell fate. This part aims to describe the most 
important features of the intrinsic pathway of apoptosis. 
 
 2.2.2.1. BCL-2 family 
 
Mitochondria are constantly protected by and under the threat 
of BCL-2 family members. This family can be subdivided into three 
different groups:  the anti-apoptotic proteins (BCL-2, BCL-XL, BCL-W, 
BCL-2A1, MCL-1 and BOO), the multi-domain pro-apoptotic proteins 
(BAX, BAK, BOK) and the pro-apoptotic “BH3 only” proteins (NOXA, 
PUMA, BAD, BIK, HRK, BIM, BMF). These three groups of proteins differ 
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from each other by the number of BCL-2 homology domains (BH) and 
the presence or not of a C-terminal transmembrane domain (Figure 7). 
Although additional subcellular localization are known, Pro-
survival BCL-2 family proteins are usually cytosolic or integrated to the 
outer membrane of the mitochondria. These proteins directly bind and 
inhibit the pro-apoptotic members. All pro-survival proteins possess four 
different BH domains: BH1, BH2, BH3 and BH4. It has been shown that 
an overexpression of each of these proteins protects cultured cells 
against different apoptotic stimuli [Müller-Röver et al., 2000; Lin et al., 
2001; Alam et al., 1997]. 
The pro-apoptotic multidomain proteins contain at least two BH 
domains but never more than three. Once activated, BAX and BAK 
oligomerize at the mitochondrial outer membrane (MOM) creating pores 
that allow the release of apoptotic effectors. It has been demonstrated 
that each of these proteins, when overexpressed in a cell line, triggers 
apoptosis. Finally, MEFs deficient for both BAX and BAK are unable to 
respond to a wide variety of apoptotic stimuli. These studies underline 
the essential role of BAX and BAK in the regulation of the apoptotic 
process [Lindsten et al., 2000; Rathmell et al., 2002]. 
The activity of BH-3 only proteins is regulated by different 
mechanisms including cleavage, sequestration, post-translational 
modification or gene expression. For example, in non-stressed cells, the 
BAD protein is phosphorylated on S112, S136 and S155 by Akt and PKA. 
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BAD phosphorylation on S112 and S136 induces 14-3-3 proteins binding 
and prevent the access of BAD to BCL-2 pro-survival proteins. In 
addition, phosphorylation of S155 inhibits the interaction of BAD with 
BCL-2 and BCL-XL [Dougherty and Morrison, 2004; Liu and Lin, 2005]. 
Under apoptotic stress, the serine/threonine phosphatase PP2A directly 
binds BAD and dephosphorylates S112. This dephosphorylation inhibits 
the interaction with 14-3-3 proteins and increases the access of other 
phosphatases. As mentioned above, BH3-only proteins can also be 
regulated through their gene expression. For example, in presence of 
DNA damages, activated p53 can induce PUMA expression and thus 
increase its intracellular levels leading to massive apoptosis [Nakano and 
Vousden, 2001]. 
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2.2.2.1. Mechanisms of action 
 
Different models explain how BCL-2 members interact at the 
mitochondrial surface and induce MOMP. Recently, a unified model has 
recently been proposed to explain all observation made so far. 
 
The “unified” model 
 
The unified model proposes a mechanism that explains all 
observations made experimentally. In this model, anti-apoptotic 
members of the family inhibit apoptosis by two “modes” and apoptosis 
relies on the cellular levels of BH3-only proteins [Llambi et al., 2011]. 
BCL-2 anti-apoptotic members bind BH3-only proteins. This inhibits 
multi-domain pro-apoptotic members activation by the same BH3-only 
proteins (MODE 1). On the other hand, anti-apoptotic members also 
bind active BAX or BAK and therefore inhibit MOMP formation (MODE 
2). When BH3-only concentration is too high, all anti-apoptotic members 
are on mode 1 and active pro-apoptotic members are free to generate 
MOMP (Figure 8). 
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Figure 8 : The unified model. Anti-apoptotic members of the BCL-2 family inhibit BAX or BAK by 
two modes. First, anti-apoptotic BCL-2 bind and sequestrate BH3-only protein (MODE1). BAK or 
BAX are loosely bound to the membrane but not embedded. If the concentration of BH3-only 
protein increases, some BAX and BAK proteins may be activated and insert into the membrane 
potentially inducing MOMP. Therefore, a second mode of inhibition exists. Once inserted, in the 
membrane, anti-apoptotic BCL-2 family member can directly sequestrate BAX or BAK. Finally, if 
too many BH3-only proteins are in presence, all anti-apoptotic proteins are in MODE1 and unable 
to inhibit BH3-only activated BAX or BAK. From Llambi et al., 2011. 
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2.2.2.3. Effects of Apoptotic effectors 
 
When MOMP is achieved, different mitochondrial 
intermembrane space apoptotic effectors (cyt C, SMAC/DIABLO, 
Omi/HTrA2, EndoG and AIF) relocate into the cytosol or nucleus. Those 
molecules act in complementarity to induce apoptosis by several 
mechanisms reviewed in this section. 
 
 2.2.2.3.1. Cytochrome C 
 
In case of mitochondrial membrane disruption, cyt C is thrown 
out of the mitochondria into the cytosol and interacts with the apoptotic 
peptidase activating factor-1 (Apaf-1). Apaf-1, a major component of the 
“apoptosome” complex, contains two WD-40 domains, a CARD domain 
and an ATPase domain8. In normal condition, the CARD domain of Apaf-1 
is trapped between the two WD-40 domains leading to Apaf-1 self-
inhibition. However, in the presence of cyt C, the CARD domain is 
exposed and Apaf-1 activated. ATP hydrolysis by the ATPase domain of 
Apaf-1 allows its oligomerization with six other Apaf-1-cyt C complexes, 
forming the apoptosome. The apoptosome recruits procaspase-9 
through CARD domains interaction. The close proximity of several 
                                                 
8
 NCBI, gene, APAF1. 
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procaspases-9 triggers their auto-activation into caspase-9 [Ledgerwood 
and Morison, 2009; Hengartner, 2000; Riedl and Shi, 2004] (Figure 9). 
 
Figure 9 : Apoptosis induction by Apoptosome formation. Following Cytochrome C release from 
the mitochondria, CARD domain of Apaf-1 is displaced by Cyt C, activating Apaf-1. Seven 
activated Apaf-1 combine to form a platform that recruits Pro-caspase-9. Pro-caspases-9 are in 
sufficient proximity to induce self-activation. From Ledgerwood and Morison, 2009. 
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2.2.2.3.2. SMAC/DIABLO and Omi/HtrA2 
 
The SMAC / DIABLO gene codes for an “inhibitor of apoptosis 
protein (IAP)-binding protein”
9
. Usually, IAPs inhibit caspase-3,-7 and -9 
activity (but not caspase-6 and -8) by obstructing the catalytic site 
and/or by ubiquitinating caspases for proteasome-dependent 
degradation [Huang et al., 2000]. In mammals, two types of IAPs exist. 
Those with a RING domain such as XIAP, c-AIP1, c-AIP2, Melanoma-IAP 
(ML-IAP) and IAP-like protein 2 (ILP2), and those without a RING domain: 
Neuronal apoptosis-inhibitory protein (NAIP), Bruce and survivin [Riedl 
and Shi, 2004]. XIAP inhibits caspase-9 by sequestering the pro-caspase 
form but in the same time inhibits caspase-3 and -7 [Shiozaki et al., 
2003]. On the other hand, casp-3 and -7 are also inhibited by c-IAP1, c-
IAP2 and NAIP trough catalytic site occlusion and degradation induction 
[Maier et al., 2002; Salvesen and Duckett, 2002]. SMAC/DIABLO inhibits 
procaspase-9 sequestration by XIAP. SMAC proteins hold a tetrapeptide 
IAP-binding motif composed of Ala-Val-Pro-Ile amino acids. This motif 
binds XIAP and competitively displaces procaspase-9 allowing its 
recruitment by the apoptosome. Worthy of note, SMAC/DIABLO cannot 
disrupt IAPs inhibition of effector caspases [Riedl and Shi, 2004]. Clear 
understanding of IAPs antagonists is lacunar and needs further 
investigations [Feltham et al., 2012] 
                                                 
9
 NCBI, gene, Diablo 
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Omi/HtrA2 also target IAPs through a tetrapetide IAP-binding 
domain. For example, it has been shown to interact with XIAP. In 
addition, Omi/HtrA2 seems to be able to cleave IAPs thanks to a serine 
protease activity. Finally, reports suggest that once in the cytosol, 
Omi/HtrA2 is able to induce caspase-independent cell death [Suzuki et 
al. 2004]. 
 
2.2.2.3.3. AIF and EndoG 
 
AIF and EndoG need caspases processing to be released from the 
intermembrane space of the mitochondria. Therefore, AIF and EndoG 
action is delayed by comparison to cyt C or SMAC/DIABLO [Arnoult et al., 
2003]. 
Apoptosis-inducing factor (AIF) was described by G. Kroemer 
[Susin et al., 1997]. AIF is a protein able to induce chromatin 
condensation as well as DNA fragmentation into large fragments [Susin 
et al., 1999]. In parallele to DNA fragmentation, AIF induces 
mitochondrial membrane permeabilization generating a kind of positive 
feedback loop. This action of AIF is inhibited in presence of an 
overexpression of BCL-2 [Susin et al., 1999]. 
Endonuclease G (EndoG) is able to relocate to the nucleus where 
it processes DNA into small fragments. Moreover, EndoG cooperates 
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with exonucleases and DNase I to facilitate DNA processing [Widlak et 
al., 2001]. 
 
2.2.3. Crosstalk between extrinsic and intrinsic 
pathways 
 
Extrinsic apoptosis may be enhanced by crosstalk with the 
intrinsic pathway. Observations report that in specific cells, such as 
Jurkat cells or CEM cells, activation of pro-caspase-8 leads to insufficient 
amount of activated caspase-8. In those cells, called Type II, an 
amplification of the apoptotic signal is required. The small amount of 
extrinsically-activated caspases-8 triggers the cleavage of Bid, a BH3-only 
BCL-2 family member, releasing a truncated form of Bid (tBid). tBid 
translocates to the mitochondria where it interacts with pro- and anti-
apoptotic members of the BCL-2 family to  trigger MOMP (Figure 10). 
The activation of effector caspases by caspase-9 is the add-on needed to 
induce apoptosis [Schütze et al., 2008]. 
 
2.2.4. Granzyme 
 
In lymphocytes, specific cellular compartments, called granules, 
sequestrate Granzymes (Grs) and perforin proteins. Grs are released by 
cytotoxic T lymphocytes and NK to induce cell death of cancer cells and 
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also virus infected cells. Perforins are pore-forming proteins that 
facilitate Grs transit to the cytosol [Bots and Medema, 2006; Ewen et al., 
2012]. Grs, on the other hand, are serine proteases and in human consist 
in 5 isoforms: A, B, H, K and M. Up to day, Granzyme H and K are orphan 
enzymes since no target has been identified and the mechanism of 
apoptosis induction remain unclear [Grossman et al., 2003].  
 
2.2.4.1. Granzyme A. 
 
Once in the cell, Granzyme A (GrA) attacks the mitochondria by 
cleaving NDUFS3, a protein implicated in the complex I of the electron 
transport chain. NDUFS3 cleavage disrupts the electron transport chain, 
generates reactive oxygen species (ROS) and induces the loss of 
mitochondrial potential. Increased ROS in the cytosol promotes the 
translocation of the ER-associated complex SET (Inhibitor of granzyme A-
activated DNase) into the nucleus. There, GrA induces SET degradation 
and releases NM23-H1 and TREX-1 known to induce nicks in the DNA. 
Moreover, GrA possesses other characteristics such as the ability to 
trigger lamins degradation leading to nuclear membrane disruption, 
PARP-1 degradation inhibiting DNA repair as well as degradation of 
transcription factors involved in the early repair response [Lieberman, 
2010; Bots and Medema, 2006]. Importantly, caspases are not activated 
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by GrA and loss of mitochondrial membrane integrity is not observed. 
[Bots and Medema, 2006] 
 
2.2.4.2. Granzyme B. 
 
On the contrary to GrA, Granzyme B (GrB) activates caspases. GrB 
induces apoptosis following several pathways. For example, GrB directly 
targets the BH3-only protein Bid and processes it into tBid leading to 
MOMP and apoptosome formation. On the other hand, GrB directly 
binds and activates caspases-8, -3 and -7 [Rousalova and Krepela, 2010]. 
Finally, GrB directly processes PARP, ICAD, Lamin B … [Bots and 
Medema, 2006; Rousalova and Krepela, 2010] 
 
2.2.3.3.  Granzyme M. 
 
Granzyme M (GrM) was originally thought to induce apoptosis in 
a caspase- and mitochondrial-independent manner.  Cells treated with 
granzyme M show a rapid degradation of the plasma membrane [Kelly et 
al., 2004]. However, contradictory informations were published recently 
suggesting the formation of ROS and the release of cyt C from 
mitochondria following GrM treatment [Hua et al., 2007]. Finally, GrM 
was reported to cleave PI-9, the main inhibitor of GrB. Therefore GrM 
may be a direct activator of GrB [Mahrus et al., 2004]. 
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Figure 10 : Summary of apoptosis induction. All proteins and mechanisms discussed above are 
summarized in this figure allows a more general view and points all interconnections between 
pathways. TNFR activation may lead to two different outcomes. First, activation may induce 
complexI formation and phosphorylate NF-κB’s inhibitor: the Iκκ complex. NF-κB enters the 
nucleus and induces the expression of inflammation-related gene. Otherwise, complex II may 
be induced and triggers caspasase-8 activation. Fas receptor activation only leads to caspase-8 
activation but may be inhibited by C-FLIP. Grz introduction through the cellular membrane via 
perforin channel also triggers cell death. Grz B directly cleaves proteins such as Bid but also 
activates caspase-3 while Grz A, however, seems to cleave NDUFS3 and to increase cellular ROS 
levels. tBid, activated by Grz but also by the caspase-2, activates the mitochondrial pathway of 
apoptosis and releases the apoptotic effectors such as cyt C (apoptosome activation), 
SMAC/DIABLO (XIAP inhibitors), AIF and EndoG (DNA cleavage). Finally, p53 is able to induce 
genes that directly induce apoptosis such as PUMA, BAX or even RAIDD that participate to 
PIDDosome formation. 
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Chapter 3: p53 
 
3.1. Introduction to p53 
 
The tumour suppressor p53 is one of the most studied protein in 
cancer research since it is estimated that at least 50% of cancers bear a 
mutated form of p53 [Levine and Oren, 2009]. In the remaining 50%, 
wild type p53 activity is altered following different mechanisms that will 
be discussed in this chapter. Today identified as a bona fide tumor 
suppressor, p53 was previously considered as an oncogene. This 
conclusion came following works from different teams analysing cancers 
related to Simian Virus 40 (SV-40) infection. A protein of ~53kDa was co-
precipitated along with the Large T antigen of SV-40 [Lane and crowford, 
1979; Linzer et al., 1979; Kress et al., 1979; Melero et al., 1979; Smith et 
al., 1979; Deleo et al., 1979]. Moreover, this protein was present in huge 
amount in different types of cancers in absence of SV-40 infection. The 
protein also seemed absent from normal cells [Benchimol et al., 1982; 
Crawford et al., 1982; Rotter, 1983]. With these observations, a 
hypothesis rapidly grew among the scientific community: this protein 
must be an oncoprotein favouring cell transformation. To demonstrate 
this theory, p53 was cloned from cancer cells and expressed in various 
cellular models. In each case, p53 promoted immortalization and 
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transformation [Eliyahu et al., 1984; Parada et al., 1984; Jenkins et al., 
1984].  
The oncogenic properties of p53 were challenged when a p53 
cDNA clone was shown to be unable to promote cell transformation. 
Rapidly, comparison with DNA sequences of clones used in previous 
studies demonstrated that mutated versions of p53 were employed. 
Moreover, this wild type form of p53 was prone to protect cells from 
transformation. 
 In order to be defined as a tumor suppressor, a protein must 
meet different criteria. First, the coding gene must be frequently 
mutated or deleted in cancer. This is the case for p53 as mentioned 
above and originally demonstrated by Vogelstein and colleagues. A 
second hallmark of tumor suppressors is that they inhibit cell 
transformation once activated or expressed. Indeed tumor suppressors 
are most often cell cycle inhibitors or programmed cell death inducers, 
which is the case of p53. Moreover, mice carrying a deletion of a tumor 
suppressor show a higher propension to develop cancer. Finally, tumor 
suppressors are often associated to a hereditary cancer syndrome. The 
Li-Fraumeni syndrome is a human pathology where humans bear a 
germline mutation of p53 and transmit it to their offspring [Levine and 
Oren, 2009]. Such individuals are prone to develop different cancers and 
have a reduced life expectancy. With knowledge of the Li-Fraumeni 
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syndrome, works on mouse models and the known cellular functions of 
p53, the protein was recognized in 1989 as a tumor suppressor. 
  The gene TP53 encodes for a transcription factor controlling 
several cellular pathways such as cell cycle [Jain et al., 2012; Tanaka et 
al., 2000], apoptosis [Mellert et al., 2011; Concannon et al., 2007], 
replicative senescence [Gannon et al., 2011; Vigneron and Vousden, 
2010], energy metabolism [Maddocks and Vousden, 2011; Hu et al., 
2009], angiogenesis [Ravi et al., 2002; Yamakuchi et al., 2009], immune 
response [Li et al., 2011], cell migration [Kim et al., 2011; Hwang et al., 
2010], cell differentiation [Jain et al., 2012; Aranha et al., 2011], 
autophagy [Livesey et al., 2012] and even EMT [Kim et al., 2011]. The 
protein p53 is stabilized and activated following a wide range of cellular 
stresses such as DNA damage [Shieh et al., 1997] or oncogene activation 
[Attardi et al., 1996; Hermeking and Eick, 1994]. In addition to its role as 
transcription factor, p53 is also able to relocate at the mitochondria and 
play a direct role in MOMP during apoptosis. 
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3.2. p53 structure 
 
The p53 protein contains 393 amino acids and is divided into 
three main parts, the N-terminal region, the DNA binding domain and 
the C-terminal region (Figure 11). 
 
 
Figure 11 : p53 protein structure. p53 N-terminal region (N-terminal domain on the figure) 
contains two transactivation domains (TAD1 and TAD2) subject to various post translational 
modifications. Moreover, the N-terminal region possesses a proline-rich domain where a 
polymorphism influencing p53 activity was identified. The central part of p53 is the DNA-binding 
domain. This region, frequently mutated in cancer, is responsible for the selective binding of p53 
to DNA. In this figure, six hotspots of mutation are presented (R175, G245, R248, R248, R273 and 
R282) and represent almost 30% of all p53 mutations in cancer. Finally, the C-terminal region (C-
terminal domain on the figure) contains a domain of tetramerization, as well as a nuclear 
localization and a nucler export signal. The C-terminal region is critical for the regulation of p53 
stability. It contains different lysines that can be ubiquitinated (K370, K372, K373, K381, K382 and 
K386). Modified from Vousden and Lu, 2002. 
 
The N-terminal region of p53 encompasses the 94 first amino 
acids of the protein. The domain is further divided into two 
transactivation domains, TAD1 (AA 1 to 40) and TAD2 (AA 40 to 61), and 
a proline-rich domain (PRD: residues 64 to 92) [Joerger and Fersht, 
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2008].  TAD domains are naturally weakly folded and responsible for 
interactions with several other proteins such as MDM2 and p300/CBP. 
They are subject to post-translational modifications that modulate p53 
stability, cellular localization or activity. There is 10 different 
phosphorylation sites located between Ser6 and Thr81. Each of them is 
thought to play a role in the modulation of p53 behavior. For example, 
Thr18 phosphorylation acts like a binary switch that disrupts the p53-
MDM2 complex. MDM2 is the main p53 repressor and affinity analysis 
demonstrated that Thr18 phosphorylation decreases MDM2 binding by 
more than 20-fold [Lee and Gu, 2010; Jenkins et al., 2012]. Moreover, a 
nuclear export signal (NES) is located in the N-terminal domain of p53. 
According to Zhang, the NES includes residues 11 to 27 and displays two 
serine residues phosphorylated after DNA damage (Ser15 and Ser20). 
Following stress, phosphorylation of these serines inhibits MDM2 
binding and in the same time inhibits NES functionality, allowing 
retention of p53 in the nucleus [Zhang and Xiong, 2001]. Finally, PRD 
function remains elusive. Some studies point its importance for proteins 
docking. For example, the prolyl isomerase Pin1 binds PRD and induces 
cis-trans prolyl isomerizations to inhibit MDM2 binding [Toledo and 
Wahl, 2007]. More recently, a team showed in vivo that mice lacking p53 
PRD were unable to elicit response to DNA damages induced by γ-
radiation and concluded that this must be an important region for signal 
integration [Campbell et al., 2012]. Finally, PRD possesses an interesting 
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polymorphism at residue 72 which can be either a proline or an arginine. 
Studies showed that this polymorphism could modify p53 structure and 
that the Pro72 allele was more represented in populations exposed to a 
higher levels of ultraviolet light. By looking at the functional differences 
between the two polymorphisms, Dumont et al. identified the Arg72 
variant as more efficient to induce apoptosis than the Pro72 variant due 
to its enhanced mitochondrial localization [Dumont et al., 2003]. 
The DNA binding domain (DBD), located between amino acids 95 
and 292 is responsible for specific interactions of p53 with DNA. 
Structurally, p53 DBD has an immunoglobulin-like β sandwich 
architecture. Two structural motifs bind the minor and major groove of 
the DNA. The L1 loop, the β-strand S2 and S2’ as well as the C-terminal 
helix are responsible for binding to the major groove. Arg273 located in 
the S10 β-strand also contacts the major groove (Figure 12 and Figure 
13). Binding to the minor groove relies on two large loops (L2 and L3) 
stabilized by a zinc ion. More specifically, the Zn ion interacts with 
Cys176, His179 from the H1 α-helix (inserted into the L2 loop), Cys238 
and Cys242 from the L3 loop. Finally, Arg248 and Ser241 directly contact 
the minor groove while the highly mutated residue Arg273 directly 
contacts the DNA backbone (Figure 13) [Joerger and Fersht, 2008]. 
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Figure 12 : Structural representation of p53 DNA binding Domain. p53 DBD contains three main 
loops: L1, L2 and L3. Alpha helices are represented by cylinder and beta strand sheats by arrow. 
Asteriks represents residues directly binding DNA. From Joerger and Fersht, 2008. 
 
Figure 13 : Structural binding of p53 to DNA. Arg282 contained in the C-terminal helix directly 
contacts the major groove of the DNA. On the other hand, Serine 241 and Arginine 248 from L3 
loop move into the minor groove and directly contact DNA. On this picture, it is possible to 
observe the Zn ion (purple dot) linking the H1 helix with the L3 loop (red and yellow arrow) [Xu et 
al., 2011].  
 
p53 binds to specific response element (RE) located in the 
promoter of its target genes. The DNA binding sequence of RE is 
composed by two decameric half sites separated by a spacer. The 
sequence may vary but a decameric consensus has been defined: 5’-
RRRCWWGYYY-3’. In other words, the sequence begins with three 
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purines (Adenine or guanine: R) followed by a cytosine (C), two adenines 
or thymines (W), a guanine (G) and three pyrimidines (thymine or 
cytosine: Y). Between each decameric half site stands the spacer. It 
consists in a variable sequence of 0 to 13 nucleotides. Analyses 
demonstrate that the shorter the spacer is, the stronger is p53 affinity 
for the RE. Therefore, a vast majority of p53 RE validated in vitro and in 
vivo possess a spacer shorter than 3 base pairs (BP) [Menendez et al., 
2009].  
The nature of the decameric sequence is extremely important. 
For example, replacing the C or the G in the CWWG sequence of the 
decameric motif drastically reduces p53 affinity for the RE. Furthermore 
quantitative analyses showed that the best CWWG sequence for 
enhancing p53 affinity was CATG [Veprintsev and Fersht, 2008]. This 
arrangement, found for example in the promoter of CDKN1, the gene 
coding for p21
Waf-1
, [Riley et al., 2009], allows a stronger activation than 
the other combinations [Menandez et al., 2009; Veprintsev and Fersht, 
2008]. The reason seems to be linked to the bending abilities of this 
sequence as compared to the other combinations [Menandez et al., 
2009; Nagaich et al., 1997].  
The majority of p53 mutations observed in cancer are located in 
the DBD. Those mutations abolish the sequence specific DNA binding of 
p53 [Brosh and Rotter, 2009]. By analyzing 25,902 cancer patients 
carrying a p53 mutation, six residues were found to be highly mutated. 
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These hot spots residues are: R248, R273, R175, G245, R249 and R282 
and represent together 28% of p53 mutation in cancer [Wong et al., 
1999; Freed-pastor and Prives, 2012]. Usually, mutations in p53 DBD are 
divided in two categories. Mutations of residues directly involved in DNA 
binding are called “DNA-contact mutation” (e.g. R248Q and R273H) and 
mutations that destabilize p53 structure are called “conformation 
mutant”. Finally, conformation mutants are further divided into local 
distortion mutants (e.g. R249S or G245S) or global structure distortion 
mutants (e.g. R175H or R282W) [Brosh and Rotter, 2009].  
The C-terminal region of p53 is 100 bp long and begins with the 
293th amino acid. It includes three different nuclear localization signals 
(NLS), a NES and a tetramerization domain. This part of p53 is subject to 
massive post-translational modifications impacting its stability, 
subcellular localization and its activity.   
The tetramerization domain (AA 325 to 356) is responsible for the 
assembly of p53 into a dimer of dimers [Joerger and Fersht, 2008]. In this 
tetrameric form, each p53 monomer binds a half site (RRRCW or WGYYY) 
of the double decameric sequence composing the RE. Nicholls et al. 
showed that p53 dimerization occurs directly after translation whereas 
the tetrameric form needs a high concentration of the dimer [Nicholls et 
al., 2002; Joerger and Fersht, 2008] and some stabilizing post-
translational modifications (such as phosphorylation of Ser392) to form 
[Sakaguchi et al., 1997].  
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The tetramerization domain of p53 contains a NES. This NES is 
efficient to relocate p53 in the cytosol via exportin 1. During 
tetramerization, NES of all four p53 monomers are masked in the center 
of the structure. This favors the nuclear retention of p53 [Stommel et al., 
1999]. MDM2 also plays a role in p53 localisation. MDM2 is an E3 
ubiquitin ligase binding the N-terminal region of p53. MDM2 is able to 
ubiquitinate p53 on specific lysines of its C-terminal region. 
Ubiquitination has been demonstrated to inhibit dimerization and 
therefore to unmask the NES. Therefore, ubiquitinated p53 undergoes 
nuclear export [Liang and Clarke, 2001]. 
There are also three NLS in the C-terminal part of p53: NLSI (313-
322), NLSII (366-372) and NLSIII (376-381) [Shaulsky et al., 1990]. NLSI 
seemed to be the most active NLS among all but more recent studies 
demonstrates that alone, NLSI is unable to induce p53 nuclear 
localization. It emerges that a motif containing Lys305 and Arg306 is 
essential, in association with NLSI, for the binding of p53 to importin α 
[Liang and Clarke, 2001].  
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3.3. Central regulation 
 
The tumor suppressor p53 is a transcription factor involved in the 
transcription of many target genes. p53 reacts to several stresses such as 
hypoxia, DNA damage or oncogene activation by modulating cellular 
processes such as cell cycle, senescence or even cell death. It is therefore 
compulsory to ensure that such pathways are inactive in normal 
condition and rapidly induced following a stress. Under normal 
condition, p53 is constantly expressed and degraded. The physiological 
advantage lies in the quicker response that may be induced following a 
stress. Indeed, the expressed p53 just needs to be stabilized in order to 
become functional [Hock and Vousden, 2014]. 
Human double minute 2 (MDM2) is a RING (Really Interesting 
New Gene) domain E3 ubiquitin ligase that mainly ubiquitinates p53. 
MDM2 promotes p53 degradation by adding ubiquitin residues on six 
lysines located in the C-terminal region of p53: K370, K372, K373, K381, 
K382, and K386 [Lee and Gu, 2010]. Following polyubiquitination, p53 
undergoes proteasome-dependent degradation. This mechanism 
represents the main pathway regulating p53 levels. MDM2 is the major 
ubiquitin ligase targeting p53, however, it is not the only one [Hoffman 
et al., 2014; Haupt et al., 1997; Honda et al., 1997]. PIRH2 [Leng et al., 
2003], ARF-BP1 [Shmueli and Oren, 2005] and COP1 [Dornan et al., 2004] 
also ubiquitinate p53 in vitro and in vivo. Interestingly, small molecules 
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inhibiting the binding between MDM2 and p53 are efficient to induce a 
p53-dependent cellular response. This underlines the importance of 
MDM2 [Issaeva et al., 2004]. 
Human double minute X (MDMX or MDM4) is closely related to 
MDM2. It also targets p53 and possesses a RING domain. Nevertheless, it 
seems that MDMX is unable to ubiquitinate p53 [Hock and Vousden, 
2014]. More analyses showed that MDMX interacts with MDM2. It has 
been demonstrated in vivo that this heterocomplex was required for a 
proper regulation and polyubiquitination of p53 [Huang et al., 2011; 
Wang et al., 2011]. Loss of MDMX or MDM2, the mouse variants, results 
in embryonic lethality in null-mice. Interestingly, loss of TP53 [Jones et 
al., 1995; Parant et al. 2001] rescues the embryonic lethality [Steinman 
et al., 2005]. In addition to point the real importance of MDM2, those 
studies also indicate that other ubiquitin ligases are not efficient, alone, 
in controlling p53 activity during embryonic development.  
The main p53 repression is due to MDM2-dependent 
ubiquitination. However, both HMD2 and MDMX repress p53 function 
by other mechanisms. For example, both proteins bind p53 on its N-
terminal region and inhibit its transcriptional activity. Indeed, they 
prevent access to co-activators such as CBP/p300. MDM2 was also 
shown to recruit HDACI [Ito et al., 2002] and MDM2 binding slightly 
modifies p53 conformation so that DNA binding is impaired [Cross et al., 
2011]. Finally, MDM2 binds and ubiquitinates JMY. JMY (“Junction-
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mediating and -regulatory protein”), is a transcription factor important 
for p53 target genes expression. It is recruited by p300 and favor gene 
transcription. In normal cells, MDM2 induces the degradation of JMY, 
impairing expression of it target genes. This adds a new layer of 
complexity in the regulation of p53 transcriptional activity regulation 
[Coutts et al., 2007]. 
More recently, MDM2 was shown to mono-ubiquitinate p53 with 
a different outcome. Indeed, instead of targeting p53 to the proteasome, 
monoubiquitination in presence of a low levels of MDM2 [Wang et al., 
2011] induces nuclear export of the protein [Li et al., 2003]. In the 
cytosol, p53 monoubiquitinated forms may either be sequestrated by E3 
ligases such as WWP1 [Laine and Ronai, 2007] or Ubc13 [Laine et al., 
2006] or either relocated to the mitochondria.  
Finally, MDM2 expression is regulated by p53. p53 is able to bind 
with high affinity to the MDM2 promoter and directly triggers its 
expression. Therefore, a negative feedback loop exists in order to 
precisely control p53 cellular levels and activity [Wu et al., 2004]. 
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3.4. Regulation of p53 transcriptional activity 
 
The classical activation pathways of p53 are reviewed by several 
papers [Riley et al., 2009; Prives and Hall, 1999; Vousden and Prives, 
2009]. It consists in successive steps: p53 stabilization, sequence specific 
DNA binding and target genes expression. 
 
3.4.1. p53 stabilization 
 
Following stresses (such as DNA damage or oncogene activation) 
p53 is stabilized and activated. Its half-life increases from minutes to 
hours. The crucial step leading to p53 increased half-life resides in the 
suppression of the MDM2/MDMX-p53 interaction. Stresses are different 
by nature, therefore mechanisms targeting p53-MDM2 interaction may 
vary. For example, oncogene activation leads to the induction of ARF. 
ARF directly binds MDM2 on its acidic region (residues 237-268) 
[Manfredi, 2010] and inhibits its interaction with p53. On the other 
hand, DNA double strand breaks will rather activate the ATM kinase 
(“Ataxia telangiectasia mutated”) while DNA damages induced by 
replication stresses or DNA crosslink will rather involve ATR (“Ataxia 
telangiectasia and Rad3-related protein”) [Meek, 2009]. ATM and ATR 
are both kinases that activate p53 by different mechansims: 1) ATM and 
ATR phosphorylate and activate other kinases involved in the 
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stabilization of p53 such as CHK1 and CHK2 [Gatei et al., 2003; Branzei 
and Foiani, 2008]; 2) ATM and probably ATR phosphorylate MDM2 and 
MDMX. MDM2 phosphorylation stimulates auto-ubiquitination and 
destruction while phosphorylation of MDMX stimulates MDM2-
dependent ubiquitination and degradation of MDMX [Stommel and 
Wahl, 2004; Chen et al., 2012; Chen et al., 2005]; 3) Finally, ATM and ATR 
directly phosphorylate p53 on Ser15 [Ollson et al., 2007]. This 
phosphorylation is important for MDM2-p53 complex disruption 
[Momand et al., 2000]. Indeed, pSer15 was shown to be necessary for 
the subsequent phosphorylation of Thr18 and Ser20 [Saito et al., 2003]. 
Altogether, these mechanisms inhibit p53 ubiquitination and stabilize 
the tumor suppressor. 
 
3.4.2. Sequence-specific DNA binding and target genes 
expression 
 
In the classical model, the binding of p53 to specific DNA 
sequences is the second main step. This step is influenced by the nature 
and the intensity of the stress. In function of the intensity, different p53 
post-translational modifications may occur which modulate its stability 
or improve its binding to the so-called low-affinity promoters.  Among 
modifier proteins that further stabilize p53, there are acetyltransferases 
(p300, CBP, TIP60 [Ollson et al., 2007; Riley et al., 2009]), 
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methyltransferases (SET9 or SMYD2 [Ollson et al., 2007]) and kinases 
(HIPK2, DYRK2, p38MAPK [Kruse and Gu, 2009; Ollson et al., 2007]). As 
discussed earlier, the RE of a promoter may be more or less suitable to 
p53 binding. For example, p53 possesses a high affinity for the promoter 
of the genes coding for p21
WAF-1
, MDM2 or GADD45α. Therefore, after 
stabilization, p53 preferentially binds and induces expression of those 
genes [Riley et al., 2009]. In other circumstances, genes involved in 
senescence may be expressed. However, this requires modifications 
such as phosphorylation of Ser376 and loss of phosphorylation of Ser392 
[Webley et al., 2000]. Finally, if the stress reaches a critical threshold, 
apoptosis is induced. Here, important post-translationnal modifications 
include phosphorylation of Ser46 [Oda et al., 2000; Li et al., 2005] and 
acetylation of Lys120 for the expression of p53AIP1, BAX and PUMA 
[Sykes et al., 2006]. These additional post-translational modifications 
increase p53 affinity for the RE located in the promoter of pro-apoptotic 
genes. According to the authors, it is not clear if these post-translational 
modifications enhance p53 affinity for the DNA sequence or if it helps to 
recruit specific cofactors [Oda et al., 2000; Sykes et al., 2006]. 
Concerning K120, since this residue is directly located in the DBD, 
recruitment of cofactors would seem less plausible than enhancement of 
p53 affinity. However, the K120R p53 mutant is still located on the 
PUMA and BAX promoters [Sykes et al., 2006] (Figure 12 and Figure 13). 
Further investigations are needed to confirm the mechanisms involved. 
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3.5. Recent advances on p53 function. 
 
Recently, several papers challenged the relative importance of 
the three canonical cellular responses of p53 and highlighted the 
importance of p53 in metabolism regulation, stem cell maintenance, 
invasion and metastasis. 
The tumor suppressor p53 classically promotes cell cycle arrest, 
senescence or apotosis. However, some teams recently suggested that 
these pathways of p53 were mainly built using radiation and 
doxorubicin, agents triggering acute DNA damages and the above 
mentonned p53-mediated responses. Therefore, our current knowledge 
about p53 would only be a part of all p53 abilities.  
In 2012, Li et al. generated mice expressing p53
3KR
. In this model, 
three normally acetylated lysines important for p53 binding to DNA are 
replaced by three arginines. MEFs generated from this model are unable 
to trigger cell cycle arrest, apoptosis and senescence in response to 
ionizing radiation. The reason lies in the unability of p533KR to induce 
several genes among which Puma, Cdkn1a (gene coding for p21), 
Serpine1 and Pml (two genes involved in senescence induction). 
However, mice Trp53
3KR/3KR
 are less prone to develop tumors than Trp53
-
/- 
mice. By analyzing the remaining transcriptional activity under acute 
DNA damage, they showed that p53
3KR
 cells were able to activate genes 
such as glutaminase 2 (Gls2), TpP53-induced glycolysis and apoptosis 
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regulator (Tigar) and gluthation peroxidase 1 (Gpx1). In addition, basal 
levels of p533KR were able to regulate glucose uptake, restrain glycolysis 
and inhibit ROS accumulation [Li et al., 2012]. These remaining activities 
were suggested to play a crucial role in tumor suppression. 
Another clue of the importance of other activities of p53 came 
from Valente et al. They generated triple knock out mice for Cdkn1a, 
Puma and Noxa. These mice are deficient for p53 dependent apoptosis 
and cell cycle arrest following DNA damage. Furthermore, fibroblasts 
isolated from the triple KO are partially deficient for senescence 
induction in presence of etoposide. However, these mice were free from 
tumor until the age of 500 days while Trp53-/- mice developped tumors 
after 250 days. Therefore, in normal cellular condition, Cdkn1a, Puma 
and Noxa are not necessary to prevent tumorigenesis. This underlines, 
the importance of other p53 pathways in tumor prevention [Valente et 
al., 2013]. 
Finally, Brady et al. analyzed a p53
25,26
 knock-in mouse model 
where p53 is mutated in the first TAD domain (L25Q, W26S) and 
therefore unable to trigger the expression of the most common p53 
dependent genes. However, p53 retained a  tumor suppressive ability. 
By analyzing differences in genes expressed by wild type p53 and p5325,26 
in oncogene-expressing MEFs, genes implicated in DNA repair, signaling 
and regulation of the cytoskeleton were identified. Further experiments 
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where those “hits” were downregulated showed an increase of tumor 
growth in allografts tumor assays [Brady et al., 2011]. 
 The above studies suggest that other pathways than the 
canonical cell cycle arrest, apoptosis and senescence pathways are able 
to be induced by p53 and participate to the maintainance of cell 
integrity. A role of p53 has now been identified in various pathways such 
as glycolysis inhibition, autophagy induction, inhibition of the 
reprogramming of differientiated cells into pluripotent cells, inhibition of 
EMT and inhibition of the modification of the surrounding ECM (e.g. by 
expression of anti-angiogenesis molecules such as Tsp1) [Bieging et al., 
2014].  It is however clear that cells harboring full p53 functions will 
rapidly undergo cell cycle arrest, senescence or apotosis in response to 
an insult such as DNA damage. These other mechanisms may also 
represent a back-up plan in case of problems with classical p53 
pathways. 
To conclude, earlier studies determined that p53 inhibits tumor 
development by triggering cell cycle arrest, senescence or apoptosis. In 
order to continue our road towards the most potent p53 based 
therapies, a full understanding of p53 many functions is crucial. All p53 
dependent mechanisms controlling cell growth and proliferation must be 
identified and characterized to determine their potential for the 
development of therapies. In the future, therapies will focus on p53 
70 
 
 
dependent mechanisms that are the most relevant for the cell type and 
the tumor environment. [Bieging et al., 2014]. 
 
3.6. Non-transcriptional functions of p53 
 
First evidences for a non-transcriptional function of p53 came 
from observations describing non-nuclear p53 accumulation during 
apoptosis [Speidel, 2009] as well as p53-dependent apoptosis in the 
absence of transcription or protein synthesis [Caelles et al., 1994; Gao 
and Tsuchida, 1999]. In 2000, Marchenko et al. crossed these 
observations with the fact that in eukaryotic cells, mitochondria are 
critical player in apoptosis. They found small amounts of p53 localized at 
the mitochondria following a stress such as DNA damage or hypoxia. 
Mitochondrial p53 was absent in normal non-stressed cells [Marchenko 
et al., 2000]. Since this first observation, mitochondrial functions of p53 
as well as the mechanisms allowing its mitochondrial localization have 
been investigated.  
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3.6.1. p53 mitochondrial translocation requires MDM2-
mediated mono-ubiquitination 
 
Mitochondrial relocalization of p53 is observed following 
different stresses such as DNA damage, hypoxia, irradiation and 
cytotoxic drugs [Speidel, 2009]. Moreover, targeting p53 to the 
mitochondria by fusing it to a mitochondrial localization signal (MLS) is 
sufficient to induce massive cell death [Dumont et al., 2003]. Rapidly, 
data suggested that the non-transcriptional apoptotic activity of p53 
relies on its ability to trigger MOMP through interactions with BCL-2 
family members [Speidel, 2009].  
In unstressed cells, observations established that p53 shuttles 
between the nucleus and the cytosol. Furthermore, it accumulates in 
both locations when stabilized [Speidel, 2009].  Muyang Li et al. 
confirmed that a high MDM2 concentration leads to the poly-
ubiquitination of p53 and its proteasome-dependent degradation. 
Nevertheless, a low levels of MDM2 induces mono-ubiquitination and 
p53 nuclear export [Li et al., 2003]. Mechanisms leading to p53 
mitochondrial relocalization are not completely resolved. However, a 
first description of the importance of p53 ubiquitination was published 
in 2003. It has been shown that the p53 Arg72 polymorphism variant 
was more relocated to the mitochondria and more prone to induce 
apoptosis as compared to the Pro72 variant. Authors linked this 
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observation to a better binding of the Arg72 variant to MDM2. This 
enhanced binding leads to a greater ubiquitination and CRM-1 
dependent nuclear export of the tumor suppressor. Moreover, the 
authors presented evidence of ubiquitinated forms of p53 at the 
mitochondria [Dumont et al., 2003]. Marchenko et al. who already 
demonstrated the presence of p53 at the mitochondria, later made the 
observation that mono-ubiquitination was a mitochondrial relocalization 
signal for p53. Moreover, by analysing a p53-BCL-2 protein complex, 
they found that all p53 proteins involved in the complex were ubiquitine 
free. Therefore they hypothesize that the protein HAUSP deubiquitinates 
p53 at the mitochondria and that non-ubiquitinated active forms of p53 
are able to induce mitochondrial apoptosis [Marchenko et al., 2007]. 
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3.6.2. Mitochondrial apoptosis: mechanisms of 
induction 
 
At the mitochondria, p53 acts as a BH3-only protein and 
modulates BCL-2 members activity. Three mechanisms were reported 
[Fuster et al., 2007]. 
 
3.6.2.1. BAK-MCL-1 complex disruption 
 
This mechanism relies on disruption of an inhibitory MCL-1-BAK 
complex located at the surface of the MOM. Following a stress, p53 is 
relocated to the mitochondria and directly interacts with BAK. p53-BAK 
complex formation correlates with BAK oligomerization, release of Cyt C 
and loss of interaction between BAK and MCL-1. Therefore, a model in 
which p53 displaces BAK from its inhibitory complex was suggested.  In 
addition, p53 was shown to induce a conformation change of the BAK 
protein required for its oligomerization [Leu et al., 2004].The authors 
also describe that p53 does not interact with BAX or BCL-XL. Moreover, 
p53 is unable to trigger MOMP and Cyt C release in presence of BAK -/- 
mitochondria. Further studies revealed that Lys120 acetylated forms of 
p53 were enriched at the mitochondria and that this post-translational 
modification was important for the ability of p53 to disrupt the BAK-
MCL-1 complex [Sykes et al., 2009]. 
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3.6.2.2. Cytosolic BAX activation 
 
Chipuk et al. demonstrated that, following a stress, p53 
accumulation in the cytosol was efficient to activate cytosolic BAX and 
trigger its oligomerization at the MOM. Here, however, no binding 
between BAX and p53 was detected by co-immunoprecipitation. 
Therefore, authors hypothesize a “hit and run” mechanism to explain 
BAX activation by p53 [Chipuk et al., 2003]. They proposed that cytosolic 
p53 binds the inhibitory BCL-XL protein. De novo synthetized PUMA, a 
transcriptional target of p53, displaces p53 from this inhibitory complex. 
This allows p53 to activate cytosolic BAX. However, authors also raised 
the possibility that the high p53 concentration in stressed cell may 
exceed cytosolic BCL-XL concentration [Chipuk et al., 2005].  
 
3.6.2.3. Inhibition of BCL-2 and BCL-XL 
 
Moll and co-workers showed the direct binding of p53 with BCL-
XL but also BCL-2 and hypothesize that p53 binding neutralizes the 
inhibitory effect of these proteins on BAX and BAK. This hypothesis is 
supported by evidences establishing that following stress, concentration 
of p53-BCL-2 complex was rather enhanced than diminished. Moreover, 
this is correlated with the loss of BCL-2-BAX or BCL-XL-BAX complexes 
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present at the mitochondria. Therefore the idea is that p53 displaces 
pro-apoptotic BCL-2 members from their inhibitory complex [Mihara et 
al., 2003]. However, Chipuk et al. described that in stressed cells, p53-
BCL-XL complex concentration decreases. According to that, the 
hypothesis is made that the BCL-2-p53 complex is an inhibitory complex 
that sequestrates p53 and prevents it to exert its pro-apoptotic function 
by activating BAX and BAK proteins [Chipuk and Green, 2004].  
 
Figure 14 : Mitochondrial pro-apoptotic activities of p53. Following a stress, activated p53 
enters the nucleus and induces the expression of genes implicated in apoptosis induction such as 
PUMA, NOXA or BAX. In parallel, p53 is relocated to the mitochondria and induces MOMP 
formation by three mechanisms. A) p53 displaces BAX from its inhibitory complex with BCL-XL 
and allows BAX to oligomerize and trigger MOMP. B) p53 displaces BAK from its complex with 
MCL-1. p53 activates BAK by inducing a change in BAK conformation allowing MOMP formation 
by BAK oligomerization. C) p53 activates cytosolic BAX following the “hit and run” model. Worthy 
of note, this model requires the implication of PUMA to displace p53 from its complex with BCL-
XL. From Fuster et al., 2007.  
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3.7. p53 alteration in cancer and p53-based 
therapies. 
 
Reasons for p53 impairment in cancer are numerous: mutations, viral 
infection, overexpression of upstream inhibitors, loss of activators or 
downstream effectors, nuclear exclusion... (Figure 15). They will be 
discussed below. 
 
3.7.1. p53 mutation 
 
As described earlier, p53 impairment may be the results of a 
mutation (missense, nonsense or insertion/deletion) of the TP53 gene 
leading to the production of a non-functional form of p53. According to 
Brosh, mutations of p53 occur in approximately 50% of cancers but 
incidence varies among cancer types. For example, TP53 mutation 
reaches only 10% in haematopoietic malignancies but reaches up to 70% 
in ovarian, colorectal and head and neck cancers [Brosh and Rotter, 
2009]. It is demonstrated that restoring p53 function sensitizes 
established cancers to apoptosis or senescence and leads to tumor 
regression [Sharpless and Depinho, 2007]. Several molecules were 
recently shown to restore p53 function and inhibit the oncogenic 
properties of p53 mutants. For example, Y220C is a mutation commonly 
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found in cancer and is responsible for the destabilization of the core 
structure of p53. Recently, several teams used compounds (such as 
benzothiazoles) and demonstrated a regain of activity of p53. For 
example, Liu et al. demonstrated that PK7088 was able to bind p53 and 
increase the concentration of mutant p53
Y220C
 with the correct 
conformation. Moreover, transcriptional analysis showed an increased 
level of p21 and NOXA whereas nutlin-3a had no effect [Liu et al., 2013]. 
Another example is PRIMA-1 (2,2-bis(hydroxymethyl)-1-
azabicyclo(2.2.2) octan-3-one) and its more active derivative PRIMA-
1MET. So far, PRIMA-1MET is the most advanced drug in clinical studies, 
already reaching phase II clinical trials [Hao and Cho, 2014]. PRIMA-1 and 
also its MET version were identified by library screening for their ability 
to restore active conformation to mutants of p53, allowing DNA binding 
and apoptosis induction [Bykov et al., 2002]. Analyses demonstrate that 
PRIMA-1
MET
 is active against several types of cancer in xenograft mouse 
models and has only little side effects [Zache et al., 2008; Zandi et al., 
2011]. Interestingly, almost all mutants are sensitive to PRIMA-1
MET
 and 
only the Phe176 mutant was shown to be insensitive to the molecule 
[Duffy et al., 2014]. In addition, PRIMA-1 enhanced the action of drugs 
currently used in cancer chemotherapy such as doxorubicin [Magrini et 
al., 2008].  
Finally, 8% of all mutations occurring in TP53 give rise to a truncated 
form of p53 due to nonsense mutation. Recent work identified drugs 
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able to promote read-through non-sense mutation [Khoo et al., 2014]. For 
example, Floquet et al. showed that aminoglycoside antibiotics, such as 
G418, are able to stabilize the mutant mRNA of p53 and to inhibit its 
degradation by non-sense mediated decay. Treatment with G418 leads 
to the production of a functional full-length p53 and a reduction of 
viability of cells bearing such mutations due to P21 and BAX expression 
[Floquet et al., 2011]. 
 
3.7.2. Viral infection 
 
Some cancers, such as cervix cancers, are linked to a viral infection 
with human papillomavirus (HPVs). HPVs family consists in more than 
100 subtypes of small DNA viruses classified in high and low risk HPVs 
[Duensing and Münger, 2004]. High-risk HPVs express two oncoproteins, 
E6 and E7 targeting p53 and RB respectively. E6 enhances the 
proteasome-dependent degradation of p53, FADD and caspase-8 [Yuan 
et al., 2012] while E7 binds and inhibits Rb protein [Thomas and Laimins, 
1998]. In addition to inhibit p53 function, E6 protein was recently shown 
to trigger cancer cell migration. E6 downregulates miR-23b expression 
and increases the expression of its main target, the urokinase-type 
plasminogen activator (uPA) [Au Yeung et al., 2014]. uPA favors EMT, 
mesenchymal stem cell migration and transendothelial migration, all 
characteristics of metastatic dissemination [Jo et al., 2009; Krstic et al., 
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2014]. Although, E6 and E7 alone are not able to transform cells and 
additional events are required [Duensing and Münger, 2004], it is clear 
that HPVs favour cell transformation by inhibiting critical cellular 
gatekeepers function and by enhancing cell motility. 
Currently, there is no effective antiviral agent available on the 
market. Although some molecules, like bortezemib were recently shown 
to block the function of the E6 protein in HPV-positive HNSCC cells [Li and 
Johnson, 2013]. Therefore, specialists focus on vaccination with Gardasil 
(Merck) or Cervarix (GlaxoSmithKline) in order to prevent infections by 
HPV-16 or -18. In the future, high throughput screening approaches will 
aim to identify compounds inhibiting E6/E6-Associated Protein (E6AP) 
association responsible for the E6-mediated degradation of p53 [Yuan et 
al., 2012]. 
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3.7.3. Upstream regulators 
 
Upstream activators inefficiency may be responsible for a decreased 
p53 activity. For example, loss of ARF reinforces MDM2 inhibition and 
therefore compromises p53 stabilization in presence of diverse 
oncogenes [Sherr and Weber, 2000]. In the same manner, dysfunction of 
kinases involved in p53 stabilization such as ATM or CHK2 may alter p53 
stabilization and activity [Johnstone et al., 2002]. On the other hand, the 
overexpression of a direct repressor of p53 like MDM2 or MDMX may 
also lead to p53 enhanced degradation [Ramos et al., 2001; Tovar et al., 
2006; Reifenberger et al., 1993]. Development of molecules inhibiting 
MDM2 and/or MDMX is currently performed. Nutlins are probably the 
most investigated family of molecules so far. Nutlins mimic p53 residues 
responsible for MDM2 binding (Phe19, Trp23 and Leu26 [Chène, 2003; 
Duffy et al., 2014]). They block the docking pocket of MDM2 and inhibit 
its interaction with p53. In animal models, a low toxicity was observed. 
Moreover, an increase in p53 concentration and an enhanced apoptosis 
is observed [Duffy et al., 2014]. However, so far, complete tumor 
regression in animal models remains elusive. Therefore the development 
of a new generation of molecules such as MI-219 has been undertaken 
with good results in cell models. Another molecule, RG7112 binds 
MDM2 similarly to Nutlin-3a but with a much higher affinity. Moreover, 
81 
 
 
in vivo experiments demonstrate a regression of tumors from various 
origins. RG7112 currently undergoes phase I of clinical trials.  
Unfortunetly, these molecules are designed to target MDM2 only. It 
is well known that in addition to MDM2, MDMX can also be 
overexpressed in cancer cells, notably in melanomas. Therefore a 
coumpound targeting both molecules would be interesting [Khoo et al., 
2014]. Even if inhibitors of MDMX exist, for example SJ-172550 [Reed et 
al., 2010], efforts are now made to develop small molecules inhibiting the 
binding of both MDMX and MDM2 to p53.  
 
3.7.4. Nuclear exclusion 
 
In 1994, Ryan et al. described, for the first time, a mechanism in 
which p53 trafficking was impaired in presence of an overexpression of 
BCL-2 [Ryan et al., 1994]. A year later, Moll et al. also noticed that wt 
p53 could be sequestrated into the cytosol and hypothesized that 
sequestration may be a novel mechanism for p53 inactivation [Moll et 
al., 1995]. Years later, Nikolaev et al. demonstrated that Parc, a Parkin-
like ubiquitin ligase, acts as a cytoplasmic anchor for p53 and inhibits its 
nuclear relocalization. Moreover, RNAi targeting of Parc significantly 
reduces cell resistance to DNA damages [Nikolaev et al., 2003].  
Chaperones of the HSP70 family can also be responsible for a 
reduced nuclear relocalization of p53. This is the case, for instance, of 
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the mitochondrial heat shock protein mortalin (aka Mot-2, GRP75 or 
HSP74) also located at the endoplasmic reticulum and in the cytosol. An 
overexpression of mortalin is observed in MCF-7, HCT-116 and Saos-2 
cell lines as well as in leukaemia and liver metastasis [Wadhwa et al., 
2006; Gestl and Böttger, 2012]. This is correlated with an enhanced p53 
cytosolic localization. The complex between p53 and mortalin inhibits 
p53 entry into the nucleus and can also abolish its interaction with BCL-2 
family members. Therefore, mitochondrial and transcriptional apoptosis 
are both inhibited. Targeting wt p53 sequestration may be an efficient 
approach to restore p53 function. Maureen Murphy and colleagues are 
currently developing molecules, notably 2-Phenylethynesulfonamide 
(PES) that interacts selectively with HSP70 and disrupts its association 
with partners such as p53. Data demonstrate that PES can suppress 
tumor development in a mouse model [Leu et al., 2011]. Besides, and in 
association with professor Murphy, our laboratory will soon test next 
generation compounds to establish their potential effects on inhibition 
of p53 sequestration as well as reactivation of mutant forms of p53.  
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3.7.5. Downstream inhibition 
 
Finally, every inhibition or alteration of effectors of the p53-
dependent response as well as overexpression of inhibitors of pathways 
located downstream of p53 may also compromise the activity of the 
tumor suppressor. A rather well documented example is the 
overexpression of the anti-apoptotic BCL-2 family members. When 
activated, p53 induces the expression of BH3-only proteins such as 
PUMA and NOXA and therefore favours MOMP. In the case of an 
overexpression of one or several anti-apoptotic BCL-2 members as 
observed in hematologic malignancies [Reed, 2008], the ratio between 
pro- and anti-apoptotic proteins is disturbed and apoptosis may be 
inhibited. 
Several molecules called BH3-mimetics were developed to restore 
the mitochondrial apoptosis pathway. Gossypol is one of them and has 
been discovered for its antifertility properties. Apogossypol, an 
analogue, seems to better target BCL-2 and MCL-1 and therefore induce 
fewer side effects. Mechanistically, gossypol targets the hydrophobic 
groove of anti-apoptotic BCL-2 members that interacts with BH3-only 
proteins. Therefore, in its presence, p53-dependent expression of BH3-
only proteins may activate BAX or BAK and trigger MOMP [Kang and 
Reynolds, 2009].  
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Figure 15 : Heterogeneity of p53 inactivation in human cancer. Mutation, viral infection, 
upstream inhibitor overexpression, nuclear exclusion and downstream inhibition are among the 
main modes of p53 inactivation in cancer. Therapies focus on restoring the wt activity to the 
mutant forms of p53, on inhibiting interactions that compromise wt p53 function as well as on 
prevention of viral infection. 
 
Therapies based on p53 were developed on our current knowledge 
of p53. As discussed above, molecules inhibiting protein-protein 
interactions or refolding mutated forms of p53 are among the most 
advanced p53 based therapies. In addition, it seems more and more 
clear that the cell type and the alterations beared by the tumor will be 
important factor to determine the best suited therapy.  With the recent 
demonstration of unknown or rather underestimated functions of p53, 
new therapies will possibly rise and bring new alternatives to treat 
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patients. Combination of old and new methods may represent the future 
of clinical therapies.   
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Table 1 : MAGEA expression measured by RT-PCR in several cancer lines, tumor samples 
(underlined entries) and normal tissues. The levels of expression is presented by +++ (strongly 
expressed), ++ (moderately expressed) and + (lightly expressed). - indicate that no signal has 
been detected.  As described in the text, MAGEA genes are not expressed in normal tissues to 
the exception of testis and placenta while cancers commonly expressed 6 of them. MAGEA5, -A8, 
-A9, -A10 and -A11 are almost not expressed in all samples analyzed (less than 2 copies per cell). 
Modified from De Plaen et al., 1994. 
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Chapter 4: MAGEA 
 
4.1. Background 
 
In the early 90’s cancer research focused its attention on the 
identification of antigens that would be cancer specific. With such 
breakthrough, the hope for a cancer vaccine could be reached and a cure 
found. In 1991, Van der Bruggen et al. published encouraging results. It 
was known that cytolytic T lymphocytes (CTL) could elicit a reaction 
towards melanoma tumor cells in vitro. Van Der Bruggen et al. selected 
CTL that were particularly effective against MZ2-MEL cells, a melanoma 
cell line derived from patient MZ2-E, and identified the antigen MZ2-E 
responsible for CTL activity . This antigen is encoded by a 2.4 kb DNA 
fragment containing an unknown gene that was named MAGE for 
melanoma antigen (known today as MAGEA1). That gene contains three 
different exons and an open reading frame located entirely in the third 
exon. During this identification phase, they also noticed by southern blot 
analysis that the probe hybridized to several additional bands suggesting 
the existence of closely related genes. Finally, two other genes were 
identified and named MAGE-2 and -3 (later renamed MAGEA2 and 
MAGEA3) [Van der Bruggen et al., 1991]. Three years later, the same 
team demonstrated that MAGEA1 was expressed in several cancers such 
as colon cancer, breast cancer, melanoma, lung cancer but never in 
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normal tissues at the exception of testis and placenta (Table 1). 
Moreover, other genes were identified. The family now contains eleven 
expressed genes that share the same structure as MAGEA1: three exons 
with the last one coding for the entire protein. The percentage of base 
pair homology among MAGEA genes varies from 64% to 84% and the 
overall protein structure is predicted to share similar features. 
Dissimilarities among MAGEA genes are mainly located in the promoter 
and in the first non-coding exon suggesting that members of the family 
may be differentially activated depending on stimuli and pathways 
activated [De Plaen et al., 1994]. 
 
4.2. Cancer testis antigens 
 
MAGEA genes are part of the the larger group of cancer testis 
antigens. Indeed, shortly after the identification of MAGEA1 by Van Der 
Bruggen et al., other teams identified different genes that could express 
tumor specific antigens. In 1997, the highly immunogenic tumor antigen 
New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1) and, in 
1998, the Synovial Sarcoma/X Breakpoint 2 (SSX-2) were discovered 
[Sahin et al. 1997, SEREX technology]. Later, a variety of genes with 
cancer and testis restricted pattern of expression were identified using 
various techniques such as comparison of genes expression between 
tumor and normal tissues. Today, these genes only expressed in cancer 
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and in normal testis are called the cancer testis antigens (CTAs). They 
include at least seventy subfamilies and more than 140 members all 
referenced online10 [Fratta et al., 2011].  
CTAs are further divided into CTAs encoded on the X chromosome (X-
CTAs) and CTAs encoded elsewhere in the genome (non-X CTAs) 
[Simpson et al. 2005]. The X-CTAs represent more than 50 percent of all 
CTAs and constitute 10 percent of all genes located on the X 
chromosome. Usually, X-CTAs are families clustered along the X 
chromosome (like MAGE but also NY-ESO-1, GAGE and BAGE families) 
while non-X-CTAs are generally lonely genes scattered on other 
chromosomes [Simpson et al., 2005].  
The biological functions of CTAs are poorly understood. 
Nevertheless, concerning the MAGE family, increasing evidences indicate 
that they could modulate gene transcription by favoring or inhibiting the 
recruitment of cofactors. Moreover, it seems more and more clear that 
they may have a role in tumorigenesis. 
 
                                                 
10
 http://www.cta.incc.br/ 
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Table 2 : Known human members of MAGE family. Genes are grouped by homology and 
localization on the chromosome. Today, more than 50 MAGEA genes are identified. However, 
some of them are only pseudogenes and therefore not expressed (notably MAGEA7, -A13, -A14 
and -A15). Class I MAGE genes (MAGEA, -B and -C) are only expressed in cancer or in normal 
testis, while Class II MAGE genes (all others) are expressed in normal somatic cells. Modified 
from Chomez et al., 2001. 
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4.2.1. MAGE Family 
 
Among CTAs, the MAGE family is one of the most studied lately. 
Following the discovery of MAGEA genes, sequence analysis of the Xp21 
region led to the discovery of a second cluster of MAGE genes: hMAGE-B 
[Dabovic et al., 1995; Lurquin et al., 1997; Muscatelli et al., 1995]. 
Finally, a third group was discovered, hMAGE-C [Lucas et al., 1998; Lucas 
et al., 2000], while previously identified MAGE genes were renamed 
hMAGEA.  Nevertheless, in 1999, Lucas et al. and Pold et al. published 
the very same year the sequence of a new MAGE gene that was 
ubiquitously expressed in normal somatic cells. This finding was the basis 
of a fourth cluster of human MAGE genes: hMAGE-D [Põld et al., 1999; 
Lucas et al., 1999]. 
In 2001, Chomez et al. published a list of human MAGE genes 
coding or not for antigens potentially interesting for cancer 
immunotherapy. Based on hMAGE-D2 sequence, a database screening 
was undergone. Table 2 presents the current members of the MAGE 
family [Chomez et al., 2001]. Nowadays, two types of MAGE genes are 
defined. The class I MAGE genes are only expressed in cancer or normal 
testis, and class II MAGE are expressed ubiquitously. 
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4.2.2. MAGE structure 
 
All class I MAGE genes are located on the X chromosome while 
class II are scattered throughout the genome. MAGE genes are 
characterized by a large third and terminal exon carrying the complete 
open reading frame, an observation first made by E. De Plaen and later 
confirmed by Chomez et al.. This feature is shared by all MAGE genes to 
the exception of MAGE-D subfamily. The MAGE-D genes contain 13 
exons, 11 of which encode for the protein. 
Concerning the structure of MAGE proteins, three main regions 
are defined. A N-terminal region where most of the divergence among 
members is recorded [De Plaen et al., 1994; Chomez et al., 2001]. The 
central region of the protein contains a Mage Homology Domain (MHD) 
of approximatively 200 amino acids and is composed of two winged helix 
motifs. Structurally, the Winged helix motif is a compact α/β structure 
composed by two wings (W1 and W2), three α helix (H1, H2 and H3) and 
three β strands (S1, S2 and S3) arranged in a specific order (H1-S1-H2-
H3-S2-W1-S3-W2). Although, it is thought to contact DNA [Gajiwala and 
Burley, 2000] to our knowledge, no evidence has been recorded of 
MAGE proteins directly binding DNA. Nevertheless, the MHD is thought 
to be responsible for protein-protein interactions [Doyle et al., 2010], 
feature also predicted for Winged motif [Gajiwala and Burley, 2000]. 
Finally, a C-terminal region is defined, usually shorter than the N-
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terminal region. The exact role of this region is not well known. The C-
terminal part of MAGEA4 is thought to confer a pro-apoptotic activity to 
the fragment in vitro. 
 
4.2.2.1. MAGEA subfamily 
 
One of the main known functions of MAGEA proteins is the 
interaction and regulation of different pathways. Here are a few 
examples. 
 
4.2.2.1.1. MAGEA1 and SKIP 
 
In 2004, Laduron et al. showed that MAGEA1 was able to directly 
bind SKI Interacting Protein (SKIP) which acts in several molecular 
pathways such as the NOTCH1 pathway. NOTCH1 pathway is a cell 
signaling cascade active among others during neuronal development 
[Gaiano and Fishell, 2002; Aguirre et al., 2010], differentiation processes 
during embryonic life [Murtaugh et al., 2003; Grego-Bessa et al., 2007] 
and  expansion of stem cell population [Aguirre et al., 2010, Dontu et al., 
2004]. There are five canonical Notch ligands in mammals: Jagged-1, 
Jagged-2, DLL1, DLL3 and DLL4. Once bound to the transmembrane 
receptor NOTCH1, a two-step cleavage of NOTCH1 is observed. First, 
A Disintegrin And Metalloproteinase (ADAM) protease cleaves the 
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extracellular domain of NOTCH1. Afterwards, the remaining internal 
domain is further cleaved by a gamma-secretase ensuing its release into 
the cytosol11. In the cytosol, the Notch intracellular domain (NICD) 
relocates in the nucleus and modulates the expression of numerous 
genes such as those encoding for p21
WAF-1
, p27, NFKB1, NFKB2… 
Mechanistically, NICD interacts with C-promoter binding factor-1 (CBF-
1). CBF-1 inhibits the transcription of genes by binding SKIP and the 
SMRT co-repressor complex containing HDACs. Repression is released 
when NCID binds SKIP and CBF-1 and forces the recruitment of HATs and 
other co-activators. MAGEA1 was found to directly interact with SKIP, to 
displace NICD and to recruit HDAC1. Since NOTCH1 pathway is impaired 
in presence of MAGEA1, MAGEA1 participates to tumor cell growth by 
inhibiting expression of genes such as p21
WAF-1
 [Laduron et al., 2004]. 
 
 
Figure 16 : MAGEA1 counteracts NICD transactivation by recruiting HDAC1. By binding to SKIP 
and recruiting HDAC, MAGEA1 counteracts Notch1-IC transactivation and thereby represses 
transcription of genes. Modified from Laduron et al., 2004. 
  
                                                 
11
 http://www.adipogen.com/media/Catalogs/PDFs/Notch_NP_final_2011.pdf 
95 
 
 
4.2.2.1.2. MAGEA11 and androgen receptor modulation 
 
Androgen receptor (AR) signaling has an important role in sex 
male development and in normal prostate function. On the other hand, 
it is also a major actor in prostate cancer [Sharifi and Auchus, 2012; 
Mateo et al., 2014]. In normal epithelial and stromal prostatic cells, ARs 
are located in the cytosol. They are bound to Heat Shock Proteins (HSPs) 
that act as repressors. Androgens, displace HSP proteins [Pratt and Toft, 
1997; Mateo et al., 2014] and allow the nuclear translocation and the 
binding of ARs to DNA. Androgen-dependent genes include IGF-1 (insulin 
like growth factor-1), CDK1, CDK2, prostate transmembrane protein-1 
(PMEPA1) and TMPRSS2 [Jariwala et al., 2007] (Figure 17).   
 
 
Figure 17: Androgen receptor modulation. Androgens are generated from cholesterol to form 
testosterone (T) and are further transformed in dyhydrotestosterone (DHT) by the 5α-reductase. 
DHT possesses a higher affinity for androgen receptor (AR). Once binded to AR, DHT induces a 
conformational change destabilizing the inhibitory complex formed by Heat Shock Protein 90 
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(HSP90) and AR. AR translocates to the nucleus where it undergoes dimerization. AR dimers bind 
DNA and recruit the transcription machinery. CBP (CREB binding protein); SRC-1 (steroid receptor 
coactivator 1); AR-associated protein 70 (ARA70). Modified from Meehan and Sadar, 2003 
12
. 
 
Figure 18 : Human androgen receptor structure. The protein is composed by a N-terminal 
domain (NTD) which contains activation function-1 (AF1), a central DNA-binding domain (DBD) 
responsible for androgen response elements binding and a C-terminal domain (LBD) responsible 
for ligand-binding activity and containing the ligand-dependent transactivation domain, AF2. 
From Lavery and Bevan, 2011. 
 
The AR is composed by a N-terminal domain called activation 
function-1 (AF1), a C-terminal domain called activation function 2 (AF2) 
and a central DNA binding domain (DBD) (Figure 18). While, AF2 is 
responsible for the interaction with the co-activator SRC1 (p160), AF1 
contains a FXXLF motif (
23
FQNLF
27
) that interacts with AF2 to mediate 
the so called “N/C interaction” required for the stabilization and the 
expression of many androgen-dependent genes [Wilson, 2010; Mateo et 
al., 2014].   
In 2005, Bai et al. showed that MAGEA11 was able to regulate AR 
activity. MAGEA11 disrupts the N/C interaction by interacting with the 
FXXLF motif responsible for the AF1/AF2 interaction. Instead of 
weakening AR-mediated transcription, this will increase it by enhancing 
the binding of SRC/p160 coactivator to the AF2 region. Moreover, Askew 
                                                 
12
 
http://upload.wikimedia.org/wikipedia/commons/thumb/e/e7/Human_androgen_receptor_and_and
rogen_binding.svg/2000px-Human_androgen_receptor_and_androgen_binding.svg.png 
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et al. in 2009 described that MAGEA11, once bound to AR, recruits TIF2, 
another coactivator important for the transcription of AR-dependent 
genes. Thus, both mechanisms lead to a better activation of AR-
dependent genes.  
In their articles, Bai et al. also describe a potential post-
translational modification of MAGEA11. The protein may be 
phosphorylated on Thr360 probably by CHK1. This induces its 
ubiquitination on Lys240 and 245 resulting in an enhanced binding to AR.  
Additionally, Askew et al. described that Ser174 may be phosphorylated 
by ERK1 [Bai and Wilson, 2008; Askew et al., 2009].  
Our in silico analysis also indicate that Ser168, Ser174 but also 
Lys225, Lys236, Lys 240 and Lys245 are conserved among all MAGEA 
proteins, while Thr360 becomes a methionine in MAGEA2.  This suggests 
that phosphorylations / ubiquitinations could play an important role in 
the regulation of MAGEA activity. These different conserved amino acids 
have yet to be investigated. 
 
4.2.2.1.3. MAGEA2 and Estrogen receptor modulation 
 
Recently, Wong et al. linked the expression of MAGEA2 to 
tamoxifen resistance in breast cancer [Wong et al., 2014]. Estrogen 
receptors (ERs) are transcription factors that transduce hormone 
signaling and trigger cell proliferation in breast and ovarian tissues 
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following oestradiol (E2) signaling [Helguero et al., 2005]. Two different 
ERs have been identified: ERα and ERβ. Like androgen receptors, they 
both possess a DNA binding domain, a C-terminal region responsible for 
ligand binding and a N-terminal part where the most divergence is 
observed. Two activation domains are determined: the N-terminal AF-1 
and the C-terminal AF-2. Both AFs recruit coregulator proteins to the 
DNA bound ER receptors
13
. Like androgens receptors, ERs are 
sequestrated in the cytosol by Heat Shock Proteins (notably HSP90). In 
response to oestradiol binding, conformational changes abolish the 
sequestration by HSP90, allowing ERs to relocate in the nucleus, bind 
their response elements and recruit transcriptional co-activators such as 
p300/CBP histone acetyl transferases (HAT). 
Tamoxifen inhibits transcription of ERs target genes since the 
complex tamoxifen-ERs binds DNA but fails to undergo the 
conformational change required for co-activators recruitment. Instead, 
repressors are recruited (Figure 19). 
Wong and colleagues analyzed gene expression of tamoxifen 
resistant breast cancer and compare it to tamoxifen sensitive breast 
cancer. Results lead to the identification of several genes among which 
stands MAGEA2. They next tested a wide range of tamoxifen resistant 
breast cancer cell lines and confirmed the expression of MAGEA2 in each 
of them. Besides, by overexpressing MAGEA2 in MCF-7 tamoxifen 
                                                 
13
 http://physrev.physiology.org/content/87/3/905 
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sensitive cells, they showed a significant difference in cell growth 
compared to untransfected control cells unable to proliferate in 
presence of tamoxifen. Annexin V/IP labelling coupled to flow cytometry 
analysis established that MCF-7 cells overexpressing MAGEA2 were 5 to 
10 times less sensitive to tamoxifen-induced apoptosis. By investigating 
the impact of MAGEA2 on ERα activity with a luciferase reporter gene 
under the control of an ER dependent promoter, they found that the 
inhibition by tamoxifen of genes normally induced by E2 was abolished. 
The underlying mechanism seems to rely on MAPK activity and 
correlates with an increased ER phosphorylation [Wong et al., 2014]. 
 
Figure 19 :  Comparison between oestradiol and tamoxifen mode of action. Oestradiol binds ER 
and disrupts the inhibitory complex existing between HSP90 and ER. Free, ER translocates to the 
nucleus. Oestradiol-ER complex induces a conformational change of ER allowing co-activator 
recruitment. Tamoxifen acts in a similar way, except that it fails to induce the conformational 
change. Modified from Ratanaphan, 2012.  
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4.2.2.1.4. MAGEA and p53      
 
 MAGEA proteins have been shown to inhibit cellular growth and 
apoptosis in several models [Monte et al., 2006; Yang et al., 2007]. In 
2006, a link between MAGEA proteins and the tumor suppressor p53 has 
been suggested. Since, the relation between those two proteins is 
subject to active research. Here, the suggested mechanisms will be 
discussed. 
 
4.2.2.1.4.1. HDAC Recruitment 
 
Monte et al. in 2006 published for the first time that a correlation 
exists between MAGEA1, -A2 and -A6 expression and a reduced p53 
activity. They used a plasmid containing a synthetic p53 promoter 
followed by a luciferase reporter gene, and co-expressed p53 and 
MAGEA proteins in H1299 p53 null cells. They observed that MAGEA 
expression decreased p53 transcriptional activity. Moreover, they 
treated with etoposide a melanoma cell line expressing MAGEA genes 
(13923M) and another one that did not (15392M) and established a link 
between a high MAGEA expression and cell survival. Using quantitative 
CHiP assays (BAX promoter), they evidenced a complex composed of 
MAGEA2, p53 and Histone Deacetylase III (HDACIII) that deacetylates 
surrounding histones and consequently reduces gene transcription by 
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favoring chromatin condensation (Figure 20). They also evidenced the 
direct binding of MAGEA2 to p53 DNA binding domain, without 
inhibition of p53 binding to its RE [Monte et al., 2006]. 
 
 
Figure 20 : Recruitment of HDACIII by MAGEA2 protein. MAGEA2 binds p53 at the p53-
dependent promoter. MAGEA2-p53 complex recruits HDACIII that inhibits transcription by de-
acetylating surrounding histones. Modified from Monte et al., 2006. 
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4.2.2.1.4.2. Enhanced degradation 
 
  Yang et al. in 2007 and, in 2010, Doyle et al. described a relation 
between MAGEA expression and an impaired p53 function. The 
suggested mechanism, nonetheless, is dissimilar and some 
inconsistences with Monte et al. are observed. Here, MAGEA2, but also -
A3, -A6 and -C2 do not directly bind p53 but rather bind to the E3 
ubiquitin ligase TRIM28 (aka KAP1). This heterodimer will enhance the 
ubiquitination of natural TRIM28 substrates among which stand p53. 
Although TRIM28 is not the major ubiquitin ligase targeting p53, it is 
suggested to enhance p53 degradation and decrease p53 intracellular 
levels. Therefore, in stress condition, p53-dependent cell cycle arrest or 
apoptosis are compromised.  Up to now, the exact mechanism 
enhancing TRIM28 activity is not understood. It may either be an 
enhanced recruitment of the E2 ubiquitin-conjugating enzyme by the 
MAGE protein or an increased ubiquitin transfer from E2 to TRIM28. 
Interestingly, Doyle et al. described for the first time the crystal structure 
of MAGEA4. It appears that the MAGEA MHD is composed of two 
winged helix motifs (WH-A and WH-B). Winged helix motifs are known to 
recognize DNA, raising the possibility that MAGEA proteins may directly 
bind DNA [Yang et al., 2007; Doyle et al., 2010] (Figure 21). 
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Figure 21 : MAGEA2 enhancement of TRIM28 activity towards p53. TRIM28 is an ubiquitin E3 
ligase that naturally targets p53. MAGEA2 complexes with TRIM28 and enhances its activity. p53 
is degraded and unable to induce pathways preventing transformation. Modified from Doyle et 
al., 2010. 
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4.2.2.1.4.3. Inhibition of p53 binding to RE  
 
In 2010, another mechanism was published by Marcar and 
collaborators. Here again, the link between MAGEA proteins and p53 
was highlighted. They describe a direct binding between MAGEA2 and 
p53 involving p53 DNA binding domain and an undefined part of 
MAGEA2, as previously published by Monte et al. However, in this 
model, interaction with MAGEA2 renders p53 unable to regulate the 
transcription of its target genes. Marcar et al. used a pepscan assay to 
decipher the region of p53 interacting with MAGEA2. Biotynilated 
oligopeptides of 15 amino acids derived from the p53 DBD were 
synthetized and incubated with MAGEA2. Immunoprecipitation of 
MAGEA2 using streptavidin-conjugated beads allowed the 
characterization of the interaction [Marcar et al., 2010]. To our opinion, 
although attractive, this method cannot take into account the 
complexity of the 3D structure of the DNA binding domain of the tumor 
suppressor. Nevertheless, these results are in accordance with Monte et 
al. since they both emphasize a direct interaction of MAGEA2 with p53 
DBD (Figure 22). 
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Figure 22 : MAGEA2 inhibits p53 binding to DNA. Left panel: the DNA binding domain of p53 
interacting with DNA. Right panel: Region of p53 binding MAGEA2. Marcar et al. suggest a 
mechanism in which MAGEA2 binds p53 residues also important for interaction with DNA. The 
interaction with MAGEA2 results in impaired DNA binding and the inhibition of p53-dependent 
transcription. Red: amino acids 261–280: high affinity for MAGEA2, blue amino acids 247–257: 
moderate affinity for MAGEA2 and green amino acids 117 – 141: moderate affinity for MAGEA2. 
Modified from Marcar et al., 2010. 
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4.2.2.1.4.4. Lack of acetylation 
 
Finally, in 2012, Peche et al. described that MAGEA2 could 
contribute to cancer early progression by interfering with Promyelocytic 
leukemia (PML) Nuclear bodies (NB) and consequently inhibiting the 
senescence program required for cell transformation prevention. 
Although pml-/- mice develop normally and live well [Lallemand-
Breitenbach and de Thé, 2010], PML-NBs are platforms facilitating 
protein interactions and seem important for apoptosis and senescence 
induction [Zhang et al., 2005; Bernardi and Pandolfi, 2003]. PML-NBs 
possess a diameter range varying from 200nm to 1µm and are mainly 
composed of two kind of proteins: the SP100 protein and the PML 
proteins (seven isoforms of PML are described so far: PML-I to VII) 
[Bernardi and Pandolfi, 2007; Lallemand-Breitenbach and de Thé, 2010]. 
These proteins possess a SUMO interacting motif (SIM) and are able to 
be sumoylated. For example, PML proteins contain three different 
sumoylation sites required for protein recruitment and for interaction 
with SP100 via the SIM domain [Zhong et al., 2000]. The SUMO-SIM 
interaction is the key to PML-NBs stabilization. For instance, 
desumoylation during mitosis breaks down the structure of PML-NBs 
[Lang et al., 2009].  
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Authors demonstrate that MAGEA2 colocalizes in the nucleus 
with PML-NBs and this correlates with the depletion of p53 acetylated 
forms. MAGEA2 inhibits PMLIV sumoylation, necessary for the PML-NBs 
stabilization. Several papers describe the relative importance of PML-
NBs for p53 post-translational modification. Moreover, several proteins 
known to interact with and modify p53 such as HIPK2, HAUSP, MDM2, 
CBP are found along with p53 on PML-NBs [Pearson et al., 2000; de 
Stanchina et al., 2004].  By abolishing those platforms, MAGEA2 could 
prevent different p53 post-translational modifications and therefore 
inhibit senescence and apoptosis induction [Peche et al., 2012]. 
 
4.2.2.2. MAGEA regulation 
 
MAGEA gene expression, like other CTAs, seems to be regulated 
by epigenetic events such as DNA methylation. Commonly, DNA 
methylation leads to the silencing of gene expression. It consists in the 
addition of a methyl group by specific enzymes called DNA 
methyltransferases. This will either inhibit the binding of cofactors that 
would normally favor gene expression or will recruit chromatin 
remodeling co-repressor complexes. 
In 1996, De Smet et al. hypothesized that the genome-wide 
demethylation was responsible for the reactivation of MAGEA1 
expression during cancer progression [De Smet et al., 1996]. In 1999, 
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they described that all CTAs possess a promoter methylated on several 
cytosine-guanine dinucleotides (CpG) in normal somatic tissues [De Smet 
et al., 1999]. Previously, in 1994, Weber et al. demonstrated that DNA 
hypomethylating agents were able to re-activate the expression of 
MAGEA1 [Weber et al., 1994]. Further evidence demonstrating the 
importance of methylation status has been given by Sigalotti et al. 
(2002). Using a reporter gene under the control of MAGEA2, -A3 and -A4 
promoters methylated or un-methylated in vitro, they showed that the 
major element driving MAGEA expression was the methylation status of 
their promoter [Sigalotti et al., 2002].  
Even if methylation seems capital for MAGEA gene expression, 
histone modifications also appear to play a role. In 2006, Wischnewski et 
al. described that the association of a HDAC inhibitor with a DNA 
methylase inhibitor induces a MAGEA gene expression three times 
higher than with the DNA methylase inhibitor alone (relative expression 
of mRNA). However, it is important to note that the HDAC inhibitor alone 
had no effect [Wischnewski et al., 2006]. 
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4.2.2.2.1. BORIS 
 
The BrOther of the Regulator of the Imprinted Site (BORIS or 
CTCF Like protein) is a transcription factor protein containing eleven Zn 
fingers and known to bind multiple DNA sequences [Martin-Kleiner, 
2012]. Only expressed in primary spermatocytes and silenced in normal 
adult tissues, it has been considered as an oncogene since BORIS is 
reactivated in cancer. BORIS is a protein that shares high homology with 
CTCF, the second member of the family. Both proteins bind in vitro the 
same DNA sequences but diverge in their N- and C-terminal region 
[Klenova et al., 2002]. It has been demonstrated that BORIS acts as an 
antagonist of CTCF in normal and in cancer cells by binding to the same 
response element. Moreover, in normal condition, the expression of 
BORIS correlates with a decrease in CTCF levels and a global reduction of 
DNA methylation [Klenova et al., 2002; Recillas-terga et al., 2006]. 
In 2011, Boris has been identified, by ChIP, on CTAs promoter and 
its presence was correlated to an increased expression MAGEA1 and NY-
ESO-1 [Bhan et al., 2011]. BORIS is also known to modify the methylation 
status of genes like the one coding for bag-1 [Sun et al., 2008]. BORIS 
switches the histones methylation status from an inhibitory (Histone H3 
trimethylated on lysine 9: H3K9) to a permissive one (Histone H3 
trimethylated on Lysine 4: H3K4) by recruiting the methyltransferase 
SET1A. Experiments undertaken by Bhan et al. showed that BORIS was 
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present on MAGEA promoters (-A2, -A3 and -A4) and it is thought to lead 
to increased MAGEA1 expression through an enhancement of activating 
histone methylations and acetylations. Concerning DNA methylation 
itself, the mechanism seems to vary among MAGEA genes. The presence 
of BORIS is correlated with an unmethylated promoter of MAGEA3 but 
no difference in CpG methylation was observed for MAGEA2 and -A4 
promoters, suggesting that an alternative mechanism of regulation could 
exist. How BORIS mediates DNA demethylation is controversial and four 
hypotheses are currently under investigation [Roldán-Arjona and Ariza, 
2009]. Finally, BORIS expression has been shown to be repressed by p53 
suggesting a role of p53 in inhibiting MAGEA expression [Necochea-
Campion et al., 2011]. 
 
4.2.2.2.2. Mi-RNA34a 
 
Micro RNAs seem to play a role in MAGEA expression. By 
analyzing several miRNA targets with prediction algorithms, MAGEA 
family members such as -A2, -A3, -A6 and -A12 were found to possess a 
miR-34a binding site in their 3’ untranslated regions (UTRs).  They were 
further confirmed as direct targets of miR-34a.  The hypothesis suggests 
that miR-34a directly targets MAGEA genes and allows p53 levels to 
increase. In turn, p53 acts as a transcriptional activator for miR-34A thus 
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inducing a positive feedback loop. This is suggested to enhance 
sensitivity to chemotherapy [Weeraratne et al., 2011]. 
 
4.2.2.3. MAGEA and cancer therapy 
 
Correlation between MAGEA expression and a poor prognosis is 
well documented [Zhou et al., 2011; Lian et al., 2012; Mengus et al., 
2012; Laban et al., 2014]. Additionally, some studies suggest that 
MAGEA expression could be used as a new diagnostic tool for patient 
care. In 2012, Shin et al. successfully detected MAGEA expression, by RT-
nested PCR in bronchial washing fluids, as cancer marker in the case of 
lung cancer invisible to bronchoscopy [Shin et al., 2012]. Similar results 
were obtained in gastric carcinoma [Jeon et al., 2010]. Recently, Sang et 
al. used blood samples to detect circulating MAGEA proteins. Results 
demonstrated that blood detection of MAGEA proteins was technically 
possible and synonym of a poor outcome for the patient. Since the only 
reason for MAGEA expression and detection is the presence of cancer 
cells, it is conceivable that MAGEA proteins may be used as an accurate 
marker for cancer detection or surveillance, and could even be more 
reliable than carcinoembryonic antigen (CEA) [Lee et al., 2014], CA15-3 
[Ali et al., 2013] or CA27-29 [Brooks, 2009] currently used for breast 
cancer. Taken together, those data underline the clinical relevance of 
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MAGEA proteins in the cancer field as well as their role in cancer 
progression.  
 
Figure 23 : Cellular effects of MAGEA proteins. MAGEA are implicated into p53 destabilization 
and inhibition of transcription. MAGEA2 expression leads to an enhanced ubiquitination of p53 
(Doylet et al.), to the inhibition of PML-NBs leading to a decreased p53 acetylation (Peche et al.), 
to the recruitment of HDAC on p53 promoters or to the inhibition of p53 binding to DNA (HDACI, 
Laduron et al.; HDACIII, Monte et al.). On the other hand, p53 also modifies MAGEA activity: p53 
induces miR34a expression that directly targets MAGEA mRNA. Moreover, p53 also inhibits the 
expression of BORIS, responsible for the demethylation of MAGEA promoter.  
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Chapter 5: Resveratrol 
 
5.1. Natural products as anti-cancer drugs 
 
Different natural molecules are currently among the most potent 
anti-cancer agents. Vincristine, etoposide and paclitaxel are examples of 
plant-derived compounds while actinomycin D, mitomycin C, 
doxorubicin and l-asparaginase are derived from bacteria. Today, even 
oceans are sources of anti-cancer drugs (e.g. cytarabine). These drugs 
induce anti-cancer effects by varied mechanisms of action: interaction 
with microtubules, inhibition of topoisomerases I or II, alkylation of DNA, 
and interference with tumour signal transduction14, 15 [Nobili et al., 
2009]. 
 
5.1.1. Alkylating agents  
 
These molecules are able to add an alkyl group to DNA bases, 
leading to DNA strand breaks when repair enzymes proceed, or to create 
crossbridges between base pairs inhibiting the separation of both 
strands during replication. A famous member of this family is mitomycin 
C that induces crossbridges in the DNA [Colvin, 2003].  
                                                 
14
 www.cancer.org 
15
 http://www.elmhurst.edu/~chm/vchembook/655cancer2 
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5.1.2. Antimetabolites 
Antimetabolites are molecules that inhibit RNA or DNA 
replication. For example, cytarabine (1β-arabinofuranosylcytosine, Ara-
C), a pyrimidine nucleoside analogue, is the first anti-cancer agent 
coming from the sea (sponge). In the cytosol, cytarabine is rapidly 
phosphorylated into tri-phospho-cytarabine (Ara-CTP) and competes 
with dCTP. DNA and RNA synthesis was shown to be impaired [Giles et 
al., 2012]. 
 
5.1.3. Anti-tumor antibiotics 
 
Two classes of anti-tumor antibiotics exist and were isolated from 
Streptomyces: the anthracycline antibiotics such as doxorubicine or 
idarubicin and non-anthracycline antibiotics such as actinomycin-D. 
Anthracyclines are intercalating drugs able to induce double strand 
breaks in the DNA and therefore to trigger p53. On the other hand, 
Actinomycin D, first discovered in 1940 while studying Actinomyces 
antibioticus, binds DNA and inhibits RNA elongation. It thus triggers 
transcription arrest [Nobili et al., 2009]. 
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5.1.4. Topoisomerase inhibitors  
 
TOPOisomerases eliminate DNA supercoiling appearing during 
DNA replication. Two classes of TOPOisomerases (TOPOI and TOPOII) 
exist based on mechanisms resolving supercoiling. TOPOI cleaves one 
strand of the DNA, eliminates supercoiling and religates. Camptothecin 
stabilizes the TOPOI-DNA cleavable complex. DNA single strand breaks 
are formed and activate p53. Camptothecin was purified from a Chinese 
tree (Camptotheca acuminate) but was too toxic for a therapeutic use. In 
1996, two camptothecin-derived molecules were designed to overcome 
such drawbacks. TOPOII removes supercoiling by creating a double 
strand break, passes another DNA molecule through the gap and 
religates (Figure 24).  Doxorubicin but also etoposide (derived from the 
roots of the Indian Podophyllum peltatum) are TOPOII inhibitors. They 
stabilize the TOPOII-DNA covalent intermediate in the open 
conformation thus inhibiting relegation (Figure 24). It generates double 
strand breaks in the DNA leading to apoptosis [Nobili et al., 2009]. 
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Figure 24 : The Topoisomerase II cycle with, for each step, inhibitory molecules. 1. TOPO II binds 
a DNA molecule. 2) ATP binding stimulates the ATPase domain of TOPOII and a second DNA 
molecule is recruited. 3) Once recruited the ATPase domain cleaves the first DNA molecule. 4) 
Through the opening TOPOII passes a second molecule. 5) The cleaved molecule is religated. 6) 
DNA is released. Doxorubicin and etoposide inhibits the fifth step of this cycle leading to double 
strand breaks. From Vos et al., 2011. 
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5.1.5. Mitotic inhibitors 
 
Vinblastine and vincrinstine are alkaloïds both isolated from 
extracts of Catharanthus roseus. They bind tubulin and prevent 
microtubules polymerisation
16,17
. The taxane paclitaxel (taxol) is a 
molecule found in the bark of Taxus brevifolia that stabilizes formed 
microtubules by binding to tubulin. Consequently, cytoskeleton 
disassembly and flexibility is lost and mitosis impaired. 
 
5.2. Resveratrol 
 
Resveratrol (trans-3, 4’, 5-trihydroxystilbene; RSV; Figure 25) is a 
polyphenol notably found in fruits (grapes) or nuts (peanuts). The 
molecule raises a lot of interest from the scientific community for 
several reasons. Some are described here below. 
 
5.2.1. RSV and caloric restriction 
 
When animals are exposed to a moderate reduction of their 
caloric intake (20%), but provided with correct amounts of minerals and 
vitamins, their lifespan increases. This concept, called “caloric 
                                                 
16
 www.cancer.org 
17
 http://www.elmhurst.edu/~chm/vchembook/655cancer2 
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restriction” is observed in a wide range of eukaryotes such as yeast, 
worms but also more advanced forms of life such as insects, fishes, 
rodents and monkeys [Kulkarni and Cantò, 2014]. Increased lifespan, 
reaching up to 50%, is observed in association with prevention of age-
related physical deterioration, prevention of tissue damages and a lower 
cancer incidence [Mattison et al., 2012; Colman et al., 2009].  
 
Figure 25 : Molecule of resveratrol. 
 
In 1999, Kaeberlein et al. associated the protein Silent 
information regulator 2 (Sir2) to yeast aging. Interestingly, by increasing 
Sir2 expression, yeast lifespan was enhanced by 30%, while deletion of 
Sir2 reduced lifespan by 50% [Kaeberlein et al., 1999]. Moreover, Lin and 
collegues demonstrated that caloric restriction advantages were lost 
when Sir2 was deleted [Lin et al., 2000]. Quickly, seven mammalian 
isoforms of Sir2 were identified: SIRT1 to 7 [Kulkarni and Cantò, 2014]. 
SIRT1, the most studied was shown to recreate some caloric restriction 
characteristics when overexpressed in mouse: decreased DNA damage, 
improved glucose tolerance, fewer carcinomas and sarcomas. However, 
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SIRT1 overexpression was not sufficient to generate an increase in 
lifespan [Herranz et al., 2010; Bordone et al., 2007]. 
Molecular analyses of SIRT1 demonstrate that FOXO transcription 
factors are SIRT1 targets. Moreover, SIRT1 activates PPAR-γ-coactivator-
1α (PGC-1α). PGC-1α regulates genes located both in the nuclear and 
mitochondrial genomes to induce pathways involved in mitochondrial 
DNA replication, fatty acid oxidation and import as well as electrons 
transport chain assembly [Rowe et al., 2010]. 
  Based on these studies, in vitro screening for SIRT1 potentiators 
began with the hope to delay aging. The most promising compound 
identified is RSV. Mice on a high fat diet supplemented with RSV, are 
protected against body weight gain, have a better metabolism and 
[Lagouge et al., 2006] an increased lifespan, as if RSV mimicked some 
aspects of caloric restriction. Effects on osteoporosis, cataract and 
vascular dysfunction were also observed [Pearson et al., 2008]. 
Nevertheless, some wondered if RSV was indeed responsible of the 
enhanced lifespan or if metabolites of RSV were responsible. Evidences 
behind this suggestion are the poor bioavailability of RSV due to its rapid 
transformation in the body and the rather long time observed between 
RSV treatment and actual SIRT1 activation [Kulkarni and Cantò, 2014].  
Identification of other proteins involved in caloric restriction led 
to the identification of the AMP-activated kinase (AMPK). AMPK is 
activated by a high AMP/ATP ratio, itself reflecting the energy status of 
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the cell.  AMPK becomes activated under energy stress such as hypoxia, 
exercise or fasting. It induces pathways such as lipid oxidation or 
glycolysis, rapidly replenishing cellular energy [Hardie et al., 2012]. In 
2006, RSV was reported to induce AMPK activation within minutes in 
several cell lines [Breen et al., 2008; Zang et al., 2006]. The mechanism 
behind RSV-dependent AMPK activation seems to rely on RSV ability to 
inhibit the F1FO-ATPase/ATPsynthase. Therefore, ATP formation is 
inhibited and the AMP/ATP ratio drastically increases leading to AMPK 
activation [Zheng and Ramirez, 2000]. Interestingly, AMPK also activates 
PGC-1α suggesting an overlapping role with SIRT1 [Jäger et al., 2007]. 
Moreover, studies report that AMPK may activate SIRT1 by enhancing 
NAD+ cell concentration [Cantò et al., 2009] and since AMPK activation 
by RSV is more rapid than SIRT1 activation, that would suggest a direct 
downstream activation. However, some contradictory reports 
demonstrate that SIRT1 may activate AMPK. Indeed, Liver Kinase B1 
(LKB1), an upstream kinase of AMPK, is a direct SIRT1 target. Therefore, 
the exact mechanism is under construction. Nevertheless, what is certain 
is that RSV action requires both AMPK and SIRT1 activation to mimic 
caloric restriction. 
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5.2.2. Resveratrol and cancer 
 
In addition to its effects on the energy metabolism, RSV was 
shown to be a cancer chemopreventive polyphenol. In 1997, Jung et al. 
demonstrated that mice on a RSV-containing diet were less prone to 
develop breast cancer when treated with carcinogen injections in the 
mammary gland. Similar results were observed in a skin cancer model. 
Moreover, RSV treatment is able to inhibit growth and elicit autophagy 
or apoptosis in multiple cellular models [Garcia-Zepeda et al., 2013; 
Rojas et al., 2014; Wu et al., 2015]. Mechanistically, different hypothesis 
have been raised for RSV anti-cancer effects. Mostly, RSV induces cancer 
regression by promoting senescence or apoptosis.  In presence of RSV, 
cyt C release is observed, BAX and p53 expression is enhanced and levels 
of anti-apoptotic BCL-2 members are decreased. However the exact 
mechanism triggering cell death or cell cycle arrest remains a subject of 
intense debate [Udenigwe et al., 2008]. Hwang et al. reported that RSV 
induced production of reactive oxygen species (ROS) mediating release 
of cyt C [Hwang et al., 2007]. Interestingly, opposite effects were 
observed in normal cardiac cells: RSV protects against ROS related to 
cardiovascular diseases [Hwang et al., 2008]. The exact mechanism of 
RSV-dependent ROS production in cancer cells is still non-elucidated. 
Clinical studies on healthy individuals demonstrate that RSV is 
generally well tolerated. This makes RSV suitable for therapeutic use. For 
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example, a one year administration of 16mg of RSV per day appears to 
be safe. No severe side effects were observed and a protection against 
cardiovascular diseases observed [Tomé-Carneiro et al., 2013]. RSV does 
not have side effects at a dose of 1g per day. However, diarrhea or 
vomiting are recorded when the daily uptake reaches 2.5g per day [Singh 
et al., 2014].  
Major drawbacks of RSV reside in its poor water solubility, its 
high instability and its low oral bioavaibility. Those issues make difficult 
the use of RSV as a potent therapy. [Singh et al., 2014; Kulkarni and 
Cantò, 2014]. Indeed, oral intake of RSV rapidly leads to its 
metabolization mainly into glucuro- and sulfo-conjugates in the liver 
[Cottart et al., 2010]. Therefore, strategies are currently developed to 
overcome these issues. For example, combinations with alkaloids such as 
piperin or with the polyphenolic compound curcumin increase RSV 
plasma concentration by inhibition of its glucuronidation [Johnson et al., 
2011; Basu et al., 2007]. Finally, it could be possible to generate RSV 
derivatives that will be less sensitive to the hepatic metabolism. 
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AIMS OF THE STUDY 
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It is commonly accepted that the tumor suppressor p53 is crucial for 
the prevention of cancer development. The fact that p53 is mutated in 
more than 50% of all cancer reinforces this statement. The apoptosis 
induced by p53 is one of the pathways triggered following an acute 
stress. Therefore, in tumor bearing the wt form of the tumor suppressor, 
a better knowledge of the mechanisms that impair its activity could be 
important for the development of new strategies to fight cancer. In 
addition, the identification of small natural molecules able to trigger 
p53-dependent apoptosis in cancer cells as well as the understanding of 
their mechanisms of action, could also lead to new therapies. This is 
why, during this four year project, my goal was to determine the effects 
of two different actors on p53 dependent apoptosis. Therefore, this 
work is divided into two parts. First, I analyzed the inhibitory effects of 
MAGEA family members on p53-dependent apoptosis. Second, I focused 
on the polyphenol resveratrol in order to understand how this molecule 
triggers the p53 pathway. 
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1) MAGEA project 
 
In 2006, Monte et al. found that MAGEA2 is able to complex with wt 
p53 and recruit the histone deacetylase III on p53-dependent promoters. 
This report was the first clue on the impact of CTAs on p53. In 2010, 
Doyle et al. hypothesized that MAGEA proteins interact with E3 ubiquitin 
ligases such as TRIM28 and enhance p53 degradation. Another paper by 
Marcar et al. suggested that MAGEA proteins bind the DBD of p53 
preventing it to interact with the promoter of its target genes. Finally, it 
has been suggested that MAGEA proteins inhibit the formation of the 
PML-NBs and reduce p53 acetylation. These publications raised the 
attention on MAGEA functions in cancer cells. 
However, these different mechanisms are in opposition on some 
points. For example, Marcar et al. and Monte et al. described a direct 
binding between MAGEA2 and the tumor suppressor while Doyle et al. 
demonstrated the contrary. Another stumbling block lies on the effects 
of MAGEA on p53 cellular levels. Doyle et al. described an increased 
degradation of p53 (although they used cell lines expressing mutant 
p53). In the meanwhile, Monte et al. did not observed an effect of 
MAGEA expression on wt p53 levels. There is also a disagreement on the 
consequences of this interaction between MAGEA proteins with the 
tumor suppressor. Both Monte et al. and Marcar et al. agree on the 
binding between these proteins, however they disagree on the ability of 
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the complex MAGEA-p53 to still interact with DNA. Finally, only MAGEA2 
has been clearly analyzed since based on the work of Monte et al., it was 
thought to be the most active member of the family. Other MAGEA 
genes were slightly analyzed. 
Therefore, since MAGE-A protein are CTAs that target p53 and since 
only MAGEA2 has been clearly analyzed, our objectives were to analyze 
how six members of the MAGEA family (MAGEA1, -A2, -A3, -A4, -A6 and 
-A12) influence p53 activity. MAGEA members selection has been based 
on the work of De Plaen et al. After studying a large range of cancer 
samples and cancer cell lines, they demonstrated that these six MAGEA 
genes were frequently expressed in cancer. More precisely, we aimed to 
analyze the impact of each of these six MAGEA on cell resistance to 
genotoxic stresses and p53-dependent apoptosis. We also aimed at 
determining the interactions with the tumor suppressor and to 
characterize the phosphorylation status of p53 in presence of MAGEA 
during a genotoxic insult. This is an original hypothesis that has not been 
investigated before. 
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2) Resveratrol project. 
 
 RSV has been shown to have beneficial effects on various 
pathologies. For example, type 2 diabetes may be treated in parts with 
RSV since it notably enhances glucoregulation and increases sensitivity 
to insulin. It has also effects on obesity by reducing adipocyte size and by 
enhancing adiponectin expression, as well as on cardiovascular diseases 
by reducing plasma lipids or cholesterol levels and by reducing blood 
pressure. Moreover, RSV has cancer chemopreventive properties. It has 
been shown to reduce the proliferation of cancer cells, to enhance 
caspase-3 activation and to reduce inflammation.  
Research on the mechansims of actions of RSV on cancer cells has 
led to the identification of notably the generation of ROS that triggers a 
senescent phenotype [Heiss et al., 2007]. However, the mechanism by 
which RSV induces apoptosis was still unclear. Before my arrival in the 
laboratory of P. Dumont, M. Hermant did a wonderful master thesis on 
the effects of RSV on cancer cells. She demonstrated that treatment of 
HCT-116 colon cancer cells with RSV induced chromatin condensation, 
formation of γ-H2AX foci and PARP cleavage. Moreover, C. 
Castrogiovanni used HCT-116 cells wt and KO for p53 to demonstrate 
that RSV-induced apoptosis was p53-dependent, at least partly. Finally, 
M. Hermant concluded that ROS formation was not involved in 
formation of γ-H2AX foci and apoptosis induction.  
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Therefore, our main goal was to identify the mechanism by which 
RSV induces DNA damage in colon cancer cells. Several mechansims 
could be responsible. Among them, we decided to analyze the following 
three: DNA intercalation, TOPOI inhibition and TOPOII inhibition. In 
addition, we also aimed at determining the pathway leading to p53 
activation and more specifically the kinases involved. 
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RESULTS 
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Preamble 
 
An early study from De Plaen et al. indicates that MAGEA1, -A2, -
A3, -A4, -A6 and -A12 are commonly expressed in various cancer cell 
lines as well as tumor samples. In contrast, MAGEA5, -A8, -A9, -A10 and -
A11 are rarely expressed [De plaen et al. 1994]. Therefore, we selected 
the first group of genes for our study. 
To determine the impact of MAGEA on p53 functions, we first 
selected a cellular model suitable for our strategy. We wanted to express 
separately these six members of the MAGEA family in a cancer cell line 
wt for p53 that does not express endogenously the different MAGEA. RT-
Q-PCR data on four p53 wt cancer cell lines available in our laboratory 
allowed us to determine that the MCF-7 (breast cancer) cell line was 
suitable for our project since it only expresses very low levels of some of 
the MAGEA (Supplemental data: Figure 34). 
To overexpress the different MAGEA in MCF-7 cells, the cDNA of 
the corresponding MAGEA was cloned in the V1899-pGATEWAY-5’CMV-
Triple-FLAG expression vector. The MAGEA cDNAs were cloned in fusion 
with a triple-FLAG tag since no specific antibodies were available at that 
time. By analyzing MAGEA structure and since Doyle et al. suggested 
that the C-terminally located MHD was responsible for MAGE activity, 
we choose to flag our proteins on the N-terminal end. Finally, and since 
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no antibiotic resistance gene were present on the V1899-pGATEWAY-
5’CMV-TripleFLAG vector, we also inserted a puromycin resistance 
cassette derived from the pPur vector. By the end of this preparation 
phase, six expression vectors V1899-pGATEWAY-5’CMV-Triple FLAG-
Puro
R
 each containing a specific MAGEA cDNA were created. 
 
To analyze the effects of MAGEA expression, MCF-7 stable clones 
were established following transfection of the different vectors and 
selection with puromycin. We selected clones based on western blot 
analysis using an anti-FLAG antibody (Supplemental data: Figure 35). 
 
We first identified which members significantly enhanced cell 
resistance to a genotoxic stress and, then focused on p53-dependent 
apoptosis. We also analyzed whether a direct binding between MAGEA 
and the tumor suppressor existed. Ultimately, we aimed to identify a 
new mechanism responsible for the reduced activity of the tumor 
suppressor in presence of MAGEA.  
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Chapter I: 
MAGEA1 and -A2 impair the stabilization and 
activation of p53 in presence of a genotoxic 
stress 
  
134 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
135 
 
 
MAGEA1 and -A2 impair the stabilization and activation of 
p53 
in presence of a genotoxic stress 
Benjamin Demoulin, Florence Wagner, Guillaume Macon, Denis Martin 
and Patrick Dumont1 
 
Laboratory of Cell Biology, Institute of Life Sciences, Université 
catholique de Louvain, Croix du Sud 4-5, Louvain-la-Neuve 1348, Belgium 
 
Running title: MAGEA inhibits p53 activation 
 
 
1 To whom correspondence should be addressed: 
Laboratory of Cell Biology, Insitute of Life Sciences, Université catholique 
de Louvain, Croix du Sud 5, 1348 Louvain-la-Neuve, Belgium. 
Tel: +32-10-473524 / Fax: + 32-10-473515 / E-mail: 
patrick.dumont@uclouvain.be 
 
  
136 
 
 
Abstract 
 
MAGEA (Melanoma AntiGEn-A) genes are members of the cancer testis 
antigens (CTAs). They are silenced in healthy human adult tissues to the 
exception of male germ cells. However, a re-expression is commonly 
observed in various types of cancer. Several studies demonstrated a 
correlation between MAGEA levels and advanced cancer stages, 
malignant transformation as well as increased resistance to 
chemotherapy. These observations emphasize that MAGEA proteins 
could have oncogenic properties and favor cancer development. 
However, the functions of MAGEA proteins in cancer cells remain largely 
unknown. In order to study the functions of the MAGEA commonly 
expressed in cancer, we used the MCF-7 breast cancer cell line to derive 
clones stably expressing them. Here, we present evidence that MAGEA1 
and MAGEA2 (but not -A3, -A4, -A6 and -A12) diminish the sensitivity of 
breast cancer cells to the chemotherapeutic agent doxorubicin. We link 
this resistance to reduced DNA damage-induced apoptosis in presence of 
MAGEA expression. Furthermore, we demonstrate that the mechanism 
is p53-dependent. MAGEA1 and -A2 proteins directly interact with the 
DNA binding domain of the tumor suppressor and inhibit the 
stabilization and activation of p53 in cells exposed to a genotoxic stress. 
We link the decreased activation and lowered half-life of stress-induced 
p53 to an impaired phosphorylation of its N-terminal region in presence 
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of MAGEA1 or -A2. Our data suggest that preventing MAGEA proteins to 
bind and inhibit p53 could be an interesting strategy to combat cancers 
that harbor the wt version of the tumor suppressor.  
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Introduction 
 
Cancer-testis antigens (CTAs) are silenced in healthy human adult 
tissus, to the exception of male germ cells. In addition, they are 
abnormally expressed in different cancers. Even if the normal functions 
of these genes seem to be related to embryonic development and more 
specifically to lineage differentiation [1], a clear identification of the 
molecular mechanisms involved remains to be performed.  
Currently, the CTAs family emcompasses more than an hundred 
different genes. The first clue on their existence was described by Van 
der Bruggen in 1991 [2]. Back then, a specific antigen (MZ2-E) carried by 
melanoma cells was shown to activate cytolytic T-lymphocytes. It turned 
out that this antigen was encoded by a portion of 2.4kb gene that was 
later named MAGEA1, the first CTA identified. This study also gives 
evidence that MAGEA1 is part of a bigger family and that the third exon 
of the gene encodes for the entire protein [2]. This breakthrough on the 
existence of tumor specific antigens raised the hope for a cancer specific 
vaccine. [3,4,5]. 
The MAGEA family contains eleven genes and four pseudo genes. 
Those genes are located in the q28 region of the X chromosome and are 
characterized by a MAGE Homology Domain (MHD) of approximately 
200 amino acids [6,7,8]. As members of the cancer testis antigens (CTAs), 
those genes are silenced in the vast majority of healthy human adult 
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tissues [9]. However, they are expressed in various types of cancer such 
as breast cancer, melanoma, lung cancer or colon cancer [10]. The main 
reason for this re-expression in cancers seems to be the demethylation 
of the promoter [11,12]. Several studies have demonstrated a 
correlation between MAGEA expression and an overall shorter survival 
of patients in different cancers such as breast cancer [13], head and neck 
cancer [14], lymphoma [15] and lung cancer [16]. Moreover, MAGEA 
expression correlates with advanced cancer stages [17], malignant 
transformation [18] and increased resistance to chemotherapeutic 
treatments [15,19,20,21]. 
Taken together, these data emphasize that MAGEA proteins could 
have oncogenic properties and favor cancer development. Surprisingly, 
the cellular functions of MAGEA remain largely unknown. Recently, 
several studies described that they could target the tumor suppressor 
p53 [19,22,23]. 
The tumor suppressor p53, also known as “guardian of the genome”, 
is a transcription factor that sets up the cellular response to numerous 
stresses. It is a major regulator of cell cycle arrest, replicative senescence 
and apoptosis [24]. It has been assessed that more than 50% of human 
cancers carry a mutation of the TP53 gene [25]. Although defined as a 
transcription factor, p53 is also able to induce apoptosis in a 
transcriptional independent manner. This activity of p53 involves its 
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translocation to the mitochondria and interactions with BCL-2 family 
members, notably BAK [26,27,28,29,30].  
In the absence of stress, the intracellular concentration of p53 is 
permanently kept at a low levels due to its degradation by the ubiquitin 
E3 ligase MDM2 [31] but also PIRH2 [32], ARF-BP1 [33] and COP1 [34]. 
Following specific stimuli such as DNA damage or oncogene activation, 
p53 is stabilized. This step involves expression of the tumor suppressor 
p14ARF, an inhibitor of MDM2, as well as several post-translational 
modifications of p53 including phosphorylations and acetylations [35]. 
These post-translational modifications occur on specific amino acids 
mainly located in the N- and C-terminal part of the p53 protein and 
modulate for instance the recruitment of transcriptional co-activators, 
the affinity of p53 for target promoters or the cellular localization of the 
tumor suppressor [36,37,38].  
In 2006, Monte et al. described a mechanism in which MAGEA2 
directly interacts with p53 on the BAX promoter and recruits HDAC3 
[19]. This allows the deacetylation of surrounding histones and by 
consequence decreases the expression of p53 target genes. A second 
hypothesis suggested by Yang et al. (2007) and developed by Doyle et al. 
(2010) is that MAGEA proteins could interact with KAP-1 (TRIM28), an 
ubiquitin E3 ligase, and act as co-repressors of p53 activity by enhancing 
its degradation [20,22]. In this study a direct binding of p53 to MAGEA 
proteins was not described. In 2010, Marcar et al. demonstrated that 
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MAGEA2 was able to directly interact with the DNA binding domain of 
p53 and inhibit its access to target promoters [23]. 
Here, we present evidence that, among the MAGEA genes commonly 
expressed in cancer, only MAGEA1 and MAGEA2 bear the ability to 
reduce the sensitivity of breast cancer cells to the chemotherapeutic 
agent doxorubicin. We link this resistance to reduced DNA damage-
induced apoptosis in presence of these MAGEA proteins. Furthermore, 
we demonstrate that the mechanism is p53-dependent, p53 function 
being altered in presence of MAGEA1 or -A2. We also describe a direct 
binding of MAGEA1 and -A2 to the DNA binding domain of p53. 
Remarkably, in cells exposed to a genotoxic stress, p53 stabilization and 
activation is altered. This decreased activation of p53 appears to be 
linked to an impaired phosphorylation of its N-terminal region in 
response to the genotoxic stress.  
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Materials and Methods 
 
Plasmids  
The pDEST-V1899-FLAG plasmid (Invitrogen) was first modified by 
insertion of a multiple cloning site and the puromycin resistance cassette 
from pPur plasmid (Clontech Laboratories). MAGEA cDNAs, a gift from 
Pr. E De Plaen (Ludwig Institute for Cancer Research, UCL, Belgium), 
were then inserted into the modified pDEST-V1899-FLAG vector through 
the Gateway method (Invitrogen) following manufacturer instructions. 
The pCR2.1-MAGEA1 and -A2 vectors were obtained by insertion of 
FLAG-MAGEA1 and -A2 sequences amplified by PCR from the previously 
created vectors. The pGEX-3X plasmids containing GST-p53, GST-N-
terminal p53 (1-92) and GST-p53 DBD (102-292) were generously given 
by Pr. M. Murphy (Wistar Institute, Philadelphia PA, USA). 
Cell Culture and Treatments  
The PA-1 human teratocarcinoma cell line (ATCC, CRL-1572) and the 
MCF-7 breast cancer cell line (ATCC, HTB-22) were grown in DMEM 
(Gibco, 42430-082) supplemented with 10% foetal bovine serum (FBS) 
and 1% penicillin-streptomycin (P/S) (Gibco, 15140-163). MCF-7 stable 
clones expressing MAGEA proteins were obtained by transfection of the 
pDEST-V1899-FLAG plasmids containing the different MAGEA cDNAs. 
Transfections were performed with FuGENE HD Transfection Reagent 
(Promega, E2311) following manufacturer instructions. Cells were 
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selected with puromycin (0.5µg/ml) before being characterized by 
western blot for MAGEA expression. Cells were treated with nutlin-3a 
(Sigma, N6287), doxorubicin (Sigma, 038K1349) and camptothecin 
(Sigma, C9911) as indicated in the figures.  
MTT Assays 
MTT assays were used to determine global cell growth after 
treatment. Briefly, cells were plated in 96-well plates at 5,000 cells per 
well and treatments started 48h later. After treatments (72h), cells were 
incubated for 3h with DMEM (10% FBS, 1% P/S) containing 0.5 mg/ml 
MTT (Sigma, M2128). Plates were then centrifuged (2100rpm) and the 
supernatants discarded. We added 200µl DMSO to dissolve the 
formazan precipitate. We then read the absorbance at 560 nm and 
subtracted that at 670 nm.  
Flow Cytometry 
 LDS751/PI labelling assays (Guava ViaCount, Millipore 4000-0041) 
and Annexin V-PE/7-AAD labelling assays (Guava Nexin, Millipore 4500-
0455) were realized to respectively determine the overall cell death after 
treatment and the proportion of apoptotic cells. Analysis was performed 
on a Guava easyCyte 6HT-2L flow cytometer (Millipore, USA). For both 
tests, cells were seeded in 25cm² flasks and treated 24h later. Following 
treatment, cells were harvested and labelled according to manufacturer 
instructions.  
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Immunoprecipitations 
Cells were harvested, washed (PBS, 4°C) and lysed with NP-40 lysis 
buffer (50mM Tris pH8, 5mM EDTA pH8, 150mM NaCl, 0.5% NP-40) 
supplemented with protease inhibitors. After removal of cell debris by 
centrifugation, protein extracts were incubated O/N at 4°C with protein-
A sepharose beads covalently bound to the anti-p53 FL-393 polyclonal 
antibody (Santa Cruz, SC-6243). Antigens were then eluted following 
manufacturer instructions (Thermo scientific, 26147) and analyzed by 
western blot. 
Expression and purification of GST-p53 constructs 
GST-p53 and deletion constructs were prepared from E. Coli BL21 
after induction of protein expression with 1mM IPTG (Sigma, I6758) for 
3h at 37°C. Bacteria were centrifuged, washed with STE buffer (10mM 
Tris pH8, 150mM NaCl, 1mM  EDTA) supplemented with protease 
inhibitor and resuspended in lysis buffer consisting of STE buffer 
supplemented with 100µg/ml Lysozyme (Sigma-Aldrich, L3790), 1mM 
PMSF  (Sigma-Aldrich, 78830), 10µg/ml aprotinin (Sigma-Aldrich, 10820), 
5 mM DTT (Sigma-Aldrich, 0632) and 1.5% sarkozyl. After sonication and 
removal of debris by centrifugation, proteins were bound to 
gluthathione-sepharose 4B beads during 3h. Beads were washed 4 times 
with PBS and proteins were elutated O/N with 5mM reduced 
glutathione. 
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GST pull-down  
In vitro translated (IVT) MAGEA1 and -A2 were produced using the 
TNT quick coupled Transcription/Translation system (Promega, L1170) 
following manufacturer instructions. We incubated for 2h at 4°C, 1µg of 
IVT MAGEA1 or -A2 proteins with 1µg of GST-p53, GST-p53 1-92 or GST-
p53 102-292 in binding buffer (20mM HEPES pH8, 150mM KCl, 1mM 
EDTA, 4mM MgCl2, 1mM DTT, 0.02% NP-40, 10% Glycerol, 0.5mM 
PMSF). Glutathione-sepharose 4B beads were then added for 30 min. 
After washes and centrifugation, pellets were resuspended in Laemmli 
buffer for western blot analysis. 
Western Blot 
Total proteins were extracted using RIPA buffer (150mM NaCl, 0.5% 
sodium deoxycholate, 50mM Tris-HCL pH 8.0, 0.1% SDS, 0.1% Triton X-
100) supplemented with protease and phosphatase inhibitors (Complete 
Mini EDTA Free, ROCHE 11836170001 ; Phosphatase Inhibitor Cocktail 2 
and 3, Sigma-Aldrich P0044 and P5720). Proteins were resolved by SDS-
PAGE and transferred to nitrocellulose membranes. Membranes were 
blocked and probed overnight. The following antibodies were used:  
mouse anti--actine (Sigma A1978), mouse anti-FLAG M2 (Sigma-Aldrich, 
F3165), mouse anti-p53 (Calbiochem, OP43), rabbit anti-pSer15 p53 (Cell 
Signaling, 9284S), rabbit anti-pThr18 p53 (Cell Signaling, 2529S), rabbit 
anti-pSer20 p53 (Cell Signaling, 9287S) and rabbit anti-pSer46 p53 (Cell 
Signaling, 2521S). After 3 washes, membranes were incubated with the 
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appropriate peroxydase-conjugated secondary antibodies: goat anti-
mouse (Dako, P0447) and goat anti-rabbit (Dako, P0448). 
Immunoreactive bands were detected using the Western Lightning kit 
(Perkin Elmer, NEL104001EA) and signal intensity quantified using Image 
J V1.41 software (NIH, USA).  
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Results  
 
MAGEA1 and -A2 but not -A3, -A4, -A6 and -A12 protect cells from 
the chemotherapeutic agent doxorubicin  
As described in the preamble, we generated MCF-7 stable clones 
expressing separately the different MAGE-A genes selected based on the 
early study of E. De Plaen [10].  For each MAGEA, three clones were 
treated with increasing concentrations of doxorubicin for 72h (0, 10, 25, 
50, 100, 250, 500nM). We measured global cell growth by MTT assays 
after treatment (Figure 26). A marked reduction of sensitivity to 
doxorubicin was observed at all concentrations in clones expressing 
MAGEA1 or -A2 (Figure 26 part 1 and 2). IC50s (concentrations that 
inhibits 50% of global cell growth) were determined. They indicate that 
clones overexpressing MAGEA1 and -A2 are 5-fold more resistant to 
doxorubicin than clones transfected with the empty vector (Figure 27). 
On the other hand, MAGEA3, -A4, -A6 and -A12 did not protect cells 
from the chemotherapeutic agent since IC50s were not significantly 
different from control clones (Figure 27) 
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Figure 26 (Part1) : Expression of MAGEA1 and -A2 enhances resistance to the genotoxic agent 
doxorubicin. (A) Curves represent the percentage of viability of MCF-7 stable clones expressing 
or not the MAGEA proteins. Cells were treated for 72h with 0, 10, 25, 50, 100, 250, and 500 nM 
doxorubicin. Untreated controls represent 100% viability.  After treatment, viability was 
measured by MTT assays as described in the Materials & Methods. Data are means of three 
different clones expressing MAGEA1, -A2, -A3 or transfected with the empty vector (Empty). 
Statistical test: Mann-whitney. ***: p-val < 0, 0001; **: p-val < 0,001; *: p-val < 0,05) (N=5, n=6).  
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Figure 26 (Part2): Expression of MAGEA1 and -A2 enhances resistance to the genotoxic agent 
doxorubicin. (A) Curves represent the percentage of viability of MCF-7 stable clones expressing 
or not the MAGEA proteins. Cells were treated for 72h with 0, 10, 25, 50, 100, 250, and 500nM 
doxorubicin. Untreated controls represent 100% viability.  After treatment, viability was 
measured by MTT assays as described in the Materials & Methods. Data are means of three 
different clones expressing MAGEA4, -A6, -A12 or transfected with the empty vector (Empty). 
Statistical test: Mann-whitney. ***: p-val < 0, 0001; **: p-val < 0,001; *: p-val < 0,05) (N=5, n=6).  
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Figure 27: Expression of MAGEA1 and -A2 enhances resistance to the genotoxic agent 
doxorubicin. IC50s (Doxorubicin concentration inhibiting 50% of global growth) were determined 
based on the viability curves. Values represented are the mean of three clones expressing a 
MAGEA protein or transfected with the empty vector. Standard deviations are indicated between 
brackets. Statistical test: Kruskal-Wallis coupled with a multiple comparison of Dunn. ***: p-val < 
0, 01. (N=5). 
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MAGEA1 and -A2 protect cells from camptothecin-induced apoptosis 
Since MTT assays are only able to measure global growth, we next 
sought to determine whether MAGEA1 and -A2 could have an impact on 
apoptotic cell death in presence of a genotoxic agent. For this purpose, 
we treated MCF-7 clones stably expressing MAGEA1 and -A2 as well as 
clones transfected with the empty vector with 1µM camptothecin for 
24h. Cell death was assessed by flow cytometry analysis after labelling 
with LDS751/PI. We found that MAGEA1 and -A2 decreased cell death by 
respectively 60% and 44% (Figure 28a). Apoptosis was next quantified by 
flow cytometry after labelling with annexin V-PE/7-AAD. As shown in 
Figure 28b, after treatment, control clones exhibit a proportion of 
apoptotic cells reaching 25.8%. By comparison, clones expressing 
MAGEA1 -and -A2 display a marked reduction of apoptosis, with 
respectively 11.1% and 13.9% of annexin V positive cells. Altogether, the 
above data allowed us to conclude that an elevated expression of 
MAGEA1 and -A2 protects MCF-7 breast cancer cells from cell death 
triggered by genotoxic agents. 
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Figure 28 : MAGEA1 and -A2 expression reduces campthotecin-induced apoptosis. (A) 
LDS751/PI staining followed by flow cytometry analysis allowed the quantification of cell death. 
MCF-7 stable clones expressing or not MAGEA1 or -A2 were treated with 1µM camptothecin for 
24h. Data are means of three clones expressing MAGEA1, -A2 or transfected with the empty 
vector. Statistical test: Kruskal-Wallis coupled with a multiple comparison of Dunn. ** : p-val < 
0,001 ; * : p-val < 0,05) (N=4). (B) MCF-7 stable clones expressing or not MAGEA1 or -A2 were 
treated with 1µM camptothecin for 24h and thereafter labelled with annexin V-PE/7-AAD. Data 
were obtained in quadruplicate and mean values with associated standard deviations are shown. 
Statistical test: Kruskal-Wallis coupled with a multiple comparison of Dunn. **: p-val < 0,001; *: 
p-val < 0,05 (N=4).  
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MAGEA1 and -A2 expression enhances resistance to the p53 
activator nutlin-3a 
A hypothesis to the reduction of sensitivity to doxorubicin and 
camptothecin observed in clones expressing MAGEA1 and -A2 involves 
inhibition of p53 function. Indeed, the tumor suppressor is activated 
following genotoxic stresses and is important for induction of apoptosis 
[39,40]. We treated the MCF-7 stable clones expressing or not MAGEA1 
or -A2 with increasing concentration of nutlin-3a (0-20µM) and 
measured overall cell growth by MTT assays after 72h of treatment 
(Figure 29). Nutlin-3a is a specific activator of p53. It interacts with the 
ubiquitin E3 ligase MDM2 and prevents it to bind and ubiquitinate p53, 
thus allowing stabilization of the tumor suppressor [41]. Data revealed 
that at every tested concentration, except 20µM, cells overexpressing 
MAGEA proteins were significantly more resistant to nutlin-3a than 
control cells (Figure 29). These data support the premises that MAGEA1 
and -A2 target p53 function, protecting cells from different apoptotic 
stimuli such as genotoxic stresses. 
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Figure 29 : Expression of MAGEA1 and -A2 protects against the p53 activator nutlin-3a. MCF-7 
clones expressing MAGEA1, -A2 or transfected with the empty vector were treated with 
increasing concentration of nutlin-3a (0, 1, 2, 5, 10 and 20 µM). After 72h of treatment, viability 
was measured by MTT assays. Data are means of three different clones. Statistical test: Student 
T-test. ***: p-val < 0, 0001; **: p-val < 0,001; *: p-val < 0, 05 (N=4, n=6).  
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MAGEA1 and -A2 interact with the DNA binding domain of p53 
Considering the above data indicating that MAGEA1 and -A2 enhance 
cell resistance to genotoxic stresses as well as the MDM2 inhibitor 
nutlin-3a, we tested for a possible interaction between these proteins 
and the tumor suppressor. We treated cells with 500nM doxorubicine 
for 18h and prepared total proteins extracts. A subsequent 
immunoprecipitation-western blot analysis revealed that stress-
activated p53 interacts with MAGEA1 and -A2 (Figure 30a). 
To determine whether the interaction between p53 and MAGEA1 or -
A2 was direct, we next performed GST pull-down assays (Figure 30). In 
vitro translated (IVT) FLAG-MAGEA1 and -A2 were incubated with GST-
p53 produced in E. coli. Western blot analysis after pull-down of the 
complex with glutathione sepharose beads indicates a direct binding 
between the tumor suppressor and both MAGEA proteins. Furthermore, 
the N-terminal region (amino acids 1-92) as well as the DNA binding 
domain (DBD, amino acids 102-292) of p53 were examined for their 
ability to bind MAGEA1 and -A2. GST-pull down assays show that the 
DBD of p53 is responsible for the direct binding. We also observed an 
interaction with the N-terminal part of p53 (Figure 30b). Although weak, 
this signal was consistent through all experiments realized, while the GST 
control was totally free from signal. These results allow us to say that 
MAGEA proteins bind directly to the DBD of the tumor suppressor and 
possibly its N-terminal region (Figure 30b). 
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Figure 30 : MAGEA1 and -A2 directly interacts with the DNA binding domain of p53. (A) MCF-7 
clones expressing MAGEA1 (A1) or -A2 (A2) as well as clones transfected with the empty vector 
(E) were treated with 500nm of doxorubicin for 18h to induce p53 expression. After treatment, 
total protein extracts were prepared and for each sample, 500µg proteins were 
immunoprecipitated with an anti-p53 polyclonal antibody. As negative control, an anti-lamin A/C 
antibody was used. After SDS-PAGE, interactions were revealed by western blot using an 
antibody targeting the N-terminal FLAG tag of the MAGEA proteins. The expression of p53, lamin 
A/C and MAGEA are also shown in the total protein extracts before immunoprecipitation 
(Inputs). (B) GST pull-down assays using on one hand in vitro translated (IVT) MAGEA1 or -A2 and 
on the other hand GST (negative control), GST-p53 wt, GST p53 1-92 (N-terminal region) or GST 
p53 102-292 (DNA Binding Domain) purified from E. Coli. GST-fusion constructs and IVT 
translated MAGEA proteins were incubated for 1h and interactions were isolated with 
gluthation-sepharose beads. A western blot analysis using anti-FLAG antibody revealed the direct 
interaction of MAGEA1 and -A2 with the tumor suppressor. 
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MAGEA1 and- A2 expression correlates with decreased p53 levels in 
cells exposed to a genotoxic stress 
We next sought to determine what would be the impact of these 
interactions on p53 stabilization and induction during a stress. In MCF-7 
stable clones treated with 500nM doxorubicin during 24h, we found a 
markedly decreased p53 levels in presence of MAGEA1 and -A2 (Figure 
31a). Densitometry analyses of three different experiments demonstrate 
that the expression of MAGEA1 and MAGEA2 reduces p53 levels by 
respectively 25% and 35% (Figure 31b). Moreover, we repeated the 
experiments in a second model. We transiently transfected PA-1 p53 wt 
ovarian carcinoma cells with MAGEA1 and MAGEA2 and treated the cells 
with 500nM doxorubicin. The levels of p53 were examined 24h later. 
Again, both MAGEA1 and -A2 markedly decreased p53 levels (Figure 
31c).  To summarize, our data show that expression of MAGEA1 or -A2 
reduces total p53 levels in cells exposed to a genotoxic agent.  
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Figure 31: MAGEA1 and -A2 expression reduces p53 levels in cells exposed to doxorubicin. (A) 
MCF-7 cells stably expressing MAGEA1 or -A2 as well as cells transfected with the empty vector 
(E) were treated with 500nM doxorubicin for 24 h and total proteins were extracted. Levels of 
p53 were analyzed by western blot using a mouse monoclonal anti-p53 antibody. Levels of p53 in 
the different clones were quantified by a densitometry analysis of the corresponding bands and 
normalization to the loading control (Actin). (B) Graph depicting the relative p53 levels in cells 
expressing or not the MAGEA proteins. The p53 levels in cells transfected with the empty vector 
was set to 1. The graph is based on three independent experiments. Statistical test: Student T-
test. **: p-val < 0,001 (N=3) (C) PA-1 ovarian cancer cells (p53 wt) were transiently transfected 
with MAGEA1, -A2 or the empty vector (E). The next day, cells were treated with 500nM 
doxorubicin for 24h. The levels of p53 were then analyzed by western blot using a mouse 
monoclonal anti-p53 antibody. The levels of p53 were quantified by a densitometry analysis of 
the corresponding bands and normalization to the loading control (Actin). 
 
  
C. 
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MAGEA1 and -A2 expression correlates with a decreased 
phosphorylation of p53 N-terminal region 
A reduced p53 levels in presence of MAGEA1 and -A2 could be the 
consequence of an impaired stabilization and activation of p53 during 
the early response phase to the genotoxic stress. A crucial step for the 
activation of p53 involves different post-translational modifications. For 
example, phosphorylation of Thr18 and Ser20 are essential to abrogate 
MDM2 dependent inhibition of p53 since they abolish the docking of 
MDM2 on the N-terminal region of p53 [37,42]. In addition, 
phosphorylation of the adjacent Ser15 enhances p53 transcriptional 
activity by favoring the recruitment of the transcriptional co-activator 
CBP/P300 [43].  
We examined whether the altered stabilization of p53 could be linked 
to a deficient phosphorylation of its N-terminal region. MCF-7 stables 
clones expressing or not MAGEA1 and -A2 were treated with 500nM 
doxorubicin for 18h and total protein extracts analyzed thereafter by 
western blot using antibodies specifically targeting phosphorylated 
forms of p53 (Figure 32). Since MAGEA1 -and -A2 reduce total p53 levels 
(Figure 31), we calibrated each sample in order to load the same amount 
of “total p53” in each well. We found that, in presence of an 
overexpression of MAGEA1 or -A2, the abundance of p53 Ser15 
phosphorylation was markedly decreased (Figure 32a). Phosphorylation 
of Ser20 is thought to be dependent on the prior phosphorylation of 
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Ser15 [43].  Data were consistent since Ser20 also displayed a reduced 
phosphorylation in presence of MAGEA1 and -A2 (Figure 32b). 
Additionally, phosphorylation of Thr18 was also impaired in presence of 
MAGEA proteins (Supplemental data: Figure 37).  
We next determined the levels of phosphorylation of Ser46. Ser46 
phosphorylation has been described as crucial for p53-dependent 
apoptosis. For instance, in MCF-7 cells, mutation of Ser46 into alanine 
markedly reduces UV light-induced apoptosis and prevents induction of 
p53 target genes such as PUMA and p53AIP1 [45,46]. When MCF-7 
clones expressing MAGEA1 and -A2 were examined after treatment with 
doxorubicin, we found a reduction of Ser46 phosphorylation (Figure 
32c). This observation is also in accordance with the increased resistance 
of these cells to apoptotic stimuli.  
Altogether, our data support the hypothesis that an elevated 
expression of MAGEA1 and -A2 impact on different post-translational 
events occurring in the early phase of p53 activation following a stress. A 
deficient N-terminal phosphorylation could explain the decreased p53 
levels in presence of MAGEA1 and -A2. Moreover, a decreased 
phosphorylation of Ser46 is known to compromise the expression of 
several p53 pro-apoptotic target genes and therefore p53-dependent 
apoptosis.  
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Figure 32: MAGEA1 and -A2 expression impairs p53 N-terminal phosphorylation. MCF-7 stable 
clones expressing MAGEA1, -A2 or transfected with the empty vector (E) were treated with 
doxorubicin for 24 h. Proteins extracts were standardized in order to load the same amount of 
total p53 in each well for western blot analysis. Western blot were realized with antibodies (Cell 
Signaling) targeting the phosphorylated forms of p53. (A) Left, western blot analysis showing the 
reduced phosphorylation of p53 Ser15 in presence of MAGEA1 or -A2. Right, Graph depicting the 
relative levels of pSer15-p53 in MCF-7 cells expressing or not the MAGEA proteins. The p53 levels 
in cells transfected with the empty vector was set to 1. Results are based on densitometry 
analysis from 4 independent experiments (N=4). (B) and (C) Analysis of respectively pSer20-p53 
and pSer46-p53 using the same strategy (N=3). 
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MAGEA1 and -A2 expression reduces p53 stability in cells exposed to 
doxorubicin 
As mentioned above, following a stress, different N-terminal 
phosphorylation events lead to a drastic enhancement of p53 half-life. 
Since we observed an impaired phosphorylation of p53 in presence of 
MAGEA1 and -A2, we examined whether p53 stability could be affected 
(Figure 33). MCF-7 clones expressing or not MAGEA1 and -A2 were 
treated with 500nM doxorubicine for 18h. Thereafter, protein synthesis 
was blocked with cycloheximide and total protein extracts prepared at 
different time points in order to evaluate the stability of stress-activated 
p53. As shown in Figure 33, the stability of the tumor suppressor was 
altered in presence of MAGEA proteins. After 8 hours of incubation with 
cycloheximide, densitometry analysis revealed a reduction of p53 level 
of 70% and 71% in presence of respectively MAGEA1 and -A2. These 
observations correlate with our previous data showing an impaired N-
terminal phosphorylation of p53 and overall decreased p53 levels in 
presence of MAGEA1 and -A2.  
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Figure 33 : MAGEA1 and -A2 expression reduces p53 half-life. MCF-7 stable clones expressing 
MAGEA1, -A2 or transfected with the empty vector (E) were treated with 500nM doxorubicin for 
24h. We next incubated cells with 30µg/ml cycloheximide (CHX) for 0, 2, 4, 6 and 8 hours and 
measured p53 levels by western blot. Half-life of p53 (T1/2) is reduced when MAGEA1 or -A2 is 
expressed as demonstrated by the densitometry. (N=3).  
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Discussion 
 
In this study, we demonstrate that among the MAGEA commonly 
expressed in cancer, only MAGEA1 and -A2 are able to increase the 
resistance of MCF-7 cells to the genotoxic agent doxorubicin. We further 
analyzed the effects of MAGEA1 and -A2 and found that they decrease 
apoptosis in presence of camptothecin, another genotoxic agent. Using 
nutlin-3a, an inhibitor of the ubiquitin E3 ligase MDM2, we also 
evidenced that cell growth inhibition triggered by this direct activator of 
p53 is reduced in MCF-7 clones stably expressing MAGEA1 or -A2, 
indicating that the tumor suppressor p53 could be a target of these 
proteins. Again, no significant protective effect was demonstrated for 
the other MAGE-A proteins when the clones were treated with 10 µM 
nutlin-3a (supplemental data: Figure 36).  
Whether MAGE-A proteins directly bind to p53 is controversial, 
therefore we aimed to study these interactions. In MCF-7 stable clones, 
we immunoprecipitated p53 and found a robust interaction with 
MAGEA1 and -A2. Moreover, GST-pull down experiments clearly 
indicated that the interaction is direct and involves the DNA binding 
domain of p53, as well as its N-terminal region. 
Moreover, in cells exposed to a genotoxic stress, we consistently 
observed markedly lower p53 levels in presence of MAGEA1 or -A2. This 
was observed in the MCF-7 stable clones and also in PA-1 cells 
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transiently transfected with MAGEA1 and -A2. Following a genotoxic 
stress, the classical model for wt p53 activation involves different N-
terminal phosphorylations that stabilize the tumor suppressor [37], 
allowing its intracellular concentration to increase. Our data indicate 
that Ser-15 phosphorylation is impaired in presence of MAGEA1 and -A2. 
This phosphorylation is an early post-translational event following a 
stress and is carried out by the ATM kinase as well as others. Ser-15 
phosphorylation is known to favor the recruitment of the acetyl-
transferase CBP/p300 and the subsequent phosphorylation of Thr-18 
and Ser-20 [42]. Our data indicate that these two phosphorylations of 
p53 are also altered in presence of MAGEA1 and -A2. Thus, MAGEA1 and 
-A2 prevent three N-terminal phosphorylations of p53 that act together 
to inhibit MDM2 binding and therefore to promote stabilization of the 
tumor suppressor. Subsequent experiments where we measured the 
half-life of stress-activated p53 in presence or not of the MAGEA 
proteins confirmed that p53 was destabilized in cells expressing MAGEA1 
or -A2.  
Finally, we examined the phosphorylation of Ser-46 and found that 
this was also altered in presence of MAGEA1 or -A2. This post-
translational modification is of interest since it is important for the ability 
of the tumor suppressor p53 to upregulate the expression of different 
pro-apoptotic genes such as those coding for PUMA and p53AIP1. 
Therefore, phosphorylation of Ser-46 is associated with enhanced p53-
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dependent apoptosis. Indeed, the S46A p53 mutant is markedly 
impaired for apoptosis induction [45,46,48]. 
Based on our different data, we propose a whole new mechanism to 
describe the impact of MAGEA expression on p53 function. MAGEA1 and 
-A2 are able to directly interact with p53. In addition, MAGE-A 
expression has a destabilizing effect on p53. In cells exposed to a 
genotoxic stress, lower p53 levels are observed in presence of MAGEA1 
and -A2. This is correlated to an impaired phosphorylation of p53 N-
terminal region, notably the phosphorylation of Ser15, Thr18 and Ser20. 
Phosphorylation of Ser46 is also affected in presence of MAGEA1 and -
A2. The absence of this post-translational modification is known to 
reduce p53 ability to trigger apoptosis. 
Several teams highlighted a relation between a high expression of 
type I MAGEs in cancer and disease aggressiveness, formation of 
metastasis, resistance to chemotherapeutic treatments and an overall 
poor patient prognosis [13,14,17,47]. Although their re-expression in 
cancer is known to be linked to the hypomethylation of their promoter, 
the biochemical functions of these proteins within cancer cells remained 
largely a mystery. The protective effect of MAGEA proteins against DNA 
damage-induced apoptosis was already described by Monte et al. (2006). 
For instance, using a siRNA pool able to target simultaneously different 
MAGEA, they evidenced in p53 wt U2OS cells an enhancement of 
apoptosis in presence of etoposide [19]. We here provide additional 
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information by pointing out that only MAGEA1 and -A2 protect from the 
DNA damaging agent doxorubicin while MAGEA3, -A4, -A6 and -A12 do 
not.  
The relation between MAGEA and p53 has been first identified by 
Monte et al. and later confirmed by other teams [22,23]. As far as we 
know, the destabilizing effect of MAGEA1 and -A2 on stress-activated wt 
p53 was never reported before. However, it was already observed that 
MAGE-C2 or mMAGE-b siRNA enhanced wt p53 levels in unstressed cells. 
Knock-down of the expression of MAGEA was also shown to increase the 
intracellular levels of mutant p53 in different cell lines [22]. Moreover, 
expression of MAGEA2 or -C2 in HCC143 cells that express the p53 
R248Q mutant results in a decreased expression of mutant p53 [22].  
 Further studies are now required to understand why the N-terminal 
phosphorylation of p53 is altered in presence of these MAGEA proteins. 
Hypothesis are numerous, one of them could be that MAGEA interaction 
prevents access to p53 N-terminal region. In favor of this, we detected a 
binding of MAGEA to the N-terminal (amino acids 1-92) of the tumor 
suppressor. On the other hand, it is also conceivable that MAGE-A 
proteins directly or undirectly regulate upstream regulators of p53 such 
as the kinase ATM, ATR, CHK1 or CHK2. This would explain why after 
acute DNA damage stress, p53 post translational modification is 
impaired. Finally, another hypothesis would involve the recruitment of 
phosphatases by MAGEA proteins. 
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 In addition to deciphering the mechanism of p53 destabilization by 
MAGEA, it would be interesting to determine in different cancer types 
whether there is a strong association between wt p53 and MAGEA1 and 
-A2. In that case, preventing MAGEA proteins to bind and inhibit p53 
could be an interesting strategy to sensitize cancer cells that retain the 
wt version of the tumor suppressor. To our knowledge, no such molecule 
exists. However, Bhatia et al. identified three compounds able to inhibit 
the binding of MAGEA to KAP1 (aka TRIM28) a RING domain protein 
tought to enhance p53 degradation in presence of MAGE-A proteins 
[49]. 
In summary, we describe a novel mechanism that shed light on the 
reduced activity of the tumor suppressor p53 in presence of MAGEA:  
MAGEA expression destabilizes p53 by impairing phosphorylation of its 
N-terminal region in cells exposed to a genotoxic stress.  
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Supplemental data 
 
 
 
Figure 34 : Relative expression of MAGEA1, -A2, -A3, -A4, -A6 and -A12 in different cancer cell 
lines harboring wt p53: WM-115 (melanoma), PA-1 (ovarian teratocarcinoma), MCF-7 (breast 
adenocarcinoma) and HCT-116 (colorectal carcinoma). RNA was extracted using Trizol method 
and a reverse transcription was performed. Expression data were obtained by qPCR and allow a 
relative quantification by comparing the Ct (Cycle threshold). Results are depicted as 2-ΔΔCt 
form. The ΔCt has been calculated by the substraction of the geometrical mean of housekeeping 
genes  Ct (SP1 and TBP) by the means Ct of each of the MAGEA genes. The ΔΔCt is determined by 
the substraction of calibrator ΔCt (WM-115 cell line ; ATCC ref : CRL-1675 ; human melanoma cell 
line) from the MAGEA specific ΔCt. By consequence, in this figure, the expression of MAGEA 
mRNA is equal to 1 (20) for the WM-115 cell line. A comparison is established between the 
expression of MAGEA mRNA in this cell line and the others : MCF-7 ( ATCC ref : HTB-22 ; 
adenocarcinoma derived cell line from human mammary gland), PA-1 ( ATCC ref : CRL-1572 ; 
human ovarian teratocarcinoma derived cell line) and HCT-116 ( ATCC ref : CCL-247 ; human 
colorectal carcinoma derived cell line). 
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Figure 35 : Expression of the different MAGEA proteins in MCF-7 stable clones. Following 
puromycin selection, each MCF-7 clone was analyzed for its MAGEA expression. The plasmid 
pDEST-v1899-FLAG allows the fusion of the MAGEA protein with a N-terminal triple FLAG tag. 
Therefore, we extracted proteins and check FLAG-MAGEA expression by western blot using the 
M2 anti-FLAG antibody (Sigma-Aldrich). Data show that clones express MAGEA proteins while 
control clones (transfected with the empty vector) do not. It is interesting to notice that MAGEA 
proteins migrate to approximatively 45kDa in 12% polyacrylamide gels when they predicted 
molecular weight is about ~34-35kDa (Expasy). Moreover, differences in migration may be 
observed among MAGEA proteins. 
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Figure 36 : Expression of MAGEA3, -A4, -A6 and -A12 does not protect against the p53 activator 
nutlin-3a. MCF-7 clones expressing the different MAGEA or transfected with the empty vector 
were treated with increasing concentration of nutlin-3a (0, 10, 25 and 50 µM). After 72h of 
treatment, viability was measured by MTT assays. Data are means of three different clones. 
Statistical test: Student T-test. ***: p-val < 0, 0001; **: p-val < 0,001; *: p-val < 0, 05 (N=4, n=3).  
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Figure 37 : MAGEA1 and -A2 expression decreases p53 phosphorylation on Thr18. MCF-7 clones 
expressing MAGEA1, -A2 or transfected with the empty vector were treated with doxorubicin for 
24h. Protein extracts were standardized in order to load the same amount of “total p53” for 
western blot analysis with an antibody (Cell signaling) targeting the Thr18 phosphorylated form 
of p53. For this post-translational modification, only one experiment was performed. 
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Supplemental data: Materials and Methods 
Cell culture. The human colorectal carcinoma cell line HCT-116 (ATCC number: CCL-
247), the human teratocarcinoma cell line PA-1 (ATCC number: CRL-1572), the breast 
cancer cell line MCF-7 (ATCC number : HTB-22) and melanoma cell line WM-115 (ATCC 
number : CRL-1675) were grown in DMEM (Gibco 42430-082) supplemented with 10% 
foetal bovine serum (FBS) and 1% Penicillin-Streptomycin (P/S) (Gibco 15140-163).  
RT-qPCR. Cell pellets were obtained by centrifugation and RNA was extracted using 
Trizol (Life Technologies). RNA extracts were reverse transcribed using Quantitect 
Reverse Transcription kit following manufacturer instructions (Qiagen, 205311). 
Primers were designed to amplify specific regions of the different MAGEA genes. 
Triplicate samples were prepared for qPCR with SYBR®Green PCR master Mix (Applied 
Biosystems N°. 4309155). Reactions contained 100ng of cDNA and 200nM of each 
primer. Reactions were submitted to the following amplification program: 95 °C for 
2min and then 40 cycles of 95 °C for 30 sec, 60 °C for 30sec. The following primers pairs 
were used:  
MAGEA1 : F: 5’ – GTAGAGTTCGGCCGAAGGAACCT – 3’  / R: 5’ – TGATGACTCTCGTCAGGGCAG – 3’  
MAGEA2 : F : 5’ – GAGGACAGTGTCTTCGCAC – 3’ / R : 5’ – GGTTCTCCACCGATCTTTAGTG -3’ 
MAGEA3 : F : 5’ – GAGATTCTCGCCCTGAGCAACGAG – 3’ / R : 5’ – CAGATCTTCTCCTTCAGTGCTCCTCC – 3’  
MAGEA4 : F : 5’ – GCGTGAAGCAGCTTTGTTAGAGGA – 3’ / R : 5’ – AAGCTGCTGCACAGGGCTGTTAG – 3’  
MAGEA6 : F : 5’ – GCTGAGTGTGTTAGAGGTGTT – 3’ / R : 5’ – CAGGAGTGGGTAGGAAATGC – 3’  
MAGEA12 : F : 5’ – CTGAGTGTGTTGGAGGCATC – 3’ / R : 5’ – GGTGGGTAGGAAATGTGAGGT – 3’  
SP1 : F : 5’ – CCGCTCCCAACTTACAGAAC – 3’ / R : 5’ – ATGATGTTGCCTCCACTTCC – 3’ 
TBP : F : 5’ – TTCGGAGAGTTCTGGGATTG – 3’/ R : 5’ – AATCAGTGCCGTGGTTCGT – 3’  
 
Western Blot. Total proteins were extracted from cells using RIPA buffer (150mM NaCl, 
0.5% sodium deoxycholate, 50mM Tris-HCl pH 8.0, 0.1% SDS, 0.1% Triton X-100) 
supplemented with protease and phosphatase inhibitors (Complete Mini EDTA Free, 
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ROCHE 11836170001 ; Phosphatase Inhibitor Cocktail 2 and 3, Sigma-Aldrich P0044 and 
P5720). Proteins were resolved by SDS-PAGE and transferred to nitrocellulose 
membranes. Membranes were blocked and then probed overnight with the following 
antibodies: mouse anti-p53 (dilution 1/1000; Calbiochem OP43) and rabbit anti-pThr18 
p53 (dilution 1/1000; Cell Signaling 2529S). After 3 washes, membranes were incubated 
with the appropriate peroxydase-conjugated secondary antibodies. Immunoreactive 
bands were detected using the Western Lightning kit (Perkin Elmer, NEL 104001EA) and 
signal intensity quantified using ImageJ V1.41 software (NIH, USA) 
 
MTT assays. Briefly, cells were plated in 96-well plates at 5,000 cells per well and 
treatments started 48h later. After treatments (72h), cells were incubated for 3h with 
DMEM (10% FBS, 1% P/S) containing 0.5 mg/ml MTT (Sigma, M2128). Plates were then 
centrifuged (2100rpm) and the supernatants discarded. We added 200µl DMSO to 
dissolve the formazan precipitate. We then read the absorbance at 560 nm and 
subtracted that at 670 nm.  
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Abstract 
Resveratrol (trans-3,4’,5-trihydroxystilbene) is a natural polyphenol 
synthesized by various plants such as grape vine.  Resveratrol (RSV) is 
a widely studied molecule, largely for its chemopreventive effect in 
different mouse cancer models. We propose a mechanism underlying 
the cytotoxic activity of RSV on colon cancer cells. Our data show that 
resveratrol induces apoptosis, as observed by the cleavage of PARP-1 
and chromatin condensation. We show that the tumor suppressor 
p53 is activated in response to RSV and participates to the apoptotic 
process.  Additionally, we show that HCT-116 p53 wt colon carcinoma 
cells are significantly more sensitive than HCT-116 p53 -/- cells to 
RSV. RSV induces DNA damage including double strand breaks, as 
evidenced by the presence of multiple γ-H2AX foci in 50% of cells 
after a 24h treatment with 25 µM RSV. The formation of DNA 
damage does not appear to rely on a pro-oxidant effect of the 
molecule, inhibition of topoisomerase I, or DNA intercalation.  
Rather, we show that DNA damage is the consequence of type II 
topoisomerase poisoning. Exposure of HCT-116 cells to RSV leads to 
activation of the Ataxia Telangiectasia Mutated (ATM) kinase, and 
ATM is required to activate p53.  
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Introduction 
Resveratrol is a natural polyphenol found in the skin of various 
fruits including grapes and berries (1). A first study published in 1997 
described that the molecule prevents the development of pre-
neoplastic lesions in cultured carcinogen-treated mammary glands 
and exerts protection against skin cancer in a mouse model (2). Since 
then, resveratrol (RSV) has been widely studied for this now fairly 
well evidenced chemopreventive properties. In addition, a potential 
use of RSV or derivatives in cancer chemotherapy is investigated. 
Indeed, reduction of tumor growth has been observed in different 
mouse cancer models including neuroblastoma, colon, prostate, liver 
and breast cancer (3-5). RSV acts as a suppressor of inflammatory 
processes that can influence cancer progression (6). The activity of 
RSV is also linked to its ability to inhibit tumor invasion, metastasis 
formation as well as neo-angiogenesis. Finally, other properties of 
RSV relevant to cancer prevention or therapy include modulation of 
cell redox status, inhibition of cell proliferation and induction of 
apoptosis (5-8). 
Among various mechanisms proposed to explain the apoptosis 
inducing properties of RSV on cancer cells, the molecule is known for 
its modulation of BCL-2 family members expression. RSV is able to 
upregulate the expression of pro-apoptotic proteins such as BAX, 
BAK, PUMA and NOXA while decreasing that of anti-apoptotic 
members like BCL-2, MCL1 and BCL-XL. Therefore, RSV could favor 
outer mitochondrial membrane (OMM) permeabilization and release 
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of the transmembrane apoptosis effectors in the cytosol (9, 10). RSV 
also modulates the extrinsic pathway of apoptosis that relies on 
binding of ligands such as TNF-α, FASL or TRAIL on their specific 
membrane receptor. RSV drives redistribution of the receptor 
FAS/CD95 to lipid rafts, therefore facilitating activation of this 
pathway (5). It also sensitizes cells to TRAIL-induced apoptosis 
presumably through similar mechanisms (5). 
The tumor suppressor p53 also appears to be a target of RSV 
since the molecule is able to activate p53 in a variety of cancer cell 
lines including breast, colon and prostate cancer cells as well as 
osteosarcoma and B-cell lymphoma (5).  However, how RSV signals to 
p53 is unknown. Alteration of pathways regulating the apoptotic 
process and direct mutation of genes involved in apoptosis is a 
hallmark of cancer (11). Central to apoptosis, the tumor suppressor 
p53 is the most frequently mutated gene in human cancer, with an 
overall mutation rate over 50% (12-15). As a transcription factor, p53 
induces or represses the expression of a variety of genes which 
products have respectively a pro-apoptotic (BAX, NOXA, PUMA, 
KILLER/DR5, FAS/CD95,…) or a pro-survival role (BCL-2, SURVIVIN, 
MDR1,…) (16, 17).  Additionally, p53 can trigger apoptosis by acting 
directly at the mitochondria. Indeed, in response to an apoptotic 
insult, p53 translocates to mitochondria and induces OMM 
permeabilization. This activity requires direct interaction of p53 with 
BCL-2 family members, and importantly BAK (18-23). 
The aim of this study is to investigate the mechanism(s) of RSV-
induced cell death in colon cancer cells, and the involvement of p53 
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in this process. We show that RSV is able to induce extensive DNA 
damage and more specifically DNA double strand breaks in human 
colon carcinoma cells, leading to p53-dependent apoptosis through 
the activation of the Ataxia Telangiectasia Mutated (ATM) kinase. We 
also provide evidence that DNA damage upon RSV treatment is due 
to topoisomerase II poisoning, and not an elevation of the 
intracellular levels of reactive oxygen species (ROS). 
  
 188 
 
 
Figure 38: Resveratrol induced apoptosis is p53-dependent. (A) DAPI staining reveals that 
RSV induces chromatin condensation. HCT-116 p53 wt cells were treated with different 
concentrations of RSV (0, 40, 80 and 160 µM) during 0, 24 or 48h. The graph represents the 
analysis of the percentage of cells presenting a nucleus with a condensed chromatin. In each 
experimental condition, countings were based on 12 images (20-100 cells per image). Data 
are presented as mean percentage ± SD of cells with a condensed chromatin. Photos are 
representative fluorescence microscopy images of DAPI stained cells. The white arrows 
indicate nuclei showing a condensed chromatin. (B) Analysis of the cleavage of PARP-1 by 
western blot in HCT-116 cells treated for 24h with 0, 50, 100 and 150 µM RSV. (C) Western 
blot analysis of the levels of p53 in untreated HCT-116 cells and cells exposed for 24h to 50 
µM RSV or 0.1 µM DOX. (D) Percentages of cell death in populations of p53 wt and knockout 
(KO) HCT-116 cells exposed to RSV. Cells were treated with 0 or 50 µM RSV during 24h and 
thereafter analyzed by flow cytometry (co-labeling with LDS751 and propidium iodide). Data 
are mean of 4 independent experiments ± SD. Statistical differences between means were 
calculated by analysis of variance, followed by the unpaired Student’s t test. (E) Western blot 
analysis of the cleavage of PARP-1 and the levels of p53 in HCT-116 p53 wt and KO cells 
treated for 24h with 0, 50, 150 and 250 µM RSV. The cleavage of PARP-1 was quantified by a 
densitometry analysis of the corresponding bands and normalization to the loading control 
(Actin).  
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Results 
 
Resveratrol induced apoptosis is enhanced in the presence of wt 
p53.  
 
Cultures of HCT-116 p53 wt colon carcinoma cells were 
exposed, for 0, 24 or 48h, to increasing concentrations of RSV and 
labeled with DAPI at the end of treatments in order to measure 
chromatin condensation, a morphological characteristic of the 
apoptotic nucleus. Following this treatment, the percentage of cells 
containing condensed chromatin increased in a time- and dose-
dependent manner (Figure 38A). PARP cleavage was also clearly 
observed in cultures incubated for 24h to concentrations of RSV 
equal or above 50 µM (Figure 38B). In addition, RSV triggered a 
marked induction of the tumor suppressor p53 (Figure 38C) as well as 
its translocation to the mitochondria, concomitant to cytochrome c 
release (Data not shown). We next examined whether RSV induced 
cell death was dependent on p53 function. HCT-116 p53 wt cells and 
their somatic-cell knock-out derivative HCT-116 p53 -/- (24) were 
incubated for 24h in the presence of 50 µM RSV and cell viability was 
thereafter quantified by flow cytometry (co-labeling with LDS751 and 
propidium iodide). Data show that the percentage of death is 
significantly higher in p53 wt cell populations (38.4 ± 5.1%) as 
compared to their null derivative (21.9 ± 4.8%) (p<0.05, Figure 38D). 
PARP cleavage was also assessed by western blotting in HCT-116 p53 
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wt and p53 -/- cells exposed to different concentrations of RSV for 
24h. A marked induction of p53 was observed in wt cells. Moreover, 
densitometry analysis of the bands revealed that PARP cleavage was 
2-fold more abundant in wt cells, indicating that presence of the 
tumor suppressor indeed enhances apoptosis (Figure 38E). A similar 
dependence of cell death on p53 function was observed using the 
PA1 ovarian teratocarcinoma cell line (p53 wt) and its derivative 
expressing the human papillomavirus (HPV) E6 protein (Figure 44). 
 
Resveratrol induces formation of multiple γ-H2AX foci.  
 
RSV was previously shown to damage plasmid DNA in vitro in 
the presence of copper cations, by an oxidative mechanism that 
requires generation of peroxides (25, 26). We therefore sought to 
determine whether RSV is able to induce DNA damage in HCT-116 
colon carcinoma cells and whether this is dependent on the 
generation of reactive oxygen species (ROS). At first, we monitored 
the formation of γ-H2AX foci. In response to DNA damage and more 
specifically DNA strand breaks, ATM and other kinases such as ATR 
and DNA-PK are known to phosphorylate the histone variant H2AX on 
Ser-139 (γ-H2AX) (27, 28). Very few cells presented with γ-H2AX foci 
in untreated controls (2.9 ± 3.4 %) or after a 24h exposure to the 
MDM2 inhibitor nutlin-3a (NUT) (0.3 ± 0.4 %), as expected (Figure 
39A).  Treatment of cells with doxorubicin (DOX) at 3 µM for 24h 
triggered formation of γ-H2AX foci (51.7 ± 10 %), in accordance with 
its described mechanism of action (29). Interestingly, we found a high 
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proportion of γ-H2AX positive cells in the presence of RSV (Fig. 2A). 
Formation of γ-H2AX foci was directly proportional to the 
concentration of the polyphenol, with 50% of cells displaying multiple 
foci after a 24h treatment in the presence of 25 µM RSV (Figure 39B).  
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Figure 39: Resveratrol triggers formation of DNA damage. (A) Representative 
immunofluorescence microscopy images of p53 wt HCT-116 cells treated or not (CTRL) for 
24h with 150 µM RSV, 35 µM NUT or 3 µM DOX. Formation of DNA damage was assessed by 
analyzing the presence of γ-H2AX foci, using an antibody that specifically recognizes the 
histone variant H2AX phosphorylated on Ser-139 (γ-H2AX). Nuclei are labeled with DAPI. (B) 
Percentage ± SD of cells presenting multiple γ-H2AX foci in cultures of HCT-116 p53 wt cells 
exposed for 24h to increasing concentrations of RSV (0, 2, 4, 8, 16, 32 and 64 µM). Countings 
were based on 6 different images for each experimental condition (100-200 cells/image). (C) 
Effect of the anti-oxidant NAC on RSV induced DNA damage. HCT-116 p53 wt cells were 
treated for 24h with 0 or 30 µM RSV in the presence or not of 5 mM NAC. Determination of 
the proportion of cells showing γ-H2AX foci was assessed by immunofluorescence 
microscopy. (D) Analysis of the effect of NAC on global cell growth. HCT-116 p53 wt cells 
were exposed for 72h to concentrations of RSV and H2O2 ranging from 0 to 500 µM, in the 
presence or not of 5 mM NAC. Global cell growth was determined by MTT assays at the end 
of treatments. Results are expressed as percentage of the control (untreated cells). Data are 
means of sextuplicates ± SD. 
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Formation of γ-H2AX foci and cell death are not inhibited by the 
anti-oxidant N-acetyl cysteine.  
 
As a polyphenol, RSV displays anti-oxidant properties (30, 31). 
However, some reports also suggest a pro-oxidant action of RSV. For 
instance, chronic exposure of HCT-116 cells to RSV was reported to 
induce senescence and this was associated to an elevation of the 
intracellular levels of reactive oxygen species (ROS), including 
hydrogen peroxide and superoxide anion (32). To determine whether 
the cell death and γ-H2AX foci were the result of pro-oxidant activity 
of RSV, we analyzed the impact of the anti-oxidant N-acetyl cysteine 
(NAC).   We found that NAC is consistently unable to inhibit 
formation of γ-H2AX foci in HCT-116 cells treated for 24h in the 
presence of RSV (Figure 39C). We also tested whether NAC was able 
to improve the viability of cell populations exposed to RSV. HCT116 
cells were incubated for 72h to increasing concentrations of RSV 
(from 0 to 500 µM) in the presence or not of 5 mM NAC. We found 
that cell viability, as determined by MTT assays, was not rescued by 
NAC (Figure 39D). In contrast, NAC was highly protective against 
hydrogen peroxide, thus verifying the efficiency of the antioxidant 
(Figure 39D).  The combined data support the premise that RSV-
induced cell death is not due to its pro-oxidant function. 
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Resveratrol is not a DNA intercalating agent and does not inhibit 
topoisomerase I. 
To determine the mechanism by which RSV induces DNA damage, 
we next analyzed whether RSV acts as a DNA intercalating agent or 
affects the activity of topoisomerases (TOPO). We first performed 
DNA unwinding tests in the presence of TOPO I, an enzyme able to 
negatively supercoil a relaxed circular DNA plasmid in the presence of 
an intercalating agent (33) (Figure 40A). We compared RSV to 
doxorubicin (DOX), a known DNA intercalator. Relaxed circular 
pRc/CMV plasmid was incubated in the presence of TOPO I, and 
increasing concentrations of RSV or DOX. The effect of DOX was 
readily observed at 5 µM, as noted by a shift of the topoisomers 
towards the supercoiled form. Our data indicate that RSV, even up to 
concentrations of 500 µM, does not intercalate into DNA (Fig. 3A and 
data not shown).  Notably, the failure of RSV to affect DNA was not 
the consequence of a direct inhibition of TOPO I enzymatic activity by 
RSV, as evidenced by our finding that TOPO I was able to relax a 
supercoiled plasmid in the presence of 200 µM RSV (Figure 40B).  
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Figure 40: Resveratrol acts as a topoisomerase II poison. (A) DNA intercalation was monitored 
by conversion of relaxed pRc/CMV plasmid to supercoiled molecules in the presence of TOPO I. RSV was 
used at concentrations of 50, 100 and 200 µM. DOX is used as positive control for DNA intercalation at 
concentrations of 5, 10 and 20 µM. A: pRc/CMV plasmid purified from E. coli and showing a mix of the 
relaxed (R) and supercoiled (Sc) forms. B, substrate of the reaction: relaxed pRc/CMV plasmid. (B) RSV 
does not inhibit TOPO I. Supercoiled pRc/CMV was relaxed in the presence of TOPO I and either RSV at 
200 µM or its solvent alone.  Sc, supercoiled pRc/CMV; R, relaxed pRc/CMV. (C) Inhibition of TOPO II 
activity was analyzed by a kDNA decatenation assay. Catenated kDNA fails to migrate during 
electrophoresis due to the large size of the network, while decatenated kDNA migrates to generate a 
major band at 2.5 kb. RSV was used at concentrations of 50, 100 and 200 µM. Etoposide was used as 
positive control for TOPO II inhibition at a concentration of 50 µM. Left, ethidium bromide stained 
agarose gel showing the inhibition of kDNA decatenation by RSV and etoposide. Right, graph presenting 
a quantification of the data based on a densitometry analysis of the bands corresponding to 
decatenated kDNA. Data are mean of 3 independent experiments and are expressed as percentage ± SD 
of decatenation relative to the control (reaction in the presence of TOPO II but without drug). Statistical 
differences between means were calculated by analysis of variance, followed by the unpaired Student’s 
t test. (D) TOPO II band depletion assay. HCT-116 p53 wt cells were exposed for 24h to 0, 50, 100 and 
200 µM RSV as well as etoposide at concentrations of 10 and 50 µM. At the end of treatments, the 
soluble nuclear fraction was isolated and the levels of free TOPO II was determined by western blot. The 
loading control is a non specific band detected at a MW of 75 kDa.  
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Resveratrol triggers DNA damage by poisoning topoisomerase II. 
The enzyme topoisomerase II (TOPO II) regulates chromatin 
topology by operating a breakage-reunion cycle that involves 
formation of an intermediate, the so-called cleavable complex, in 
which each subunit of the TOPO II homodimer is covalently linked to 
the newly created 5’ phosphate ends (34). To test the possibility that 
RSV was a TOPO II poison, we compared the effect of RSV to that of 
etoposide, a reference TOPO II poison (34). Kinetoplast DNA, which 
consists of a large network of small interlocked circular DNA 
molecules, is too large to enter an agarose gel. However, in the 
presence of TOPO II, monomers are released from the network and 
migrate into the gel generating a major band at 2.5 kb. We observed 
that both etoposide (50 µM) and RSV (100 and 200 µM) are able to 
inhibit TOPO II-mediated kDNA decatenation (Figure 40C). 
Quantifications obtained by measuring the densitometry of the 
bands indicate that 200 µM RSV causes 80% inhibition (p=0.0014, 
Figure 40D), which is comparable to the effect of 50 µM etoposide 
(90% inhibition) (p=0.0004, Figure 40D). Next, we tested whether RSV 
stabilizes the cleavable complex. We used the well-known ‘band 
depletion’ assay that allows determination of the relative amount of 
chromatin-bound (cleavable complex) and free TOPO II in a nuclear 
fraction. We found that a 24h treatment of HCT-116 p53 wt cells with 
100 or 200 µM RSV leads to the depletion of TOPO II from the soluble 
nuclear fraction, indicating that the enzyme is trapped on chromatin. 
A similar effect was observed in the presence of 50 µM etoposide 
(Figure 40E). The combined data are consistent with the premise that 
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RSV acts as bona fide TOPO II poison, by stabilizing a covalent 
enzyme-DNA intermediate. This correlates with the presence of γ-
H2AX foci in RSV-treated cells since the histone variant H2AX is 
indeed phosphorylated on Ser-139 by different kinases including ATM 
following DNA double strand breaks.  
 
The tumor suppressor p53 is phosphorylated on serine 15 by the 
kinase ATM in response to resveratrol.  
In order to probe the RSV signaling pathway upstream of p53, 
we next monitored phosphorylation of this protein. After a 24h 
treatment of HCT-116 cells with RSV, we observed phosphorylation 
of p53 on Ser-15, Ser-33 and Ser-37 (Figure 41A). Ser-15 
phosphorylation constitutes an early post-translational modification 
of p53 following DNA damage and can be performed by different 
kinases including ATM, ATR and DNA-PK (35, 36). To understand the 
signaling pathway triggering p53 activation in response to RSV, we 
aimed to identify the protein kinase responsible for Ser-15 
phosphorylation. Since TOPO II poisoning and formation of γ-H2AX 
foci occur in the presence of RSV, we first investigated the possible 
role of ATM. When HCT-116 cells were treated with RSV for 24h in 
the presence of caffeine, an ATM kinase inhibitor (37), we observed a 
reduced stabilization of p53, as well as reduced Ser-15 
phosphorylation (Figure 41B). We repeated the experiments using 
KU55933, a specific ATM kinase inhibitor (38). Similar to caffeine, 
KU55933 prevented the stabilization of p53 after a 24h treatment 
with RSV and decreased p53 Ser-15 phosphorylation (Figure 41C). To 
 198 
 
confirm the specificity of the phospho-specific antibody, SAOS-2 cells 
(p53 -/-) were transiently transfected with wt p53 or the p53 mutant 
S15A, where Ser-15 has been replaced by an alanine. An antibody 
against “total p53” detected both the mutant and wt forms of the 
protein, while the phospho-specific antibody only recognized p53 wt 
(Figure 45). We also found that caffeine can markedly reduce p53 
activation in the presence of RSV or DOX, but fail to do so in the 
presence of the MDM2 inhibitor, nutlin-3a (NUT) (Figure 41D). The 
combined data indicate that RSV-induced DNA damage leads to the 
activation of ATM and that this kinase participate to stabilization of 
p53.  
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Figure 41: The ATM kinase phosphorylates p53 on Ser-15 in response to RSV treatment. (A) 
Western blot analysis of different N-terminal phosphorylations of p53 after a 24h treatment 
of HCT-116 cells with increasing concentrations of RSV. Membranes were probed with 
primary antibodies specifically recognizing the p53 forms phosphorylated on serines 15, 33 
and 37. Actin was used as loading control.  (B) Caffeine inhibits p53 stabilization and its 
phosphorylation on Ser-15. HCT-116 cells were treated or not for 24h with 250 µM RSV. (C) 
The ATM inhibitor KU55933 decreases p53 induction and Ser-15 phosphorylation in HCT-116 
cells exposed or not for 24h to 250 µM RSV. (D) Effect of caffeine on p53 stabilization 
following an apoptotic stimulus. HCT-116 cells were treated for 24h with 250 µM RSV, 60 µM 
NUT or 750 nM DOX, in the presence or not of 4 mM caffeine. The effect of caffeine was 
quantified by a densitometry analysis of the p53 bands and normalization to the loading 
control (Actin). The value of 1.0 was attributed to the levels of p53 in cells exposed to the 
apoptotic agent in the absence of caffeine. 
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p38MAPK and ERK1/2 are not involved in serine 15 
phosphorphorylation of p53.  
It has been described that p38MAPK and ERK1/2 are activated 
in the presence of RSV and may play a role in stabilization of the 
tumor suppressor p53 (39). HCT-116 p53 wt cells were treated with 
DOX, RSV or NUT in the presence or not of the well-described 
p38MAPK inhibitor, SB203580 (40). We found that the inhibition of 
p38MAPK has no effect on the intracellular concentration of the p53 
protein or its phosphorylation on Ser-15 (Figure 42A, top). In order to 
monitor the efficiency of SB203580, we studied its effects on Ser-46 
phosphorylation since this residue is also the target of p38MAPK: we 
previously published that SB203580 inhibits p53 phosphorylation on 
Ser-46, as well as apoptosis, in MCF-7 breast carcinoma cells exposed 
to UV light (41). We found that SB203580 was able to prevent DOX-
induced Ser-46 phosphorylation of p53 (Figure 42A, bottom). Next, 
similar experiments were performed to test for a role of ERK1/2. 
HCT-116 p53 wt cells were treated for 24h with RSV, DOX or NUT in 
the presence or not of the MEK1 inhibitor PD98059 (42). As shown in 
Figure 42B, this compound does not affect the overall levels of p53 
protein or its phosphorylation on Ser-15, suggesting that ERK1/2 is 
not involved.  
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Figure 42: p38MAPK and ERK1/2 are not involved in p53 Ser-15 phosphorylation. (A) HCT-
116 colon carcinoma cells were treated for 24h with 250 µM RSV, 60 µM NUT or 750 nM 
DOX in the presence or absence of the p38MAPK inhibitor SB203580. The molecule was 
added 30 min before the apoptotic agents at a final concentration of 20 µM. An analysis of 
the levels of p53 as well as of its phosphorylations on Ser-15 and -46 was performed by 
western blot. (B) HCT-116 cells were treated as in (A) in the presence or not of the MEK1 
inhibitor PD98059 used at a concentration of 35 µM. We analyzed by western blot the levels 
of p53 and its form phosphorylated on Ser-15.  
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Discussion 
 
Here we provide data that RSV is cytotoxic to colon cancer cells 
and that it induces apoptosis at least partly in a p53-dependent 
manner.  Specifically, we find that p53 is stabilized and activated in 
the presence of RSV, as noted by the increase of its intracellular level 
and presence of different phosphorylations such as P-Ser15, P-Ser33 
and P-Ser37. These phosphorylation events are part of an initializing 
cassette of N-terminal post-translational modifications that allow p53 
activation in response to detrimental stimuli. Within this cassette, 
Ser-15 phosphorylation is believed to be one of the earliest events in 
response to DNA damage but also hypoxia or nutrient deprivation. 
Depending on the stimulus, different kinases including ATM, ATR, 
DNA-PK, mTOR, AMPK, RSK and CDK5 can phosphorylate the Ser15 of 
p53 (35-36).  Since we observed extensive development of γ-H2AX 
foci in cells exposed to RSV, we first investigated for a role of ATM, 
the major kinase involved in C-terminal Ser139 phosphorylation of 
histone variant H2AX in response to DNA double strand breaks (43) 
Using two different ATM kinase inhibitors, caffeine and KU55933, we 
demonstrate that Ser15 phosphorylation of p53 is highly dependent 
on the activity of this enzyme (Figure 43).  
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Figure 43: Model depicting the mechanism of RSV induced apoptosis. RSV acts as a genuine 
TOPO II poison, converting the enzyme into an intracellular toxin that generates DNA double 
strand breaks. This results in ATM kinase activation and phosphorylation of its substrates, 
including Ser139 of the histone variant H2AX and the tumor suppressor p53. In response to 
RSV, p53 is phosphorylated on Ser15 by the ATM kinase and is stabilized. Its intracellular 
levels increases markedly and this is blocked by ATM kinase inhibitors such as caffeine and 
KU55933. Other post-translational modifications can also be detected on p53, including 
Ser33 and Ser37 phosphorylation. Ultimately, RSV triggers apoptosis in a p53-dependent 
manner.  
 
Extensive DNA damage in presence of RSV as well as p53 and 
ATM activation led us to analyze whether the polyphenol could act as 
a DNA intercalating agent or modulate the activity of type I and II 
TOPO. The experiments described here allow concluding that RSV 
does not show the features of a DNA intercalator. Moreover, 
concentrations of RSV as high as 500 µM do not affect type I TOPO. 
Interestingly, in vitro kDNA decatenation assays revealed inhibition of 
type II TOPO. In correlation, band depletion assays performed in 
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colon cancer cells indicate that the enzyme is depleted from the 
soluble nuclear fraction in presence of RSV. Thus our data suggest 
that, similary to etoposide, RSV behaves as a TOPO II poison, 
stabilizing a covalent DNA-protein intermediate that is transiently 
formed during the catalytic cycle of the enzyme. Resolution of this 
intermediate ultimately generates DNA double strand breaks, a 
stimulus sufficient to trigger ATM activation and p53-dependent 
apoptosis (Figure 43). Our study is not the first to report that 
stilbenes target TOPO II. It has been described since several years 
that polyphenolic fractions from grape cell cultures exhibit inhibition 
of TOPO II catalytic activity (46). Among this fraction, RSV was 
identified (47). Similar properties have also been reported for 
nepalensinol (resveratrol oligomers) (48). More recently, similar 
activity of RSV towards TOPO II was documented by Leone et al. in 
glioblastoma cells (49). In addition, when RSV is combined to 
doxorubicin, a reduction of the TOPO II poisoning effects of 
doxorubicin is observed, suggesting a competition between the two 
molecules (50). TOPO II poisoning is a common and well known 
mechanism of action among drugs used in cancer chemotherapy. 
Further studies are now needed to precisely quantify the effect of 
RSV by comparison to a panel of well described TOPO II poisons. Our 
data already suggest that RSV is less efficient than etoposide: 
depending on the assay employed, we found that a 2- to 4-fold 
higher RSV concentration was required to match the effect of 
etoposide.   
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In this study, formation of DNA damage or cell death induced 
by the dietary polyphenol was not affected, even marginally, by co-
incubation with the general antioxidant NAC. This strongly suggests 
that RSV does not cause an increase, even at high doses, of 
intracellular ROS such as H2O2. Our results are in apparent 
contradiction with previous work. For instance, RSV was recently 
shown to trigger the senescence of non-small cell lung cancer 
(NSCLC) cell lines. This was associated with presence of DNA damage 
and ROS production. Moreover, DNA damage (formation γ-H2AX foci) 
and entry into premature senescence (SA-β-gal activity) induced by 
RSV were both significantly decreased in the presence of NAC (44). 
An earlier study, in 2007, described that chronic exposure of HCT-116 
cells to low doses of RSV leads to development of a senescent 
phenotype. Again, this was associated with an elevation of the 
intracellular level of ROS, including hydrogen peroxide and 
superoxide anion and inhibited by NAC (32) Thus, depending on 
different parameters such as the cell line employed, expression of 
identified or yet unknown intracellular targets and likely the dose 
applied, RSV could trigger different responses in the target cells. One 
response is cell death by apoptosis and appears to be independent of 
ROS generation whereas a second involves entry into premature 
senescence and is tightly linked to ROS production. Indeed, exposure 
of cancer or normal cells, such as human fibroblasts, to sublethal 
doses of oxidants are known to cause a senescent phenotype 
characterized among others by an irreversible cessation of cell 
division and presence of the SA-β-gal activity (45).  
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To conclude, it is reasonable to believe that usage of RSV as a 
cancer chemotherapeutic drug is conditioned to the development of 
analogs with an improved bioavailability and/or TOPO II poisoning 
activity, a strategy that we are currently exploring. In addition, 
cancers from the gastrointestinal tract and more specifically 
colorectal cancer, an important cause of death in developed 
countries, could be a good target for RSV. Recently, Patel et al. (2010) 
measured the RSV concentrations in tumor tissues of patients 
suffering from colon cancer and given 1g of the polyphenol daily for 8 
days (51). They found mean concentrations of 2.07 and 94.1 nmol/g 
(or 94.1 µM assuming that 1g of tissue represents 1 ml) in 
respectively left (descending colon) and right (ascending colon) sided 
tumors (51). Thus, it can reasonably be hypothesized that high doses 
of RSV or derivatives given orally could locally achieve concentrations 
high enough to trigger inhibition of tumor cell proliferation or 
apoptosis induction.  
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Materials and Methods 
 
Cell culture and treatments. We used the p53 wt HCT-116 human 
colorectal carcinoma cell line (ATCC CCL-247) and its knockout 
derivative (p53 -/-) described by Bunz et al. (1998) (24), as well as the 
p53 null Saos-2 human osteosarcoma cell line (ATCC HTB-85). All 
cells, routinely tested for mycoplasma contamination, were grown in 
DMEM (Gibco 42430-082) supplemented with 10% fetal bovine 
serum and 1% penicillin-streptomycin (Gibco 15140-163). Resveratrol 
(RSV) (Sigma-Aldrich R5010), nutlin-3a (NUT) (Sigma-Aldrich N6287) 
and doxorubicin (DOX) (Sigma-Aldrich 038K1349) were used as 
indicated in the figures. The following protein kinase inhibitors were 
employed: caffeine (4 mM) (Sigma-Aldrich C0750), KU55933 (10 µM) 
(Tocris Bioscience), SB203580 (20 µM) (Sigma-Aldrich S8307) and 
PD98059 (35 µM) (Cell Signaling CST9900). The inhibitors were 
applied 30-60 min before treatments of cells with the apoptosis 
inducers. The anti-oxidant N-acetyl cysteine (NAC) was used at a 
concentration of 5 mM (Sigma-Aldrich A9165).  
Western blot. Proteins were extracted with ice-cold radio-
immunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl pH 8.0, 150 
mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 0.1% Triton X-100) 
supplemented with protease (Complete Protease Inhibitor Cocktail, 
Roche Diagnostics 11836170001) and phosphatase (Phosphatase 
Inhibitor Cocktail 2 & 3, Sigma Aldrich P5726 & P0044) inhibitors. 
Protein concentration of the lysates was determined using the Dc 
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Protein Assay Kit (Bio-Rad Laboratories). For each sample, equal 
amounts of proteins were resolved on polyacrylamide gels and 
transferred to nitrocellulose membranes. Membranes were blocked 
for 30 min with PBS containing 0.2% Tween-20 (PBS-T) and 5% non 
fat dry milk or alternatively 3% BSA. After blocking, membranes were 
incubated with the primary antibodies either 1h at room 
temperature or overnight at 4°C. The following primary antibodies 
were used: mouse anti-actin antibody (ab) (dilution of 1:5,000; 
Sigma-Aldrich A1978), mouse anti-p85-PARP ab (dilution of 1:2,000; 
Cell Signaling 9546), mouse anti-p53 ab (dilution of 1:1,000; Millipore 
OP43), rabbit anti-pSer9 p53 ab (dilution of 1:1,000; Cell Signaling 
9288); rabbit anti-pSer15 p53 ab  (dilution of 1:1,000; Cell Signaling 
9284); rabbit anti-pSer20 p53 ab (dilution of 1:1,000; Cell Signaling 
9287); rabbit anti-pSer33 p53 ab (dilution of 1:1,000; Cell Signaling 
2526); rabbit anti-pSer37 p53 ab (dilution of 1:1,000; Cell Signaling 
9289); rabbit anti-pSer46 p53 ab (dilution of 1:1,000; Cell Signaling 
2521) and rabbit anti-pThr18 p53 ab (dilution of 1:1,000; Cell 
Signaling 2529). After 3 washes with PBS-T, membranes were 
incubated with the appropriate peroxydase-conjugated secondary 
antibodies at a 1:2,500 dilution: goat anti-mouse ab (Dako P0447); 
goat anti-rabbit ab (Dako P0448). Immunoreactive bands were 
detected using the Western Lightning Kit (Perkin Elmer). 
Densitometry analysis of the bands was performed with Image J 
1.47v software (NIH, USA).  
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MTT assay. Cells seeded in 96-well plates (5,000 cells / well) were 
treated for 72h as described in the figures, each experimental 
condition being performed in sextuplicates (6 wells). After treatment, 
cells were incubated for 3h in culture medium supplemented with 0.5 
mg/ml 3-(4,5-dimethylthiazolyl-2)-2,5 diphenyltetrazolium bromide 
(MTT) (Sigma-Aldrich M2128). Then, plates were centrifuged at 
1,000g and the supernatant was discarded. We added 200µl DMSO 
(Sigma 154938) to dissolve the formazan precipitate. Global cell 
growth was assessed by measuring the absorbance at 560 nm and 
subtracting for each well that at 670 nm.  
Immunofluorescence. Cells growing on glass coverslips in 12-well 
plates (20,000 cells/well) were treated as described in the figures. 
After treatment, cells were washed with PBS, fixed for 20 min with 
PBS supplemented with 4% formaldehyde and permeabilized for 15 
min with PBS containing 0.2% Triton X-100. After blocking at 37°C for 
10 min with PBS supplemented with 0.05% Tween 20 and 3% BSA, 
cells were incubated overnight at 4°C with a primary antibody 
directed against γ-H2AX (dilution of 1:400; Cell Signaling 2577). After 
washing, cells were incubated with a goat anti-rabbit ALEXA 
Fluor488-conjugated secondary antibody (dilution of 1:400; 
Invitrogen A11034). After three additional washes, cells were 
mounted in Vectashield (Vector laboratories INCH1000) / DAPI 
(Roche 10236276001) (9:1 v/v).  
Flow cytometry. Cell viability was determined by co-labeling with 
LDS751 and propidium iodide, using the Guava Viacount reagent 
(Millipore, USA) according to the instructions of the manufacturer. 
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After 5 min of incubation, cells were analysed on a Guava easyCyte 
6HT-2L flow cytometer (Millipore, USA).  
DNA unwinding assay. Circular pRC/CMV plasmid (0.8 µg) 
(Invitrogen) purified from E. coli and predominantly supercoiled was 
first relaxed with 2U of topoisomerase I (TOPO I) during a 20 min 
reaction at 37°C, in 30µl of 50 mM Tris-HCl (pH 7.5), 50 mM KCl, 0.5 
mM dithiothreitol, 50 µM EDTA and 30 µg/ml BSA. Molecules were 
then added at concentrations of 50, 100 and 200 µM for RSV or 5, 10 
and 20 µM for DOX. After 1h of incubation at 37°C, the reactions 
were stopped by addition of SDS to a final concentration of 0.2% 
(wt/v) and digestion of TOPO I with proteinase K (50 µg/ml, 30 min at 
37°C). The plasmid was extracted using phenol/chloroform (1:1 v/v) 
and a 1% agarose gel electrophoresis was performed overnight at 30 
mV. Gels were stained the next day with ethidium bromide to 
visualize distribution of the pRC/CMV topoisomers.  
Topoisomerase II kDNA decatenation assay. Effect of RSV on 
topoisomerase II (TOPO II) catalytic activity was assessed using 
kinetoplast DNA (kDNA) from C. fasciculata as substrate. Briefly, 250 
ng of kDNA (Vaxron Corp., USA) were incubated with 1U of TOPO II in 
the presence or not of RSV and etoposide in 10 µL of 0.5 M Tris-HCl 
(pH 8.0), 1.0 M NaCl, 10 mM dithiothreitol, 0.1 M  MgCl2, 20 mM ATP 
and 200 µg/ml BSA. After 15 min at 37°C, reactions were stopped by 
addition of SDS. TOPO II was then digested with proteinase K and the 
entire reaction was resolved on a 1% agarose gel.  
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Topoisomerase II band depletion assay. Cells were treated for 24h 
with 0, 50, 100 or 200 µM RSV. Etoposide at 10 and 50 µM was used 
as positive control for TOPO II poisoning. After treatment, cells were 
collected, centrifuged and washed with NB buffer (2 mM KH2PO4, 5 
mM MgCl2, 150 mM NaCl, 1 mM EGTA, 0.2 mM dithiothreitol, pH 
6.5). The cell pellet was resuspended in 5 ml NB buffer supplemented 
with 0.35% Triton X-100, incubated for 5 min on ice and then 
centrifuged at 1,000g for 10 min. The obtained nuclear pellet was 
washed once and proteins were extracted with NB buffer containing 
0.35 M NaCl (4°C, 30 min). Chromatin and non soluble material were 
pelleted during a 10 min centrifugation at 17,000g. The supernatant 
(soluble nuclear fraction) was then collected and stored. For each 
sample, 50 µg of proteins were resolved on a 6% polyacrylamide gel 
and transferred to nitrocellulose membranes. A western blot analysis 
with an antibody against TOPO II allowed to detect the presence of 
the enzyme in the different samples. 
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Figure 44 : Inhibition of global cell growth by RSV is p53-dependent. To confirm in a second 
model that the activity of RSV relies at least partly on the tumor suppressor p53, we used 
the PA-1 ovarian teratocarcinoma cell line (p53wt) and its derivative overexpressing the HPV 
E6 protein. The E6 protein binds and recruits E6-AP (E6-Associated Protein) that has an 
ubiquitin ligase activity. This results in ubiquitination of p53 and its targeting for 
proteasomal degradation. Thus, these cells fail to stabilize p53 in the presence of an 
apoptotic stimulus. The two cell lines were exposed during 72h to increasing concentrations 
of three different apoptotic agents: DOX, NUT and RSV. After treatment, MTT assays were 
performed as described in the material and methods. The table shows the calculated IC50s 
concentration that inhibits global cell growth by 50%) for each drug in both cell lines. Data 
indicate that the cell line harboring an active p53 is more sensitive to the three apoptotic 
stimuli. 
 
 
Figure 45 : Specificity of the antibody directed against the Ser-15 phosphorylated form of 
p53. SAOS-2 cells ( p53 -/-) were transiently transfected with pRc/CMV p53 wt, the p53 S15A 
mutant as well as the empty pRC/CMV (-). An antibody against  “total p53” detected both 
the mutant and wt forms of the protein, while the phospho-specific antibody only recognizes 
p53 wt. 
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1. MAGEA 
 
1.1. Main findings of the study 
 
By the end of this work, we identified a new mechanism of 
p53 inhibition by MAGE-A proteins. We demonstrate that the 
presence of MAGEA1 and -A2, but not -A3, -A4, -A6 and -A12, is 
correlated with a reduced sensitivity of MCF-7 cells to DNA damage. 
Moreover, we show that this reduced sensitivity is, at least in part, 
due to lower apoptosis induction. 
Cells expressing MAGE-A1 or -A2 display lower intracellular 
levels of the tumor suppressor p53 after exposure to the genotoxic 
agent doxorubicin. By looking for potential causes, we identified that 
major stabilizing post translational modifications such as 
phosphorylation of Ser15, Thr18 and Ser20 were impaired. 
Moreover, phosphorylation of Ser46, important for apoptosis 
induction, was also reduced in cells expressing MAGEA1 and -A2. Our 
data (immunoprecipitation-western blot analysis) also indicate that 
stress-activated p53 interacts with MAGEA1 and -A2. GST pull down 
experiments show that both the DNA binding domain and the N-
terminal region of p53 interact with MAGEA proteins.  To our 
knowledge, it is the first time that MAGEA expression is associated to 
an impaired phosphorylation of the p53 N-terminal region and 
correlated to reduced p53 levels in presence of DNA damage. 
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1.2. Integration to the current knowledge 
 
In 2012, Ladelfa et al. proposed a unified model, combining 
preexisting models, to described the complex relations between 
MAGEA and p53 (Figure 46). In absence of stress, two mechanisms 
co-exist. First, the E3 ubiquitin ligase TRIM28 sees its action 
enhanced by MAGEA2. This leads to an enhanced degradation of p53 
either by a better recruitment of the E2 enzyme on the E3 ubiquitin 
ligase or by an optimized transfer of ubiquitin to the substrate [Doyle 
et al.]. On the other hand, in absence of stress, MAGEA proteins 
directly bind the DNA binding domain of p53 impairing its access to 
DNA [Marcar et al., 2010]. 
 In stress condition, MAGEA proteins action switches to the 
recruitment of HDAC3 to p53-dependent promoters [Monte et al.]. In 
the same time, MAGEA causes impaired p53 acetylation by inhibition 
of PML-NBs formation [Peche et al.]. 
 Our results give a new dimension to this unified model. 
During a genotoxic stress, cells display reduced p53 levels when 
MAGEA1 or-A2 are present. This is concomitant to a decreased 
phosphorylation of Ser15, Thr18 and Ser20. Absence of these 
phosphorylations compromises stabilization of the tumor suppressor. 
Moreover, phosphorylation of Ser46 is also impaired, partially 
explaining the reduced apoptosis. Our results are not in opposition to 
this unified model but rather complementary. 
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Figure 46:  Ladelfa et al. model for MAGEA inhibition of p53 function: (I and II) In 
transformed unstressed cells expressing MAGEA, a low activity of p53 may be the results 
of the combined mechanisms of Marcar et al. and Doyle et al. causing a low concentration 
of p53 in the cell and an impairment of p53 binding to DNA. (III) In stress condition, such as 
chemotherapy, p53 levels and activity is modulated by the recruitment to p53 target 
promoters of HDACs by MAGEA proteins. This reduces histones acetylation and also 
probably p53 acetylation. Inhibiton of PML function by MAGEA could also participate to 
the inhibition of p53 acetylation. 
 
Therefore, our mechanism may be integrated to the current 
knowledge on the relations between MAGEA and p53. In Figure 47, 
the p53-MAGEA network is extended with the new mechanism.  
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Figure 47 : Updated version of MAGEA activities. MAGEA are implicated into p53 
destabilization and inhibition of transcription. MAGEA2 expression leads to an enhanced 
ubiquitination of p53 (Doylet et al.) and to the inhibition of PML-NBs leading to decreased 
p53 acetylation (Peche et al.), to the recruitment of HDAC on p53 promoters or to the 
inhibition of p53 binding to DNA (HDACI, Laduron et al.; HDACIII, Monte et al.). On the other 
hand, p53 also modifies MAGEA activity: p53 induces miR34a expression that directly targets 
MAGEA mRNA. Moreover, p53 also inhibits the expression of BORIS, responsible for the 
demethylation of MAGEA promoter. Here, we add a layer of complexity to this network by 
showing that phosphorylations important for p53 stabilization (Ser15, Thr18 and Ser20) and 
apoptosis induction (Ser46) are impaired in presence of MAGE-A proteins. 
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1.3. Discussion 
 
1.3.1 MAGEA family and resistance of cancer cells to 
genotoxic stress 
 
In 2006, Monte et al. showed the protective effect of MAGEA 
by comparing cell lines expressing various MAGEA genes (13923M, 
879M and 20706M) with cell lines that do not express MAGEA genes 
(15392M,18732M and3962M). They treated cells with increasing 
concentrations of etoposide and show that 13923M, 879M and 
20706M cell lines were more resistant. However, in their 
experiments, the MAGEA genes responsible for the reduced 
sensitivity to etoposide were not identified [Monte et al., 2006].  
Therefore, we created clones expressing separately the different 
MAGEA commonly expressed in cancer to assess their effects on cell 
resistance to genotoxic stresses. MTT assays determined that only 
MAGEA1 and -A2 diminish the sensitivity of MCF-7 breast cancer cells 
to doxorubicin while MAGEA3, -A4, -A6 and -A12 do not. Let’s 
continue our analysis for each of them. 
Concerning MAGEA1 overexpression, our results clearly show 
an increased resistance of MCF-7 cells to doxorubicin as well as 
camptothecin. Other studies linked the expression of MAGEA1 to an 
enhanced resistance to paclitaxel and docetaxel [Suzuki et al., 2007]. 
On the other hand, in 2007, Yang et al. specifically knocked down 
MAGEA1 in the Hs-294T cell line without seeing a clear drop in cell 
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survival [Yang et al., 2007] suggesting that MAGEA1 is not required to 
ensure cancer cell viability in the absence of a stress. Our results 
show for the first time the importance of MAGEA1 expression to 
maintain viability in presence of a genotoxic stress. 
MAGEA2 also shows protective effects in our model. Several 
studies described the effect of MAGEA2 on cellular growth and 
resistance to genotoxic drugs [Yang et al. 2007; Duan et al., 2003, 
Nardiello et al., 2011]. For example, Duan et al. transfected cells 
originally sensitive to doxorubicin with the MAGEA2 cDNA and 
observed a clear increase in the resistance to the drug thereafter. 
Our results are concordant and further emphasize the importance of 
this member of the family. 
MAGEA3, -A6 and -A12 are phylogenetically close since they 
share 94% (A3 vs A6) and 84% (A3/A6 vs A12) of homology for the 
MHD [Doyle et al., 2010]. In the literature, Yang et al. mentioned a 
stop of cell growth when MAGEA3 and -A6 expression were knocked 
down and Nardiello et al. correlated the expression of MAGEA3 with 
disease progression although MAGEA3 silencing did not affect the 
cell cycle [Nardiello et al., 2011]. Our data demonstrate that 
MAGEA3, -A6 and -A12 are not able to reduce the sensitivity of 
breast cancer cells to doxorubicin. 
Finally, in the literature, MAGEA4 is clearly different from the 
other family members since two different teams described that 
MAGEA4, and more precisely a cleaved formed of MAGEA4, is able to 
induce apoptosis instead of preventing it [Sakurai et al., 2004; Peikert 
et al., 2006]. Our results are in opposition since no drop in cell 
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survival has been observed when we overexpressed MAGEA4 in MCF-
7 breast cancer cells. On the other hand, Peche et al., demonstrated 
that MAGE-A2 was able to reduce p53 acetylation while MAGE-A4 
has no effects on the tumor suppressor [Peche et al., 2012]. This lack 
of activity corroborates our results. In addition, it is interesting to 
note that MCF-7 cells lack caspase-3 [Wesierska-Gadek et al., 2011]. 
It is possible that the absence of a pro-apoptotic effect in our model 
is due to a failure to cleave MAGEA4 since it seems to be caspase-
dependent [Sakurai et al., 2004]. However, MCF-7 cells do express 
caspase-7 which shares almost the same substrates and inhibitors 
specificity than caspase-3 [Fuentes-Prior and Salvesen, 2004]. 
In summary, our work analyzed for the first time, the individual 
impact of each MAGEA, commonly expressed in cancer, on cell 
resistance to a genotoxic stress. We thus, provide additional 
information on the MAGEA family by pointing out that only MAGEA1 
and -A2 are able to increase resistance to doxorubicin in the MCF-7 
cell line. Differences in activity towards p53 between MAGEA family 
members, despite the close homology, raise questions. By analyzing 
the amino acids sequences, no particular features could be identified 
to explain the specific activity of MAGEA1 and -A2 on cell resistance 
to a genotoxic agent. As proposed by Ladelfa et al., it seems obvious 
that the cellular context may play a critical role by determining the 
MAGEA interactions with other proteins [Ladelfa et al. 2012]. 
Moreover, it has been recently shown that MAGEA proteins could be 
post-transcriptionally modified.  Bai et al. demonstrated that 
MAGEA11 may be phosphorylated on residues like Thr360 by CHK1 
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[Bai and Wilson, 2008]. Thus, it is plausible that post-translationnal 
modifications may also modulate the interactions of MAGEA proteins 
and their activity.   
 
1.3.2 Connection of MAGEA to the p53 pathway 
 
After treatment with camptothecin, we observed a reduced 
apoptosis in cells expressing MAGEA1 or -A2 as compared to control 
cells. Altogether, our data suggest that MAGEA1 and -A2 have an 
inhibitory effect on the apoptotic process induced by genotoxic 
agents. We next examined the relationship between MAGEA and the 
p53 pathway. When cells overexpressing MAGEA1 or -A2 were 
treated with nutlin-3a, we observed a reduction of cell growth 
inhibition, suggesting a connection between some MAGEA family 
members and the p53 pathway.  
Since a conflict exists in the literature regarding the direct 
binding of p53 to MAGEA proteins, we examined potential 
interactions by immunoprecipitation and GST-pull down assays. Our 
data are concordant with these of Monte et al. and Marcar et al. 
When p53 is immunoprecipitated with the FL-393 polyclonal 
antibody, MAGEA1 and -A2 are co-immunoprecipitated. Moreover, 
data from GST-pull down assays show a direct binding of MAGEA1 
and -A2 to the DNA binding domain of p53. This is in opposition with 
the studies of Yang et al. and Doyle et al. since both studies do not 
evidence a direct binding. The reason for this difference remains 
 227 
 
unknown since we also used GST-pull down assays with in vitro 
translated tagged-MAGEA proteins. 
 
1.3.3 MAGE-A and p53 activation following a genotoxic stress 
 
We next analyzed p53 levels in MCF-7 clones expressing or not 
MAGEA1 or -A2, following a treatment with doxorubicin. Our data 
show that when MAGEA1 and -A2 are expressed, the cellular levels of 
p53 is reduced in stressed cells.  
Two hypotheses were proposed: either p53 is more degraded 
or its stabilization following a stress is impaired. In the literature, the 
classical model for p53 activation asserts that p53 requires post-
translational modifications in order to be stabilized [Riley et al., 2008; 
Lavin and Gueven, 2006]. Therefore, we sought to analyze different 
N-terminal phosphorylations of p53 known to impact on its stability. 
Data identified a reduction of the phosphorylation of p53 Ser15 in 
presence of MAGEA. Since phosphorylation of Ser15 favors the 
subsequent phosphorylation of Thr18 and Ser20, we next analyzed 
these two post-translational modifications. We found that both 
Thr18 and Ser20 phosphorylations were decreased in cell expressing 
MAGEA as compared to control cells transfected with the empty 
vector. Phosphorylation of Ser15, Thr18 and Ser20 are reported to be 
crucial to inhibit MDM2/MDMX binding to p53. Ser15 seems to be 
more important for the subsequent phosphorylation of Thr18 and 
Ser20 rather than for p53 stabilization itself [Dumaz and Meek, 1999; 
Saito et al. 2003; Lavin and Gueven, 2006]. Phosphorylation of Thr18 
 228 
 
and Ser20, on the other hand, is essential to prevent MDM2 binding. 
Lee et al. demonstrated that Thr18 phosphorylation impairs MDM2 
binding to p53 by more than 20 fold while the double 
phosphorylation of Ser15 and Thr18 inhibits it even more.  
Our results are original since Monte et al. did not observe 
differences in total p53 or its Ser15 phosphorylated form. Doyle et al. 
for their part, detected a reduced p53 level in presence of MAGEA 
but measures were done in unstressed cells expressing mutant p53. 
According to Doyle et al., in unstressed cells expressing MAGEA, p53 
levels is very low due to its enhanced degradation by KAP1 [Doyle et 
al., 2010]. Therefore, in presence of a stress such as oncogene 
activation, cells will be unable to activate p53. We demonstrate by 
western blot that wt p53 is detectable and activated after a stress in 
presence of MAGEA proteins. Therefore MAGEA expression is not 
sufficient to totally prevent p53 induction following a stress. We 
propose that the impaired phosphorylation of p53 in presence of 
MAGEA leads to an unstable p53 protein prone to be degraded. This 
leads to reduced intracellular p53 levels as observed in stressed cells.  
Phosphorylation of Ser46, on the other hand, is important for 
apoptosis induction [Oda et al., 2000]. We shown that this 
phosphorylation is also decreased in presence of MAGEA1 or -A2. 
This gives a new insight into the mechanism by which MAGEA 
proteins decrease p53-dependent apoptosis. Ser46 has been shown 
to be phosphorylated by DIRK2 (following DNA damage [Ollson et al., 
2007]) but also by HIPK2 (following UV light exposure [Ollson et al., 
2007]) and p38MAPK (following UV light exposure [Li et al. 2005]) 
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and is considered as a switch increasing p53 affinity for the promoter 
of its apoptotic targets such as the genes coding for NOXA or PUMA.  
 
1.3.4 Perspectives 
 
The mechanism responsible for the impaired phosphorylation 
of Ser15, thr18, Ser20 and Ser46 remains to be elucidated. 
Hypotheses are numerous. Interestingly, Peche et al. suggested a 
mechanism in which MAGEA proteins inhibit PML-NBs formation 
[Peche et al., 2012]. PML-NBs are platforms thought to play a role in 
p53 post-translational modification by recruiting in a same place 
modifiers and the tumor suppressor. Proteins recruited on PML-NBs 
are numerous and HIPK2 phosphorylation of p53 has been shown to 
depend on PML-NBs formation [Moller et al., 2003]. Therefore 
impairment of PML-NBs formation could be a hypothesis to explain 
the impaired p53 Ser46 phosphorylation. To our knowledge, no 
evidence of the presence of DYRK2 or p38MAPK on PML-NBs has 
been published. Could ATM (ser15), CK2 (Thr18), CHK1 (Ser20), CHK2 
(Ser20)… be recruited on such platforms? As far as we know, there is 
no evidence in the literature of a presence of these kinases on PML-
NBs. Moreover, it is ignored whether PML-NBs are required or not to 
ensure the phosphorylation of p53 by ATM or other kinases. This 
requirement has only been shown for HIPK2. To our opinion, this 
hypothesis deserves a priority in further investigations. 
Another hypothesis is that MAGEA proteins could target kinases 
involved in the post-translational modification of p53. For example, 
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in presence of DNA damage, Ser15 phosphorylation is performed by 
DNA-PK or ATM [Ollson et al., 2007]. It would be interesting to 
determine if MAGEA proteins could directly interact with them and 
inhibit their action. Alternatively, MAGEA could also inhibit upstream 
signals necessary for ATM or DNA-PK activation.  
In addition, MAGEA proteins interacting with p53 may inhibit 
the recruitment of protein kinases by steric hindrance. Therefore, 
MAGEA proteins could be directly responsible for the impaired N-
terminal phosphorylations of p53. Finally, the activation by MAGEA of 
specific phosphatases, like PP1 that would dephosphorylate p53 on 
Ser15 [Haneda et al., 2004]) could also result in a decreased p53 
stabilization.  
These different hypotheses also require further investigations in 
order to identify the mechanism(s) responsible for the impaired N-
Terminal phosphorylations of p53 in presence of MAGEA. This could 
bring useful informations on how to fight cancers expressing 
MAGEA1 and -A2.  
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1.4. CTAs: past, present and future. 
 
  Cancer testis antigens were first analyzed for their potential 
use in cancer immunotherapy. Targeting antigens that are only 
expressed by cancer cells may represent the best anti-cancer therapy 
so far. The enthusiasm was so strong that it was published in Nature 
Medecine in 2011 that “wiping out cells expressing CT antigens 
should theorically cause no side effects, no-off target effects on 
normal tissues, none at all.” [Scudellari, 2011]. However, clinical trials 
based on strategies targeting well characterized CT antigens have 
shown limited success [Suri et al., 2012]. A good example is the 
recent failure of the vaccine targeting MAGEA3 (GSK1572932A), 
designed to treat non-small cell lung cancer. By compiling evidences, 
it seems that the expression of MAGEA1 but also -A2 and -A3 is 
responsible for resistance to TNF-α cytoxicity, one of the main death 
pathways induced by NK and LTc to elicit cell death [Parc et al., 
2002].  
However, the use of CTAs as therapy is not withdrawed. A 
technology, named CAR-T Cell, recently reaches clinical trials. CAR-T 
cell, for Chimeric Antigen Receptor T cells, is based on the use of 
genetically engineered T-Cell lymphocytes that express a single-chain 
variable fragment (scFv) (derived from monoclonal antibodies) fused 
to CD3-zeta transmembrane- and endo-domain. More precisely, the 
external part of this receptor is composed by the variable part of the 
heavy and light chains of the antibody. Both parts are fused by a 
linker to form a scFv. This construction keeps the specificity toward 
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the antigen and LTc expressing such construction will be sensible to 
the antigen normally targeted by the antibody. Following binding, the 
CD3-zeta chain will trigger a signal activating LTc toxicity. For 
example, using a construction based on antibodies recognizing 
MAGEA1, Willemsen et al. demonstrated a drastic increase of the 
cytolytic capacity of cells expressing their scFv [Willemsen et al. 
2005]. Today, clinical trials evaluating the potential of this technology 
are currently ongoing.   
For the future, CTAs analysis will be compulsory. It becomes 
more and more obvious that multiple cancer testis antigens and in 
particular several MAGEA are implicated in cellular pathways that 
reinforce cell resistance to death signals or increase cell growth. For 
example, in 2014, a team also demonstrated that in presence of 
growth factors, CT45A1 overexpression (Cancer Testis Antigen-45 
family member) activated ERK and CREB signaling, promoted 
epithelial to mesenchymal transition and increased stem cell 
characteristics [Shang et al., 2014]. Moreover, recent publications 
linked MAGEA expression to EMT and the generation of cancer stem 
cells [Yang et al., 2015]. Consequently, in addition to an increased 
resistance to classic chemotherapies, CTAs favor cancer cell 
dedifferentiation, migration and invasion of other tissues. In the light 
of these diverse properties conferred, a systematic analysis of all 
CTAs should be undertaken. The goal would be to determine their 
functions and to identify the underlying mechanisms. With this 
knowledge, it must be possible to develop new therapies and with 
the rising of the personalized medicine, a screening and identification 
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of the cancer testis antigens expressed may help the physician in 
choosing the best treatment. For example, we describe here the 
effects of MAGEA1 and -A2 expression on the inhibition of p53-
dependent apoptosis. Since MAGEA1 and -A2 increase resistance to 
DNA damage-based chemotherapies, the physician could in the 
future prefer to use alternative treatments. On the other hand, when 
new mechanisms of CTAs actions are identified, research could focus 
on finding molecules inhibiting the gain of function induced by CTAs. 
Such molecules would restore a less aggressive behavior to the 
cancer as well as sensitize it to regular chemotherapies. Ultimately, 
this will decrease the disease burden and hopefully lead to a better 
outcome for the patient.  
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2. Resveratrol 
 
2.1. Main findings of the study 
 
In this work, we shown that RSV induces p53-dependent 
apoptosis in colon cancer cells and identified the molecular 
mechanism involved. After cell treatment, we observed a chromatin 
condensation that was dose- and time-dependent. We further 
confirmed the apoptotic phenomenon by analyzing PARP cleavage, 
p53 intracellular levels and the morphological features of the treated 
cells. Moreover, by measuring the presence of γ-H2AX foci, we 
determined that RSV causes DNA damage. We tested whether ROS 
could be responsible for the observed loss of cell viability and DNA 
damage formation. However, we failed to observe differences in cell 
growth or formation of γ-H2AX foci when combining RSV treatment 
with the anti-oxidant NAC, suggesting that ROS are likely not 
responsible for DNA damage and apoptosis induction in RSV-treated 
HCT-116 cells. 
 We next wondered if RSV could act as a DNA intercalating 
agent or modulate the activity of type I and II TOPO. Our data 
revealed that RSV is neither a DNA intercalating drug nor a TOPOI 
inhibitor. By checking for TOPOII inhibition in presence of kinetoplast 
DNA, we demonstrated that RSV inhibits TOPOII activity. We further 
demonstrate by performing “band depletion assays” that the 
polyphenol presumably stabilizes the so-called “cleavable complex”, 
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a covalent DNA-TOPOII intermediate. The hypothesis is that RSV 
prevents the religation step, leading to the formation of DNA double 
strand breaks. 
Thus, RSV acts as a TOPOII poison and does not seem to 
possess other activity that may lead to DNA damage such as ROS 
production, DNA intercalation or TOPOI inhibition. Moreover, it is 
interesting to notice that this mechanism of action of RSV is valid for 
different cellular models [Leone et al., 2012]. Our study also indicates 
that RSV, at similar concentrations, is less efficient than the well-
known TOPOII poison etoposide.  
We further analyzed the molecular mechanism associated to 
RSV-induced apoptosis. Using two different ATM kinase inhibitors, 
caffeine and KU55933, we show that p53 induction in cells treated 
with RSV relies on the activity of the ATM kinase. Moreover, we 
demonstrate that p38MAPK and ERK1/2 are not involved in p53 
stabilization in HCT-116 colon cancer cells.  
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2.2. Discussion  
 
Benefic effects of resveratrol have been identified in several 
domains. For example, RSV shows activity against cardiovascular 
diseases [Park and Pezzutto, 2015] and inflammation [Ma et al., 
2015]. In a narrower point of view, RSV also seems to display anti-
cancer activities [Wang et al., 2015; Khan et al., 2014].  
Previous observations reported an increased ROS level in HCT-
116 cells treated with RSV, concomitant to cell cycle arrest and the 
development of a senescent phenotype [Heiss et al., 2007]. Using 
NAC, an antioxidant molecule, that was previously shown to be 
protective on RSV-induced entry into senescence, we failed to 
observe differences in cell growth or γ-H2AX foci formation when 
combining RSV treatment with NAC. Similarly, at 25µM of RSV, 
almost the concentration used by Heiss et al. (30µM), no differences 
were observable. In the opposite, NAC was highly protective against 
H2O2 treatment. To conclude, our experiments suggest that ROS are 
not responsible for inhibition of cell growth or DNA damage 
formation in RSV-treated HCT-116 cells.  
RSV is neither a DNA intercalating drug nor a TOPOI inhibitor. 
This is an original result since, to our knowledge, this was not 
analyzed before.  However, the activity of RSV toward TOPOII was 
previously reported by an Italian team [Leone et al., 2012]. Here we 
confirm those results obtained in glioblastoma cells.  
Results concerning p38MAPK and ERK1/2 are in opposition 
with previous publications [She et al., 2001]. In 2001, She et al. used 
 238 
 
inhibitors of ERK1/2 and p38MAPK to demonstrate the implication of 
these two kinases in the stabilization of p53 as well as its 
phosphorylation on Ser15 in cells treated with RSV. Our data suggest 
the opposite : these two kinases are not involved in p53 stabilization 
in presence of RSV. However, differences with our work could lie in 
the cellular model used. In their study, She et al. used a normal 
mouse skin epidermal cell line (JB6 Cl41)
18
.  Therefore, variations 
observed using the same P38MAPK inhibitor (PD98059) could be the 
consequence of a particular HCT-116 cellular context. However, 
Olsson et al. described that P38MAPK and ERK1/2 phosphorylate 
Ser15 of p53 only following UV light exposure [Olsson et al., 2007]. 
Finally, ATM implication in the phosphorylation of Ser15 has also 
been identified by Heiss et al. Here, we confirm the role of ATM  in 
p53 Ser15 phosphorylation and further emphasize it since kinases 
previously thought to mediate RSV-dependent effects are not 
involved. 
  
                                                 
18
 http://www.lgcstandards-atcc.org/products/all/CRL-2010.aspx?geo_country=be 
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2.3. Conclusion and future of resveratrol in cancer 
therapy 
 
RSV has been shown to induce apoptosis in cancer cells, to 
reduce angiogenesis by suppressing VEGF expression [Bishayee et al., 
2010] and has little side effects in human, even at high doses. All 
these characteristics make RSV a good candidate for chemotherapy. 
However, some important issues must be faced.  
First RSV has a very poor oral bioavailability due to its rapid 
metabolization. New formulation could improve this. A rapidly 
dismissed solution came from oligomers of RSV. It consists in the 
polymerization of two to eight RSV units. Several studies 
demonstrated in vitro the enhanced activity of those forms compared 
to monomeric RSV [Xue et al., 2014]. The hypothesis was that the 
metabolism would be less active on such molecules and that these 
molecules would progressively release free RSV. However a recent 
publication determined that the intestinal absorption rate of two RSV 
oligomers, ε-viniferin and hopeaphenol, is low and negligible when 
compared to RSV itself [Willenberg et al., 2015]. Therefore, to 
overcome this problem, injection in the bloodstream may be a 
solution. Nevertheless, analyses of such compounds are at the early 
stages. Basic toxicological studies are still ongoing.  
Another solution may come from a recent rapport in Science. 
This study describes that metabolized forms of RSV circulating in the 
blood can be absorbed by cells, transiently stored and converted 
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again into RSV. Indeed, monosulfate metabolites were shown to be 
re-converted into RSV in human colorectal cancer cells and 
toparticipate to the in vivo effects of RSV [Patel et al., 2013]. This is 
particularly interesting since it raises the possibility to create 
modified forms of RSV that may act as a Trojan horse. Conjugated 
forms of RSV, designed to be easily absorbed by the gut epithelium 
may safely travel to the cancer cells through the circulation. Ideally, 
the conjugated form would be cancer specific and would depend on 
enzymes expressed by the cancer cell for its activation. Theorically, 
after absorption, the cancer cell would naturally regenerate RSV and 
senescence or apoptosis could be induced.  
Another issue lies in the fact that it is not clear whether RSV 
metabolites play a role in the effects attributed to RSV. To add a layer 
of complexity, it seems that the type of metabolites formed is related 
to the RSV dose. For example, at low doses, sulfation represents the 
main form of metabolization while at higher doses, glucuronidation 
prevails [Szekeres et al. 2011]. A clear understanding of the activity, 
toxicity and behaviour of each metabolite will be important for the 
further evaluation of RSV in clinical trials. 
In conclusion, a lot of work on RSV and its metabolization 
remains to be done prior to a use in chemotherapy. However, our 
work emphasizes the pro-apoptotic and anti-cancer potential of this 
polyphenol and the hope it raises for the development of future 
therapies. 
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